Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"
AASS	"LKRSDH, LORSDH"	ENSG00000008311	"Aminoadipate-semialdehyde synthase"	Q9UDR5	7	122075647-122144280	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"		"Multifunctional enzyme, Oxidoreductase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 26.1;NTERA-2: 25.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 3.5"	"Group enriched"	"Detected in many"	4	"B-cells: 1.0;granulocytes: 3.5;T-cells: 1.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020637, HPA020728, HPA020734"	Enhanced		Enhanced	Vesicles,Mitochondria			17000	Mitochondria	Vesicles	"HPA020637: AB_1844415, HPA020728: AB_1844416, HPA020734: AB_1844417"	"unprognostic (4.84e-2)"	"unprognostic (2.29e-1)"	"unprognostic (7.91e-4)"	"unprognostic (6.08e-2)"	"unprognostic (1.49e-2)"	"unprognostic (8.00e-2)"	"prognostic favourable (9.81e-4)"	"unprognostic (4.48e-3)"	"unprognostic (2.38e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.99e-1)"	"unprognostic (7.76e-3)"	"unprognostic (8.56e-3)"	"unprognostic (1.55e-1)"	"unprognostic (6.50e-2)"	"unprognostic (2.67e-1)"	13.9	9.5	7.4	4.8	11.8	1.6	11.2	2.7	9.8	16.0	8.1	12.5	8.2	2.2	16.8	11.6	6.4	14.9	6.7	12.6	8.8	3.7	14.4	35.8	9.1	3.3	15.2	5.0	36.7	10.7	14.9	10.4	7.1	9.9	9.2	3.8	9.2	5.4	10.4	11.3	4.4	5.5	9.3	12.1	5.2	9.0	5.1	13.2	0.8	7.8	8.3	3.1	11.0	9.0	1.0	0.4	3.5	0.1	0.3	1.2	0.1	0.1	0.0	16.2	26.1	13.5	8.7	6.3	4.4	4.7	4.6	6.7	7.4	0.2	0.0	0.3	3.1	2.8	18.6	8.4	6.3	0.0	6.8	5.6	3.6	4.8	11.1	0.0	1.8	7.6	0.2	5.5	5.8	11.0	1.5	10.3	3.1	0.0	0.5	0.0	25.5	1.0	8.4	8.6	0.3	2.1	1.8	1.6	0.5	1.4	0.0	2.7	0.4	0.0	5.0	9.0	2.7	4.1	4.2	2.2	1.6	0.0	3.3	0.5	3.4	3.5	0.1	0.0	0.7	0.0	0.1	0.5	0.8	0.0	0.4	1.0	1.2	0.5	0.0	0.3	0.0	0.0	0.7	0.1	7.4	11.8	2.7	7.3	8.8	3.7	15.2	5.0	9.9	13.2
ABHD14A	"DKFZP564O243, DORZ1"	ENSG00000248487	"Abhydrolase domain containing 14A"	Q9BUJ0	3	51971426-51981199	"Predicted intracellular proteins, Predicted membrane proteins"		Hydrolase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 34.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038153, HPA056913"	Approved		Enhanced	Vesicles			260000	Vesicles		"HPA038153: , HPA056913: "	"unprognostic (4.15e-3)"	"unprognostic (6.73e-2)"	"unprognostic (1.98e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.71e-1)"	"unprognostic (1.08e-2)"	"unprognostic (8.92e-2)"	"prognostic favourable (4.72e-4)"	"unprognostic (3.96e-1)"	"unprognostic (2.46e-2)"	"unprognostic (5.52e-3)"	"unprognostic (1.51e-2)"	"unprognostic (1.97e-2)"	"unprognostic (9.74e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.30e-2)"	11.8	28.0	23.3	6.0	25.8	9.0	9.2	39.6	45.0	18.3	7.3	12.2	8.5	8.0	6.9	23.2	5.4	19.6	9.3	16.4	22.3	27.8	26.2	13.0	9.7	8.9	16.6	23.4	14.8	20.6	15.6	21.3	7.0	18.7	11.6	5.6	26.1	17.7	12.5	23.8	3.9	6.6	8.8	14.5	7.7	11.0	6.2	7.0	6.6	24.1	8.4	8.8	9.2	7.4	15.4	13.9	4.5	6.0	12.0	30.9	15.3	2.8	5.4	3.4	10.4	34.7	17.5	1.9	3.7	6.2	4.5	6.1	6.1	11.3	3.1	2.6	9.2	2.4	3.8	4.1	1.4	10.2	4.2	9.2	15.9	20.2	9.7	12.6	12.4	16.5	2.9	3.8	1.9	5.8	3.7	10.7	7.0	3.2	5.8	12.9	1.9	12.8	4.2	1.8	29.8	8.6	4.4	7.1	11.1	9.4	2.0	5.5	2.9	13.9	3.4	4.1	4.5	9.9	4.3	15.7	14.6	2.6	7.7	20.2	5.9	2.1	6.0	4.5	30.2	3.5	30.9	15.4	26.7	26.8	10.4	12.4	24.6	26.2	0.6	12.0	2.2	13.9	25.7	15.3	23.3	25.8	39.6	45.0	22.3	27.8	16.6	23.4	18.7	7.0
ADCYAP1R1	"PAC1, PAC1R, PACAPR"	ENSG00000078549	"ADCYAP receptor type I"	P41586	7	31052461-31111479	"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Differentiation, Spermatogenesis"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 71.2;fallopian tube: 25.1"	"Group enriched"	"Detected in some"	6	"AF22: 5.4;NTERA-2: 7.2;SCLC-21H: 6.1;SH-SY5Y: 10.9"	"Cancer enriched"	"Detected in some"	11	"glioma: 45.4"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA030739, HPA049877"	Enhanced		Enhanced	Vesicles				Vesicles		"HPA030739: , HPA049877: "	"unprognostic (5.43e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.16e-2)"	"prognostic favourable (5.78e-4)"	"unprognostic (2.17e-1)"	"unprognostic (8.36e-2)"	"unprognostic (4.93e-2)"	"unprognostic (5.75e-2)"	"unprognostic (3.50e-2)"	"unprognostic (3.88e-1)"	"unprognostic (1.58e-1)"	"unprognostic (6.67e-3)"	"unprognostic (6.43e-4)"	"unprognostic (1.09e-3)"	"unprognostic (9.55e-2)"	"unprognostic (3.85e-2)"	"unprognostic (2.75e-4)"	5.4	10.6	23.6	2.7	24.2	0.9	2.9	13.7	71.2	12.8	2.7	13.4	0.0	1.6	5.4	2.3	3.3	25.1	2.0	2.8	22.1	21.6	1.0	1.1	1.6	1.0	19.0	20.2	1.9	2.2	2.9	4.4	1.0	18.7	2.1	2.0	0.0	2.6	3.7	1.9	1.8	2.0	3.9	6.5	1.3	1.6	2.2	13.3	0.0	2.3	0.9	1.6	1.4	1.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.3	0.0	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	6.1	10.9	0.0	0.0	0.0	0.0	0.0	0.3	0.9	1.3	0.2	0.1	0.0	0.0	0.0	1.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	23.6	24.2	13.7	17.3	22.1	21.6	19.0	20.2	18.7	13.3
AKAP9	"AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO"	ENSG00000127914	"A-kinase anchoring protein 9"	Q99996	7	91940867-92110673	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes, Disease mutation, Long QT syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008548, CAB012909, HPA026109"	Supported		Enhanced	"Golgi apparatus,Vesicles,Centrosome"				"Golgi apparatus"	"Vesicles, Centrosome"	"CAB012909: AB_2533235, HPA008548: AB_1078121, HPA026109: AB_1844688"	"unprognostic (9.57e-2)"	"unprognostic (1.66e-1)"	"unprognostic (2.13e-1)"	"unprognostic (5.97e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.47e-1)"	"unprognostic (4.75e-2)"	"unprognostic (1.31e-2)"	"unprognostic (1.28e-1)"	"unprognostic (6.59e-2)"	"unprognostic (7.59e-2)"	"unprognostic (6.32e-2)"	"prognostic favourable (2.10e-6)"	"unprognostic (8.89e-2)"	"unprognostic (1.73e-1)"	"unprognostic (7.77e-2)"	"unprognostic (3.96e-2)"	13.7	15.9	18.0	22.6	17.1	14.9	15.6	35.8	17.5	14.4	24.5	4.7	17.2	25.5	13.0	17.1	15.3	12.4	15.0	14.8	13.3	7.0	19.5	25.1	19.9	13.2	12.4	12.3	22.3	21.3	22.1	40.5	12.9	14.0	11.9	25.3	11.1	20.1	25.9	29.6	16.1	29.1	12.0	11.1	10.4	15.0	6.9	14.4	10.3	14.9	15.7	8.6	14.0	14.2	34.4	39.5	31.9	16.6	10.6	20.3	3.4	11.2	7.0	10.4	6.6	14.9	11.0	7.4	8.4	5.7	4.3	5.5	11.9	9.8	10.2	12.2	7.4	10.4	10.0	5.5	8.1	9.2	8.5	11.2	12.2	7.8	6.1	18.5	11.9	6.9	8.8	8.9	10.2	9.3	16.6	16.7	7.3	16.3	12.6	7.3	8.0	8.7	7.7	17.4	8.2	5.9	12.4	17.0	11.9	17.8	20.0	8.6	5.2	9.0	17.1	8.7	11.2	15.2	11.4	12.0	13.2	13.7	7.7	9.4	9.8	31.9	16.6	21.4	18.4	9.3	15.4	31.4	18.7	16.7	7.2	34.4	20.3	19.3	23.2	10.6	16.3	39.5	14.9	3.4	18.0	17.1	35.8	17.5	13.3	7.0	12.4	12.3	14.0	14.4
ANKRD2	ARPP	ENSG00000165887	"Ankyrin repeat domain 2"	Q9GZV1	10	97572499-97583884	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	10	"skeletal muscle: 472.2"	"Cell line enhanced"	"Detected in some"		"A-431: 14.5;BJ hTERT+ SV40 Large T+: 5.4;HaCaT: 11.5;RPTEC TERT1: 12.8"	"Cancer enhanced"	"Detected in many"		"testis cancer: 5.3"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	18	"neutrophil: 1.7"	"Lineage enriched"	"Detected in single"	18	"granulocytes: 1.7"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA040842, HPA040884"	Enhanced		Enhanced	Vesicles				Vesicles		"HPA040842: AB_10963794, HPA040884: AB_10969453"	"unprognostic (1.27e-2)"	"unprognostic (9.99e-2)"	"unprognostic (2.86e-1)"	"unprognostic (1.39e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.61e-2)"	"unprognostic (2.53e-1)"	"unprognostic (5.60e-3)"	"unprognostic (2.17e-1)"	"unprognostic (3.12e-1)"	"unprognostic (4.91e-2)"	"unprognostic (2.22e-1)"	"unprognostic (1.05e-2)"	"unprognostic (3.69e-3)"	"unprognostic (4.56e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.13e-1)"	2.3	0.2	0.1	0.0	0.2	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.1	0.0	0.0	1.2	2.7	0.0	0.1	47.2	0.0	0.1	1.6	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.1	0.3	472.2	0.4	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	3.0	1.2	1.1	0.3	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	14.5	5.0	0.0	0.0	0.2	0.0	0.4	0.7	0.0	5.4	3.5	0.2	4.5	0.0	0.6	0.1	11.5	0.0	3.9	3.6	0.1	0.2	0.0	0.2	0.0	0.4	0.0	0.0	0.6	1.7	3.2	0.2	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.3	0.0	12.8	0.7	0.0	0.0	0.0	3.7	0.0	1.8	0.3	0.0	0.1	1.3	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0
ANKRD6	KIAA0957	ENSG00000135299	"Ankyrin repeat domain 6"	Q9Y2G4	6	89433170-89633834	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 47.8"	"Cell line enhanced"	"Detected in many"		"AF22: 10.0;BEWO: 30.6;HAP1: 9.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"eosinophil: 3.0;intermediate monocyte: 2.9"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB020693, HPA035694, HPA064642"	Approved		Enhanced	Vesicles				Vesicles		"CAB020693: , HPA035694: , HPA064642: "	"unprognostic (3.80e-1)"	"unprognostic (3.16e-2)"	"unprognostic (2.39e-3)"	"unprognostic (2.03e-1)"	"unprognostic (1.36e-1)"	"unprognostic (3.06e-2)"	"unprognostic (2.91e-2)"	"unprognostic (3.29e-2)"	"unprognostic (4.95e-2)"	"unprognostic (2.09e-1)"	"unprognostic (7.84e-2)"	"unprognostic (2.26e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.43e-3)"	"unprognostic (2.28e-1)"	"unprognostic (3.01e-1)"	"unprognostic (2.10e-1)"	3.9	2.2	11.7	3.0	7.8	1.6	3.9	47.8	17.8	5.7	2.9	2.8	1.1	1.0	6.1	4.4	4.9	11.7	5.7	8.9	7.8	9.1	5.4	4.5	5.7	2.5	4.2	12.0	15.6	4.3	9.3	4.2	4.3	7.3	3.6	1.1	6.6	7.7	2.3	4.0	1.9	1.8	5.4	5.0	2.0	2.6	6.1	3.7	2.0	5.6	3.3	2.5	4.4	4.0	0.3	0.1	3.0	2.9	0.6	1.0	0.3	0.0	1.2	10.0	4.2	0.1	0.4	30.6	0.1	0.1	0.0	0.6	0.3	0.8	0.0	1.0	0.0	0.0	9.1	5.1	0.4	0.0	6.8	3.6	0.0	0.3	0.1	0.0	1.4	0.6	1.4	0.0	0.0	1.0	0.3	2.3	0.0	1.1	0.1	0.3	2.8	1.0	3.6	0.0	0.0	1.5	5.1	6.6	2.3	0.8	6.7	3.3	1.9	2.2	0.0	1.6	0.6	0.1	0.8	0.3	0.0	0.0	0.1	0.0	1.2	0.0	0.4	3.0	1.0	2.9	0.0	0.0	0.7	0.0	0.1	0.3	0.3	0.4	0.7	0.6	0.0	0.0	0.2	0.3	11.7	7.8	47.8	11.6	7.8	9.1	4.2	12.0	7.3	3.7
AP1B1	"ADTB1, AP105A, BAM22, CLAPB2"	ENSG00000100280	"Adaptor related protein complex 1 beta 1 subunit"	Q10567	22	29327680-29423179	"Plasma proteins, Predicted intracellular proteins, Transporters"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA065226, HPA068520"	Approved		Enhanced	"Golgi apparatus,Vesicles,Cytosol"			1000000	"Golgi apparatus, Vesicles"	Cytosol	"HPA065226: AB_2685438, HPA068520: AB_2685998"	"unprognostic (1.78e-1)"	"prognostic favourable (4.81e-4)"	"unprognostic (2.40e-1)"	"unprognostic (2.21e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.03e-1)"	"prognostic unfavourable (5.55e-5)"	"unprognostic (4.99e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.27e-1)"	"unprognostic (4.98e-3)"	"unprognostic (1.60e-1)"	"prognostic favourable (7.24e-6)"	"unprognostic (1.85e-2)"	"unprognostic (3.78e-2)"	"unprognostic (2.94e-2)"	"unprognostic (3.76e-2)"	22.2	25.8	28.0	32.3	35.2	29.9	17.2	37.3	43.1	17.2	23.9	26.5	23.9	32.1	14.8	18.4	46.4	17.7	22.0	16.6	24.4	30.4	24.2	25.8	21.2	37.2	29.4	24.1	12.7	28.4	48.2	31.1	32.3	31.9	27.3	21.8	24.1	29.5	31.2	31.3	34.0	28.7	19.3	22.4	33.0	24.9	23.4	16.7	25.2	21.6	25.5	37.4	25.6	21.0	12.2	16.9	3.1	17.3	4.0	5.8	11.6	26.9	15.4	16.0	17.0	12.3	9.0	20.0	19.0	21.2	23.4	22.4	23.5	11.1	14.9	12.6	21.6	24.3	22.9	32.0	14.9	19.1	33.4	24.7	20.0	13.3	13.7	35.2	34.2	12.9	11.9	22.3	18.0	32.4	16.9	18.2	15.4	29.5	14.8	11.7	12.4	17.5	28.4	17.6	39.6	16.5	61.4	25.4	18.0	23.5	27.6	11.8	22.4	16.1	27.9	27.0	16.7	15.4	19.8	19.8	10.3	27.3	19.2	15.3	15.7	0.0	15.5	3.1	5.8	17.3	5.8	10.1	3.9	4.9	16.9	12.2	3.2	3.2	1.7	4.0	17.3	5.2	5.2	11.6	28.0	35.2	37.3	43.1	24.4	30.4	29.4	24.1	31.9	16.7
AP1G1	"ADTG, CLAPG1"	ENSG00000166747	"Adaptor related protein complex 1 gamma 1 subunit"	O43747	16	71729000-71809201	"Predicted intracellular proteins, Transporters"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009049, HPA041224"	Approved		Enhanced	Vesicles,Cytosol			150000	Vesicles	Cytosol	"CAB009049: AB_2058329, HPA041224: "	"unprognostic (4.84e-2)"	"unprognostic (5.07e-2)"	"unprognostic (2.65e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.75e-1)"	"unprognostic (2.22e-1)"	"unprognostic (1.01e-1)"	"unprognostic (8.90e-2)"	"unprognostic (9.16e-2)"	"unprognostic (2.72e-1)"	"unprognostic (2.22e-2)"	"unprognostic (4.30e-2)"	"prognostic favourable (2.96e-8)"	"unprognostic (1.27e-1)"	"unprognostic (2.04e-1)"	"unprognostic (5.68e-2)"	"unprognostic (1.75e-1)"	23.2	29.8	20.4	19.2	26.3	59.1	22.4	31.8	29.2	19.7	20.4	29.2	19.8	19.2	19.6	23.9	30.1	17.9	18.7	14.5	18.5	17.4	32.8	29.5	23.8	20.0	24.2	20.1	18.3	25.6	53.5	27.4	25.1	27.9	20.8	23.4	20.8	28.2	20.2	30.0	27.7	24.4	16.0	20.3	24.3	24.8	26.5	26.7	30.0	23.1	21.8	28.3	18.1	20.1	7.5	8.5	17.6	8.8	7.6	9.0	4.2	16.2	23.8	18.3	18.6	19.7	18.7	15.9	16.9	16.2	22.7	21.9	22.9	18.1	20.2	16.3	23.0	20.8	24.8	18.6	30.6	8.1	12.7	13.2	12.5	17.4	11.6	15.8	43.9	15.6	13.2	30.2	18.7	19.2	17.5	8.6	22.2	29.0	14.6	13.3	16.7	10.4	23.6	14.7	21.6	21.2	18.7	16.9	10.1	20.9	13.2	9.4	23.1	12.5	22.6	19.5	15.2	10.4	12.3	13.6	17.5	41.8	15.7	12.8	16.6	5.8	7.9	10.9	8.3	8.8	8.3	6.3	7.3	9.0	8.5	7.5	5.9	7.2	17.6	7.6	6.8	6.0	7.3	4.2	20.4	26.3	31.8	29.2	18.5	17.4	24.2	20.1	27.9	26.7
ARCN1	COPD	ENSG00000095139	"Archain 1"	P48444	11	118572390-118603033	"Disease related genes, Plasma proteins, Predicted intracellular proteins"	"ER-Golgi transport, Protein transport, Transport"		Dwarfism	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA037573, HPA044874"	Approved		Enhanced	"Golgi apparatus,Vesicles"			340000	Vesicles	"Golgi apparatus"	"HPA037573: AB_10696938, HPA044874: "	"unprognostic (1.46e-2)"	"unprognostic (4.97e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.20e-1)"	"unprognostic (9.99e-2)"	"unprognostic (2.30e-2)"	"prognostic unfavourable (2.97e-5)"	"unprognostic (3.10e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.67e-3)"	"unprognostic (9.39e-2)"	"unprognostic (3.56e-2)"	"unprognostic (7.99e-2)"	"unprognostic (9.20e-2)"	"unprognostic (4.14e-3)"	"unprognostic (5.56e-3)"	46.9	37.4	26.7	30.3	32.9	15.0	35.7	34.4	38.8	48.8	36.7	37.3	39.9	36.0	39.8	61.6	38.6	32.6	38.0	39.5	28.7	30.6	39.1	61.4	34.0	27.3	30.4	24.7	45.1	65.2	49.7	64.7	46.0	38.3	42.4	39.6	29.3	62.0	46.9	25.8	31.9	47.1	41.9	34.3	34.9	38.1	37.9	29.7	39.0	44.1	29.3	39.2	46.9	42.1	22.7	29.1	46.2	33.0	34.1	39.5	26.7	24.3	20.4	35.8	26.1	44.1	47.1	19.3	61.5	54.7	27.9	33.3	64.4	32.3	25.7	52.8	68.6	33.0	40.0	36.2	38.9	35.3	18.7	55.1	14.8	35.0	50.1	33.8	32.3	41.1	30.1	46.0	42.9	42.2	28.4	36.1	52.4	39.1	30.4	30.1	22.5	27.3	26.5	34.8	39.1	33.7	26.5	24.6	24.7	34.2	33.4	17.3	42.5	30.3	38.5	35.2	17.3	33.2	28.4	21.2	18.8	37.4	20.7	31.7	41.8	46.2	26.4	26.3	30.5	33.0	39.5	22.7	30.2	29.3	29.1	20.7	29.1	26.6	23.1	34.1	32.1	24.4	28.3	26.7	26.7	32.9	34.4	38.8	28.7	30.6	30.4	24.7	38.3	29.7
ATP11A	"ATPIH, ATPIS, KIAA1021"	ENSG00000068650	"ATPase phospholipid transporting 11A"	P98196	13	112690329-112887168	"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Lipid transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035583, HPA035584"	Approved		Enhanced	Vesicles				Vesicles		"HPA035583: AB_10671106, HPA035584: AB_10672096"	"unprognostic (1.67e-1)"	"unprognostic (5.06e-3)"	"unprognostic (1.58e-1)"	"unprognostic (5.27e-2)"	"unprognostic (6.58e-2)"	"unprognostic (8.84e-2)"	"unprognostic (5.87e-3)"	"unprognostic (1.80e-2)"	"unprognostic (6.97e-2)"	"unprognostic (1.54e-3)"	"unprognostic (3.93e-2)"	"unprognostic (4.23e-1)"	"prognostic favourable (7.44e-4)"	"unprognostic (3.85e-2)"	"unprognostic (3.69e-1)"	"unprognostic (3.26e-2)"	"unprognostic (7.40e-3)"	11.1	11.5	7.2	8.3	16.4	15.7	7.9	5.0	12.5	13.6	5.8	24.4	8.7	9.5	13.7	9.2	8.5	10.8	14.6	19.6	7.2	5.4	12.9	12.3	36.9	7.5	17.7	6.9	8.6	13.2	36.1	17.8	11.2	12.8	5.0	3.6	10.0	12.0	9.0	11.2	11.4	8.7	9.1	12.5	10.2	6.1	9.7	16.2	2.1	16.4	6.4	6.0	5.7	11.3	4.2	1.1	6.4	3.1	0.0	1.0	0.6	13.8	7.1	9.0	10.6	4.6	6.2	16.1	6.6	3.9	5.7	4.6	22.3	16.1	7.0	8.1	5.6	11.8	8.1	5.5	5.5	7.0	7.6	8.1	5.9	11.6	7.3	15.2	13.3	4.2	4.2	6.8	4.2	14.8	5.6	1.2	3.9	5.2	6.9	9.6	3.9	5.1	6.0	3.6	4.0	30.9	3.2	14.5	4.0	6.4	8.4	5.5	3.2	20.3	9.7	0.0	12.3	7.3	5.0	3.8	7.5	2.9	2.5	14.3	6.2	0.0	2.3	3.1	1.0	3.1	0.6	1.3	0.6	0.5	1.1	4.2	0.7	0.4	6.4	0.0	2.7	1.1	0.1	0.6	7.2	16.4	5.0	12.5	7.2	5.4	17.7	6.9	12.8	16.2
ATP23	"KUB3, XRCC6BP1"	ENSG00000166896	"ATP23 metallopeptidase and ATP synthase assembly factor homolog"	Q9Y6H3	12	57941541-57957269	"Enzymes, Predicted intracellular proteins"		"Hydrolase, Metalloprotease, Protease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 39.5"	"Cell line enhanced"	"Detected in many"		"NB-4: 14.8;RH-30: 48.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035804, HPA043204"	Uncertain		Enhanced	"Vesicles,Plasma membrane,Cell Junctions,Cytosol"				"Vesicles, Plasma membrane"	"Cell Junctions, Cytosol"	"HPA035804: AB_10601026, HPA043204: "	"unprognostic (2.56e-1)"	"unprognostic (1.31e-2)"	"unprognostic (8.82e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.30e-2)"	"unprognostic (6.16e-2)"	"unprognostic (1.20e-1)"	"unprognostic (5.28e-2)"	"unprognostic (5.41e-3)"	"unprognostic (1.03e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.06e-1)"	"prognostic unfavourable (1.44e-5)"	"unprognostic (4.36e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.27e-1)"	6.7	4.9	4.3	5.2	5.3	11.3	4.8	6.1	4.8	5.6	8.2	1.3	2.5	3.9	3.2	4.2	7.3	3.1	2.4	6.4	4.2	3.6	5.4	6.2	2.7	6.8	2.7	3.8	4.2	5.8	3.2	3.0	3.5	2.9	5.1	8.2	2.3	3.4	3.3	11.7	5.6	4.3	6.5	3.4	3.7	3.8	39.5	2.0	20.8	4.7	5.9	4.7	6.3	6.2	3.0	4.5	12.0	4.5	2.6	5.6	3.0	1.9	1.5	1.9	2.2	2.8	2.7	1.0	1.9	1.9	2.2	2.1	1.2	2.4	6.8	2.4	1.4	1.8	1.8	1.9	3.8	3.4	1.8	4.4	1.2	1.9	1.2	8.9	3.0	1.4	1.5	1.3	0.5	1.5	4.6	4.9	1.8	3.0	4.8	14.8	1.6	3.7	3.1	48.8	2.8	1.8	2.5	1.2	1.8	3.0	2.8	1.5	4.9	8.4	0.8	1.6	2.8	2.1	1.8	4.0	2.1	3.5	1.8	9.6	2.7	7.6	4.5	12.0	3.5	2.4	2.6	3.0	4.0	3.3	4.5	3.0	4.3	4.0	1.9	2.6	4.2	2.1	5.6	3.0	4.3	5.3	6.1	4.8	4.2	3.6	2.7	3.8	2.9	2.0
AZU1	"AZAMP, AZU, CAP37, HBP, HUMAZUR, NAZC"	ENSG00000172232	"Azurocidin 1"	P20160	19	825097-832018	"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Chemotaxis	"Antibiotic, Antimicrobial, Heparin-binding, Serine protease homolog"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	7	"bone marrow: 238.2"	"Cell line enriched"	"Detected in some"	7	"THP-1: 150.8"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"classical monocyte: 3.3;neutrophil: 7.6"	"Group enriched"	"Detected in many"	6	"granulocytes: 7.6;monocytes: 3.3"					"Not detected"	"Not detected"			"HPA055851, HPA075964"	Enhanced		Enhanced	Vesicles	"Secreted to blood"		290000	Vesicles		"HPA055851: , HPA075964: "	"unprognostic (1.12e-2)"	"unprognostic (3.71e-2)"	"unprognostic (4.44e-2)"	"unprognostic (8.85e-3)"	"unprognostic (1.62e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.39e-1)"	"unprognostic (8.12e-2)"	"unprognostic (3.32e-1)"	"unprognostic (4.22e-3)"	"unprognostic (2.58e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.01e-6)"	"unprognostic (1.11e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.46e-2)"	"unprognostic (3.04e-2)"	0.3	0.2	0.4	0.2	0.5	238.2	0.6	0.0	0.6	0.2	0.2	1.0	0.0	0.2	0.2	0.2	0.2	0.8	0.2	34.6	0.4	0.5	0.2	1.5	15.3	0.2	0.2	0.0	0.5	0.1	0.1	0.9	3.8	0.2	0.2	0.2	0.2	0.6	0.2	1.0	0.4	0.2	0.2	0.1	18.6	0.2	1.2	0.0	20.6	1.3	0.0	0.2	0.1	0.4	0.0	0.8	7.6	3.3	0.0	0.3	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	150.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.0	0.0	0.0	3.3	0.2	0.3	0.8	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	7.6	0.0	0.5	0.0	0.0	4.1	0.4	0.5	0.0	0.6	0.4	0.5	0.2	0.0	0.2	0.0
BMP2	BMP2A	ENSG00000125845	"Bone morphogenetic protein 2"	P12643	20	6767664-6780280	"Cancer-related genes, Predicted secreted proteins"	"Chondrogenesis, Differentiation, Osteogenesis"	"Cytokine, Developmental protein, Growth factor"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CACO-2: 20.7;HeLa: 13.5;hTERT-HME1: 12.2;RT4: 16.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	7	"NK-cell: 2.2"	"Lineage enriched"	"Detected in single"	7	"NK-cells: 2.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA058610, CAB078457"			Enhanced	Vesicles	"Secreted to blood"	24353		Vesicles		"CAB078457: AB_2532532, HPA058610: "	"unprognostic (2.22e-2)"	"unprognostic (9.32e-2)"	"unprognostic (6.12e-2)"	"unprognostic (3.56e-2)"	"unprognostic (1.94e-2)"	"unprognostic (2.48e-1)"	"unprognostic (3.70e-3)"	"unprognostic (3.12e-3)"	"unprognostic (8.51e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.53e-3)"	"unprognostic (5.39e-3)"	"unprognostic (7.81e-2)"	"unprognostic (3.76e-1)"	"unprognostic (2.77e-1)"	"unprognostic (3.01e-2)"	"unprognostic (7.49e-2)"	11.1	1.1	1.6	10.5	3.1	0.6	5.3	1.8	7.5	3.7	13.1	2.6	1.9	4.2	3.4	6.7	3.7	3.7	15.6	3.9	2.4	1.6	3.6	3.8	12.8	1.3	2.9	1.3	3.1	9.2	4.7	2.3	7.6	2.7	8.8	9.5	18.3	2.0	1.2	2.6	9.1	13.4	3.4	1.4	8.0	13.8	1.1	2.7	0.3	13.2	6.2	3.1	14.1	9.1	0.0	0.0	0.3	0.0	2.2	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.1	0.0	0.5	2.3	0.0	0.0	20.7	0.0	0.0	0.3	0.7	6.9	4.1	1.8	0.0	0.0	3.7	0.0	13.5	0.0	1.0	0.0	0.5	0.1	6.3	0.0	12.2	4.2	0.0	0.0	0.1	0.0	0.0	3.9	0.5	0.5	4.0	0.0	0.3	1.5	16.5	0.7	1.0	4.9	0.0	0.0	0.0	4.3	1.0	1.2	1.8	0.0	0.5	0.2	0.5	0.0	2.1	1.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.2	0.0	0.0	0.0	0.0	1.6	3.1	1.8	3.3	2.4	1.6	2.9	1.3	2.7	2.7
C7orf43	FLJ10925	ENSG00000146826	"Chromosome 7 open reading frame 43"	Q8WVR3	7	100154420-100158715	"Predicted intracellular proteins"			"Disease mutation, Primary microcephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019359, HPA029463, HPA029464"	Approved		Enhanced	"Vesicles,Plasma membrane,Centriolar satellite"				Vesicles	"Plasma membrane, Centriolar satellite"	"HPA019359: AB_1848677, HPA029463: AB_10600001, HPA029464: AB_10600205"	"unprognostic (1.57e-2)"	"unprognostic (1.24e-1)"	"unprognostic (6.19e-3)"	"unprognostic (2.59e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.06e-1)"	"unprognostic (9.36e-3)"	"unprognostic (5.68e-3)"	"unprognostic (6.97e-3)"	"unprognostic (1.25e-1)"	"prognostic favourable (6.19e-5)"	"unprognostic (2.42e-2)"	"unprognostic (1.85e-2)"	"unprognostic (4.26e-2)"	"unprognostic (2.81e-1)"	"unprognostic (3.26e-1)"	"unprognostic (6.54e-3)"	7.0	10.4	10.6	23.0	11.3	12.2	12.2	24.8	23.2	6.7	14.0	9.4	13.6	16.2	9.6	10.8	12.1	8.4	10.5	6.4	12.8	13.9	12.3	12.9	19.0	21.4	10.8	10.6	5.7	11.6	18.7	14.5	21.6	14.6	10.2	13.5	8.8	13.5	10.8	10.1	28.1	16.4	6.9	6.0	25.8	14.9	26.8	6.9	17.6	12.2	7.4	14.0	8.5	7.8	2.1	0.7	5.2	1.7	0.5	2.6	1.0	4.8	6.2	7.3	12.3	4.6	2.5	8.2	9.0	7.1	6.2	4.6	4.8	5.7	6.1	8.3	6.8	9.3	3.5	7.1	2.4	11.4	6.7	4.5	7.8	4.2	5.5	5.7	21.4	5.1	4.9	6.1	4.7	5.4	9.9	11.1	8.1	14.9	12.8	12.2	8.2	9.0	7.7	3.3	6.8	5.4	5.5	9.3	9.9	8.0	23.5	4.8	4.8	6.9	7.5	12.4	10.6	16.5	6.9	16.6	15.6	6.1	7.0	7.8	13.2	1.7	1.0	3.5	2.0	1.6	1.4	0.9	2.6	1.8	0.7	2.1	1.5	2.2	5.2	0.5	1.7	0.6	0.2	1.0	10.6	11.3	24.8	23.2	12.8	13.9	10.8	10.6	14.6	6.9
CAT		ENSG00000121691	Catalase	P04040	11	34438925-34472062	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Hydrogen peroxide"	"Mitogen, Oxidoreductase, Peroxidase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 258.3;liver: 184.8"	"Cell line enhanced"	"Detected in many"		"HL-60: 75.2;THP-1: 62.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in all"	13	"eosinophil: 258.3"	"Lineage enriched"	"Detected in all"	13	"granulocytes: 258.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001515, HPA051282, HPA055838"	Enhanced		Enhanced	Vesicles			960000000	Vesicles		"CAB001515: AB_384710, HPA051282: AB_2681419, HPA055838: AB_2682937"	"unprognostic (3.62e-2)"	"unprognostic (2.72e-1)"	"unprognostic (3.59e-3)"	"unprognostic (5.43e-2)"	"unprognostic (4.44e-2)"	"unprognostic (5.80e-3)"	"prognostic favourable (9.67e-4)"	"unprognostic (9.95e-3)"	"unprognostic (3.22e-1)"	"unprognostic (7.23e-2)"	"unprognostic (3.34e-2)"	"unprognostic (9.77e-2)"	"prognostic favourable (1.96e-8)"	"unprognostic (1.01e-1)"	"unprognostic (7.31e-2)"	"unprognostic (4.77e-2)"	"unprognostic (6.59e-3)"	70.0	33.0	9.4	10.1	9.6	54.2	36.1	3.1	7.7	15.3	26.6	18.6	15.7	22.2	13.5	9.5	14.8	14.2	19.0	22.4	10.7	5.2	50.4	184.8	26.1	21.3	14.5	6.0	11.0	24.7	7.1	5.0	16.4	10.2	23.2	11.3	11.4	14.5	13.2	27.8	19.7	29.2	11.6	11.3	17.9	15.9	6.2	11.6	23.4	41.7	14.9	11.5	20.4	24.9	7.6	19.9	258.3	17.5	5.5	5.0	17.8	6.1	6.8	5.0	7.8	48.4	21.1	10.6	7.8	9.9	8.8	9.7	3.8	6.2	15.2	7.6	15.5	14.7	8.4	8.5	9.8	13.2	7.7	12.8	7.3	21.9	5.7	75.2	6.4	11.3	5.9	2.6	1.0	10.6	26.5	6.3	11.1	5.8	15.4	13.4	0.0	16.6	10.9	23.8	12.4	24.1	23.3	2.6	4.0	8.8	14.2	11.6	20.3	62.8	7.5	5.3	5.2	13.2	4.6	5.1	2.9	3.2	10.4	51.8	3.8	12.5	17.5	258.3	3.2	14.7	3.8	7.6	3.8	3.6	19.9	6.8	3.8	4.0	17.1	5.5	15.5	13.4	5.0	17.8	9.4	9.6	3.1	7.7	10.7	5.2	14.5	6.0	10.2	11.6
CCDC93	FLJ10996	ENSG00000125633	"Coiled-coil domain containing 93"	Q567U6	2	117915478-118014133	"Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054183	Approved		Enhanced	"Vesicles,Plasma membrane"				Vesicles	"Plasma membrane"	"HPA054183: "	"unprognostic (1.47e-1)"	"unprognostic (6.55e-2)"	"unprognostic (8.29e-2)"	"unprognostic (1.02e-2)"	"unprognostic (3.32e-2)"	"unprognostic (2.47e-3)"	"prognostic unfavourable (2.97e-6)"	"unprognostic (2.51e-1)"	"unprognostic (8.12e-2)"	"unprognostic (8.99e-2)"	"unprognostic (1.52e-3)"	"unprognostic (8.56e-2)"	"unprognostic (4.87e-1)"	"unprognostic (1.79e-2)"	"unprognostic (2.67e-1)"	"prognostic unfavourable (9.66e-4)"	"unprognostic (2.40e-2)"	23.0	20.6	12.9	21.9	14.3	27.2	14.5	23.9	15.6	12.3	18.1	12.8	16.0	17.3	16.8	16.9	10.9	12.3	14.9	23.4	13.1	13.0	14.6	11.0	15.9	16.0	11.8	11.5	20.3	18.0	24.0	26.8	18.6	13.3	11.4	16.0	14.6	13.6	24.9	20.6	16.0	18.1	17.2	15.1	17.1	12.1	15.9	12.0	17.4	17.1	10.2	20.4	11.9	19.2	4.2	3.0	6.3	5.5	3.9	5.7	2.3	13.5	6.0	16.6	14.6	24.1	16.6	14.1	16.1	10.6	10.6	10.9	13.0	8.7	11.6	11.1	12.6	11.8	9.6	8.3	13.9	15.0	9.8	14.6	10.5	17.4	10.7	15.8	16.7	11.3	8.7	16.6	19.8	11.2	8.0	8.2	11.8	5.8	10.0	17.2	7.5	9.8	12.8	13.0	7.8	8.8	14.5	13.3	7.9	10.5	8.0	11.3	6.7	9.8	15.7	18.3	15.4	15.4	11.1	10.9	11.3	18.4	10.6	11.8	10.6	6.3	4.2	4.5	5.7	5.5	5.6	4.2	4.1	4.7	3.0	4.1	5.6	4.8	4.4	3.9	3.4	1.5	1.8	2.3	12.9	14.3	23.9	15.6	13.1	13.0	11.8	11.5	13.3	12.0
CCZ1	"C7orf28A, CCZ1A, CGI-43"	ENSG00000122674	"CCZ1 homolog, vacuolar protein trafficking and biogenesis associated"	P86791	7	5898725-5926550	"Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA045114, HPA050006"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA045114: , HPA050006: "	"unprognostic (1.91e-1)"	"unprognostic (2.97e-3)"	"unprognostic (3.15e-2)"	"unprognostic (1.25e-2)"	"unprognostic (1.82e-1)"	"unprognostic (5.35e-2)"	"unprognostic (3.74e-3)"	"unprognostic (4.10e-1)"	"unprognostic (9.25e-3)"	"unprognostic (7.66e-2)"	"unprognostic (6.64e-2)"	"unprognostic (2.67e-2)"	"unprognostic (5.27e-3)"	"unprognostic (3.25e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.74e-1)"	"unprognostic (4.41e-1)"	17.2	33.0	19.0	16.5	22.6	25.7	27.9	19.5	28.2	15.5	15.7	15.4	10.5	16.5	18.9	15.8	23.2	15.2	16.7	23.3	19.1	17.0	15.9	21.2	17.1	32.3	17.8	23.5	13.5	39.1	25.7	17.2	15.7	19.4	15.6	19.9	13.7	28.9	13.9	33.3	19.3	18.5	16.7	18.6	18.4	16.0	36.1	12.6	19.4	17.7	23.9	20.3	19.7	15.8	3.7	7.1	10.2	10.4	9.2	16.6	2.8	47.0	18.4	25.3	32.5	26.3	24.3	17.7	18.8	22.5	18.7	20.0	8.9	24.2	28.9	10.8	28.0	25.5	17.5	20.0	20.5	12.9	26.8	14.5	22.7	16.2	26.6	29.3	17.0	24.7	24.7	13.9	13.5	33.9	33.7	22.3	27.0	28.2	19.3	38.5	47.5	25.0	27.7	25.2	23.5	15.1	28.4	24.2	43.3	18.2	36.4	19.0	26.8	37.3	25.4	19.0	49.4	22.3	29.6	17.0	28.8	34.6	12.9	39.3	41.3	10.2	4.9	8.6	5.5	7.6	5.5	3.7	7.2	7.1	7.1	2.7	4.6	5.4	4.7	9.2	10.4	4.3	16.6	2.8	19.0	22.6	19.5	28.2	19.1	17.0	17.8	23.5	19.4	12.6
CCZ1B	"C7orf28B, DKFZP586I1023, H_NH0577018.2, MGC19819"	ENSG00000146574	"CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated"	P86790	7	6794134-6826770	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA045114, HPA050006"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA045114: , HPA050006: "	"unprognostic (8.06e-3)"	"unprognostic (1.53e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.00e-1)"	"unprognostic (4.94e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.88e-3)"	"unprognostic (2.74e-1)"	"unprognostic (9.14e-2)"	"unprognostic (1.06e-1)"	"unprognostic (2.15e-1)"	"unprognostic (2.86e-1)"	"unprognostic (2.96e-3)"	"unprognostic (9.61e-2)"	"unprognostic (1.27e-1)"	"unprognostic (2.73e-2)"	"unprognostic (1.24e-1)"	2.5	4.5	3.6	2.1	4.4	3.2	4.2	3.8	8.4	2.7	3.5	10.7	2.1	2.6	3.5	7.0	5.7	5.3	3.5	2.6	4.0	3.6	3.0	2.4	3.4	3.7	2.9	2.1	3.0	3.3	11.8	2.6	2.7	9.1	3.0	2.5	5.2	6.6	7.0	10.6	3.4	2.7	2.1	2.7	3.0	3.2	5.4	2.1	3.0	2.5	2.1	3.5	4.3	2.6	4.3	5.6	10.5	9.5	6.1	6.6	1.8	12.8	4.7	9.3	23.1	8.3	8.2	10.3	8.0	12.1	9.8	10.8	5.3	8.5	5.4	9.6	11.5	8.8	17.5	10.1	11.1	3.2	6.2	3.8	5.7	13.2	8.6	27.2	19.3	5.4	5.4	9.3	4.9	8.4	7.2	6.3	9.7	22.1	13.0	12.2	25.9	8.7	8.1	20.0	6.7	7.2	9.6	14.5	23.2	9.0	17.6	12.0	14.4	31.2	9.2	2.7	8.7	11.3	17.2	6.4	13.1	3.9	9.0	28.5	16.6	10.5	3.8	6.5	3.8	4.6	4.5	4.3	4.5	5.6	4.8	3.9	3.2	4.2	4.8	6.1	9.5	5.6	6.6	1.8	3.6	4.4	3.8	8.4	4.0	3.6	2.9	2.1	9.1	2.1
CD24	CD24A	ENSG00000272398	"CD24 molecule"		6	106969831-106975627	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"				"Tissue enriched"	"Detected in many"	6	"kidney: 383.7"	"Cell line enhanced"	"Detected in many"		"NTERA-2: 65.1;RPTEC TERT1: 307.7;SK-BR-3: 89.5"	"Low cancer specificity"	"Detected in all"							"Group enriched"	"Detected in some"	26	"eosinophil: 30.4;memory B-cell: 23.4;naive B-cell: 15.0"	"Group enriched"	"Detected in many"	202	"B-cells: 23.4;granulocytes: 30.4"									"HPA045879, CAB078471"			Enhanced	Vesicles	"Intracellular and membrane"			Vesicles		"CAB078471: AB_10983158, HPA045879: "	"prognostic unfavourable (2.44e-5)"	"unprognostic (6.64e-2)"	"prognostic favourable (3.29e-4)"	"unprognostic (1.87e-1)"	"unprognostic (1.41e-2)"	"unprognostic (9.98e-2)"	"prognostic unfavourable (7.58e-4)"	"unprognostic (2.32e-1)"	"unprognostic (2.74e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.51e-1)"	"unprognostic (5.10e-2)"	"unprognostic (2.92e-1)"	"unprognostic (1.16e-1)"	"unprognostic (2.01e-1)"	"unprognostic (3.13e-1)"	0.5	0.5	12.8	2.4	9.9	17.9	25.5	0.5	2.9	69.5	30.6	0.7	1.6	1.2	34.5	5.9	38.1	6.0	25.1	4.2	22.7		383.7	0.8	0.7	0.9	4.8	7.2	15.6	40.0	0.0	5.7	48.2	13.0	3.2	21.2	0.7	15.9	16.6	0.4	0.5	0.8	2.2	4.9	0.7	16.4	0.5	6.5	0.4	48.8	1.2	11.3	4.0	8.1	23.4	0.0	30.4	0.1	0.0	0.0	0.6	22.9	14.2	0.2	1.8	0.0	0.0	27.0	0.0	0.1	0.1	0.0	0.2	0.1	2.2	7.1	0.0	47.5	8.1	17.9	0.1	0.0	0.1	0.0	17.6	1.0	0.0	0.3	0.1	0.1	20.7	0.2	1.2	0.1	0.5	0.0	0.4	28.8	0.1	0.1	65.1	5.5	53.8	0.0	0.2	307.7	59.3	40.3	29.7	16.3	89.5	0.0	41.3	0.1	0.0	0.0	0.2	0.2	0.7	0.0	0.1	30.4	0.3	0.1	0.1	0.1	0.0	30.4	0.0	0.0	0.0	23.4	0.0	0.0	0.0	15.0	0.0	0.0	0.8	0.0	0.1	0.0	0.0	0.6										
CDKL1	KKIALRE	ENSG00000100490	"Cyclin dependent kinase like 1"	Q00532	14	50329404-50416461	"Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"SK-BR-3: 16.5"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA059605, HPA065919"	Uncertain		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"HPA059605: , HPA065919: "	"unprognostic (4.12e-3)"	"unprognostic (3.22e-1)"	"unprognostic (4.54e-2)"	"unprognostic (8.04e-2)"	"unprognostic (1.64e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.23e-3)"	"unprognostic (9.36e-3)"	"unprognostic (2.63e-1)"	"unprognostic (9.99e-2)"	"unprognostic (1.20e-1)"	"unprognostic (9.36e-2)"	"unprognostic (5.53e-8)"	"unprognostic (1.21e-1)"	"unprognostic (7.96e-2)"	"unprognostic (9.39e-3)"	"unprognostic (3.31e-3)"	7.1	2.1	7.5	1.8	5.1	0.9	3.0	2.7	20.2	14.1	5.9	1.6	2.5	8.4	12.1	2.3	2.6	16.4	2.6	2.9	7.1	2.4	18.8	1.1	4.3	3.0	2.0	12.3	10.5	2.0	1.4	1.4	4.9	2.9	4.0	5.7	1.6	2.5	8.4	1.7	3.0	3.0	7.7	3.1	3.7	2.0	1.9	1.4	1.3	5.0	6.1	2.1	7.0	5.6	5.7	1.3	6.0	2.5	3.8	6.7	2.6	6.0	4.8	0.6	2.4	6.5	7.8	0.3	2.1	3.8	2.2	2.5	1.9	5.7	0.4	2.6	4.6	4.2	0.9	0.6	2.5	6.6	2.3	6.4	2.1	1.7	7.3	5.8	3.5	1.7	3.5	4.5	10.0	8.4	2.6	2.6	1.0	0.3	1.9	3.1	0.7	2.3	0.7	2.8	1.8	6.9	2.3	1.1	1.3	2.4	16.5	0.6	0.2	4.9	2.6	5.7	2.9	5.6	4.7	0.8	0.4	0.4	0.9	6.1	6.9	6.0	2.5	4.4	6.3	2.3	6.2	4.6	4.4	6.7	1.3	5.7	3.4	3.7	1.4	3.8	0.3	1.2	4.1	2.6	7.5	5.1	2.7	20.2	7.1	2.4	2.0	12.3	2.9	1.4
CHGB	"SCG1, SgI"	ENSG00000089199	"Chromogranin B"	P05060	20	5911430-5925361	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 424.9;pituitary gland: 177.5"	"Group enriched"	"Detected in some"	23	"SCLC-21H: 65.1;SH-SY5Y: 99.7"	"Cancer enriched"	"Detected in many"	6	"pancreatic cancer: 154.2"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 2.6;T-reg: 1.1"	"Lineage enhanced"	"Detected in single"		"T-cells: 2.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008759, CAB009403, HPA012602"	Enhanced	Supported	Enhanced	Vesicles	"Intracellular and membrane"		24000000	Vesicles		"CAB009403: AB_2081255, HPA008759: AB_1846704, HPA012602: AB_1846706"	"unprognostic (1.79e-3)"	"unprognostic (7.72e-2)"	"unprognostic (3.48e-1)"	"unprognostic (2.90e-2)"	"unprognostic (1.68e-2)"	"prognostic unfavourable (1.89e-4)"	"unprognostic (7.96e-3)"	"unprognostic (2.86e-1)"	"unprognostic (6.18e-3)"	"unprognostic (7.93e-2)"	"prognostic favourable (9.96e-4)"	"unprognostic (8.56e-2)"	"unprognostic (8.21e-2)"	"unprognostic (1.56e-1)"	"unprognostic (2.81e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.01e-2)"	3.4	424.9	8.2	1.4	10.2	0.8	1.0	82.5	16.4	0.8	3.0	2.1	1.2	7.7	0.9	1.3	0.8	2.5	0.8	7.6	20.7	15.4	1.7	0.7	1.0	1.1	7.2	9.1	3.0	17.0	0.8	177.5	0.8	51.8	5.6	2.5	0.7	0.9	1.2	2.1	0.9	4.4	0.9	2.3	0.8	19.7	2.4	0.8	0.0	1.9	0.4	0.9	0.8	0.1	0.0	0.6	0.0	0.0	0.0	2.6	0.2	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.2	0.0	0.7	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.1	3.5	0.0	0.0	0.0	0.0	0.0	0.0	65.1	99.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.5	0.0	0.1	0.4	0.1	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.1	0.2	8.2	10.2	82.5	16.4	20.7	15.4	7.2	9.1	51.8	0.8
CHIC2	BTL	ENSG00000109220	"Cysteine rich hydrophobic domain 2"	Q9UKJ5	4	54009789-54064690	"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026782, HPA026784, HPA076603"	Uncertain		Enhanced	"Vesicles,Plasma membrane"				"Vesicles, Plasma membrane"		"HPA026782: AB_1846654, HPA026784: , HPA076603: "	"unprognostic (4.56e-2)"	"unprognostic (2.24e-3)"	"unprognostic (3.47e-3)"	"unprognostic (9.58e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.25e-2)"	"unprognostic (7.87e-2)"	"unprognostic (1.22e-1)"	"unprognostic (3.65e-2)"	"unprognostic (7.81e-3)"	"unprognostic (2.94e-2)"	"unprognostic (5.63e-2)"	"prognostic unfavourable (1.56e-4)"	"unprognostic (2.89e-1)"	"unprognostic (1.77e-1)"	"unprognostic (4.56e-2)"	"unprognostic (9.40e-2)"	17.0	17.5	9.5	14.6	9.7	23.7	17.1	17.9	12.0	12.8	14.2	7.1	11.9	13.0	16.8	14.9	25.3	11.0	22.1	14.3	7.3	7.9	12.3	20.2	17.7	13.5	6.6	10.0	13.2	9.9	5.5	16.7	18.5	9.9	12.3	9.6	15.9	15.3	9.9	10.9	24.7	20.6	10.8	8.1	18.5	12.9	50.1	8.3	32.3	11.8	11.6	20.5	12.9	16.3	8.4	10.9	63.8	15.9	13.6	15.6	13.6	11.5	2.1	6.4	5.6	10.7	8.2	6.3	16.0	17.0	9.6	9.7	8.3	10.4	9.8	14.4	10.3	3.5	8.6	11.7	10.4	5.4	4.4	5.3	2.0	6.2	32.1	8.7	11.1	11.1	9.6	14.5	22.2	14.0	5.7	7.4	19.1	3.1	10.2	14.0	4.2	7.9	6.6	3.5	3.8	11.0	3.9	9.3	8.8	3.8	5.6	11.7	3.0	13.0	23.9	12.3	9.6	17.6	10.3	8.8	4.2	8.0	9.1	8.7	8.9	56.0	15.9	32.2	12.6	12.4	12.1	8.4	12.8	14.2	10.9	8.2	11.8	12.7	63.8	13.6	12.5	9.1	15.6	13.6	9.5	9.7	17.9	12.0	7.3	7.9	6.6	10.0	9.9	8.3
CLIP4	"FLJ21069, RSNL2"	ENSG00000115295	"CAP-Gly domain containing linker protein family member 4"	Q8N3C7	2	29097705-29189643	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 29.9;hTERT-HME1: 31.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043366, HPA056246"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA043366: AB_10963051, HPA056246: "	"unprognostic (1.97e-2)"	"unprognostic (1.49e-2)"	"unprognostic (2.14e-2)"	"unprognostic (2.47e-3)"	"unprognostic (3.64e-1)"	"unprognostic (6.82e-2)"	"unprognostic (1.15e-2)"	"unprognostic (8.82e-3)"	"unprognostic (3.62e-1)"	"unprognostic (4.32e-2)"	"unprognostic (2.73e-1)"	"unprognostic (7.99e-2)"	"prognostic unfavourable (1.83e-4)"	"unprognostic (3.59e-3)"	"unprognostic (6.35e-2)"	"unprognostic (2.14e-1)"	"unprognostic (1.99e-2)"	16.8	9.7	12.1	8.6	19.5	2.0	18.8	12.7	19.7	8.3	13.4	17.3	7.2	4.8	13.1	8.8	22.1	12.5	12.7	26.6	13.7	12.1	7.7	4.6	17.2	8.7	19.8	12.8	22.3	6.2	12.1	22.9	39.2	15.8	16.5	7.1	15.7	10.4	15.2	46.0	28.0	7.3	23.5	18.4	9.1	8.1	15.2	14.4	7.1	31.1	16.8	9.8	19.6	13.0	1.1	1.8	1.3	17.5	3.9	9.8	3.7	28.7	8.0	1.2	4.4	11.8	17.8	0.0	11.4	19.6	6.4	7.4	0.2	19.0	3.6	5.8	19.6	11.9	1.3	8.8	9.2	6.6	1.9	0.0	10.1	0.4	29.9	0.0	5.9	12.4	22.6	8.5	31.0	4.4	0.1	11.4	9.7	0.2	2.7	1.2	0.3	1.8	0.0	7.3	0.5	11.8	5.1	1.9	5.0	9.9	4.0	10.3	0.0	1.7	14.0	1.5	11.7	5.0	4.9	5.9	0.0	0.0	7.0	0.0	4.6	1.3	4.6	0.1	6.3	10.7	9.8	1.1	4.8	6.5	1.8	0.4	5.5	5.4	0.9	3.9	17.5	0.0	1.7	3.7	12.1	19.5	12.7	19.7	13.7	12.1	19.8	12.8	15.8	14.4
CLOCK	"bHLHe8, KAT13D, KIAA0334"	ENSG00000134852	"Clock circadian regulator"	O15516	4	55427903-55547138	"Enzymes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, DNA damage, Transcription, Transcription regulation"	"Activator, Acyltransferase, DNA-binding, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001867, HPA027565"	Supported		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA001867: AB_1078537, HPA027565: AB_1846975"	"unprognostic (1.30e-2)"	"unprognostic (9.02e-2)"	"unprognostic (4.25e-3)"	"unprognostic (2.48e-1)"	"unprognostic (3.94e-2)"	"unprognostic (2.00e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.52e-2)"	"unprognostic (4.32e-2)"	"unprognostic (3.01e-2)"	"unprognostic (5.96e-2)"	"unprognostic (4.07e-2)"	"unprognostic (8.31e-2)"	"unprognostic (1.69e-1)"	"unprognostic (5.18e-2)"	"unprognostic (7.16e-2)"	9.3	9.2	7.8	5.8	11.7	1.7	8.4	16.2	14.3	12.5	9.5	5.2	9.2	7.1	10.5	8.4	13.9	8.1	6.7	10.5	7.9	7.9	12.4	9.1	8.2	9.4	7.0	9.8	11.7	8.6	18.7	21.9	8.5	8.4	9.7	8.4	5.6	8.2	9.2	16.1	9.4	12.6	13.8	8.3	9.1	9.6	18.5	5.0	4.0	14.7	5.9	5.2	8.4	17.1	2.5	3.6	0.6	3.0	2.9	4.7	1.4	13.4	5.9	5.3	8.3	8.0	8.1	2.6	13.9	11.4	9.7	9.0	3.7	10.7	3.6	7.2	16.1	11.3	6.8	10.8	16.5	4.4	2.4	2.9	6.2	4.6	7.1	4.7	3.4	4.7	10.7	13.4	13.2	9.1	6.6	7.4	14.6	7.4	2.6	2.6	3.8	6.8	1.7	6.1	2.4	7.5	7.3	5.2	4.7	10.0	12.4	6.3	4.2	2.6	12.5	13.2	14.1	4.3	18.7	6.7	4.8	2.3	11.7	4.2	10.4	0.0	3.0	0.6	2.8	3.0	4.7	1.4	3.2	2.5	3.6	2.5	1.9	2.4	0.6	2.9	2.7	2.1	3.1	1.4	7.8	11.7	16.2	14.3	7.9	7.9	7.0	9.8	8.4	5.0
CLTA	Lca	ENSG00000122705	"Clathrin light chain A"	P09496	9	36190856-36304781	"Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002665, HPA050918, HPA054667"	Enhanced		Enhanced	Vesicles,Endosomes,Lysosomes			2100000	"Vesicles, Endosomes, Lysosomes"		"CAB002665: , HPA050918: , HPA054667: "	"prognostic favourable (5.64e-4)"	"unprognostic (7.62e-2)"	"unprognostic (9.22e-2)"	"unprognostic (8.45e-3)"	"unprognostic (1.71e-1)"	"unprognostic (1.92e-1)"	"prognostic unfavourable (9.46e-5)"	"unprognostic (1.42e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.92e-3)"	"unprognostic (7.27e-2)"	"unprognostic (2.15e-1)"	"unprognostic (1.23e-3)"	"unprognostic (5.92e-2)"	"unprognostic (1.56e-1)"	"prognostic favourable (1.01e-4)"	"unprognostic (4.98e-2)"	60.0	64.8	65.0	46.9	60.8	35.4	55.5	68.6	86.3	58.1	71.4	55.5	35.8	65.6	58.1	64.5	63.8	65.2	56.4	31.4	62.6	62.0	72.2	60.0	48.7	53.1	67.1	67.0	78.1	52.8	42.8	47.0	78.2	67.9	53.3	67.6	48.1	58.8	47.6	33.2	47.5	58.3	52.4	71.5	59.6	56.3	48.3	41.9	58.2	77.1	49.4	54.5	46.2	60.5	31.3	57.3	29.1	59.5	22.6	40.5	45.9	60.3	48.5	36.6	27.8	53.5	53.9	59.0	62.7	47.8	50.5	59.5	36.3	27.2	45.7	34.8	41.7	25.8	45.8	43.6	46.5	30.9	37.0	35.0	49.4	37.1	71.9	37.1	32.5	59.2	48.4	57.9	46.0	62.3	30.4	24.1	76.0	21.0	33.3	47.3	58.4	69.5	32.2	24.3	25.9	68.2	43.3	28.4	47.8	26.2	30.8	51.5	27.8	45.9	79.6	40.8	45.9	46.6	65.2	16.2	38.0	48.5	50.3	52.2	35.9	29.1	56.6	28.0	26.5	59.5	27.8	31.3	28.9	27.2	57.3	30.6	26.4	22.8	22.2	22.6	45.6	49.5	40.5	45.9	65.0	60.8	68.6	86.3	62.6	62.0	67.1	67.0	67.9	41.9
CLTC	"CLTCL2, Hc"	ENSG00000141367	"Clathrin heavy chain"	Q00610	17	59619689-59696956	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Autophagy, Cell cycle, Cell division, Mitosis"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"CAB010389, CAB011571, CAB017155, HPA059143"	Approved		Enhanced	"Vesicles,Endosomes,Lysosomes,Mitotic spindle,Cytosol"			51000000	"Vesicles, Endosomes, Lysosomes"	"Mitotic spindle, Cytosol"	"CAB010389: AB_2083184, CAB011571: AB_2083165, CAB017155: , HPA059143: "	"unprognostic (1.56e-1)"	"prognostic unfavourable (7.35e-4)"	"prognostic favourable (7.65e-4)"	"unprognostic (1.03e-1)"	"unprognostic (2.62e-1)"	"unprognostic (5.23e-3)"	"prognostic unfavourable (5.54e-4)"	"unprognostic (1.11e-1)"	"unprognostic (6.43e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.22e-2)"	"unprognostic (1.10e-1)"	"prognostic unfavourable (2.02e-4)"	39.5	45.7	47.4	35.1	57.6	30.7	57.9	59.1	83.6	38.1	45.0	25.1	47.7	27.9	38.7	52.3	32.1	30.9	34.1	39.9	47.1	53.7	48.6	46.0	46.5	60.7	53.9	59.3	29.8	23.3	96.1	30.0	51.5	57.0	38.9	48.9	22.7	28.6	54.4	44.2	30.5	27.7	45.8	47.8	28.0	34.2	29.4	28.8	28.0	43.7	26.6	31.2	37.1	40.6	10.0	24.6	13.9	24.6	12.3	15.6	13.1	46.9	71.1	35.1	34.7	59.3	48.3	40.1	50.5	53.3	45.3	47.3	43.5	28.9	32.7	58.0	71.7	31.0	52.2	42.0	60.5	35.1	28.1	53.6	45.0	67.5	45.2	36.6	31.0	45.7	25.7	68.8	44.4	50.0	53.3	46.3	70.5	83.7	21.7	10.9	30.2	41.5	19.3	58.8	39.6	50.7	66.7	31.5	37.5	31.3	20.5	29.9	48.7	23.1	63.9	83.1	49.6	39.6	51.7	36.5	51.2	30.2	60.9	24.8	50.7	10.5	20.9	13.9	12.7	24.6	15.6	10.0	11.7	13.7	24.6	9.1	10.0	11.0	13.4	12.3	20.7	16.1	14.5	13.1	47.4	57.6	59.1	83.6	47.1	53.7	53.9	59.3	57.0	28.8
CNNM2	ACDP2	ENSG00000148842	"Cyclin and CBS domain divalent metal cation transport mediator 2"	Q9H8M5	10	102918293-103090221	"Disease related genes, Predicted membrane proteins"	"Ion transport, Transport"		"Disease mutation, Epilepsy, Mental retardation, Primary hypomagnesemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 35.6"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA059954, HPA071631"			Enhanced	Vesicles				Vesicles		"HPA059954: , HPA071631: "	"unprognostic (2.18e-1)"	"unprognostic (6.46e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.65e-3)"	"unprognostic (3.19e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.93e-1)"	"unprognostic (4.80e-2)"	"unprognostic (4.51e-3)"	"unprognostic (3.75e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.39e-1)"	"prognostic favourable (2.39e-8)"	"unprognostic (2.44e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.65e-3)"	"unprognostic (1.56e-1)"	5.7	19.8	9.5	6.6	13.8	13.3	5.0	16.8	15.1	6.0	11.8	12.5	8.0	6.9	6.6	5.8	3.3	8.9	9.4	4.1	7.8	10.9	15.6	7.9	6.4	4.1	10.4	8.6	8.8	6.8	35.6	10.6	14.3	9.6	5.0	11.2	7.7	5.2	7.1	3.0	7.2	7.7	6.9	9.3	4.1	5.4	8.0	12.7	3.3	10.0	1.9	3.0	6.2	5.4	1.3	1.3	2.8	0.8	4.5	1.1	0.4	4.6	7.7	3.1	8.1	7.8	3.1	8.3	2.2	9.3	3.0	3.8	5.4	4.2	1.8	3.4	3.2	6.2	6.5	4.3	2.3	3.0	11.5	2.6	4.2	11.0	4.5	1.8	3.5	4.2	6.3	3.0	10.4	1.8	4.4	10.5	1.7	7.9	2.1	2.1	4.9	4.8	5.1	3.9	2.2	2.3	2.8	4.4	5.6	5.5	1.3	5.8	10.0	3.5	1.5	4.2	6.2	2.9	3.9	11.4	12.7	3.3	7.3	6.2	1.7	1.9	0.8	0.7	1.0	0.8	0.8	1.3	0.7	0.5	0.6	0.7	0.8	0.7	2.8	4.5	0.4	1.3	1.1	0.4	9.5	13.8	16.8	15.1	7.8	10.9	10.4	8.6	9.6	12.7
CSF2	"GM-CSF, GMCSF"	ENSG00000164400	"Colony stimulating factor 2"	P04141	5	132073790-132076170	"Cancer-related genes, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 9.5;lung: 6.8;pancreas: 4.5"	"Cell line enriched"	"Detected in some"	4	"BJ hTERT+: 44.0"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	11	"NK-cell: 9.5"	"Lineage enriched"	"Detected in single"	11	"NK-cells: 9.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA057404, HPA062006"			Enhanced	Vesicles	"Secreted to blood"	36150		Vesicles		"HPA057404: , HPA062006: "	"unprognostic (7.29e-2)"	"unprognostic (2.49e-3)"	"unprognostic (8.77e-2)"	"unprognostic (2.09e-2)"		"unprognostic (1.05e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.47e-2)"	"unprognostic (2.64e-1)"	"unprognostic (3.68e-3)"		"unprognostic (1.87e-8)"	"unprognostic (4.81e-2)"	"unprognostic (1.22e-1)"	"unprognostic (9.07e-2)"	"unprognostic (2.06e-2)"	0.2	0.1	0.1	3.9	0.1	1.1	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.0	0.7	0.0	1.5	0.1	1.1	0.2	0.1	0.1	0.3	0.9	6.8	0.3	0.1	0.0	0.1	4.5	0.0	0.1	0.5	0.0	0.2	0.7	0.0	1.9	0.0	0.1	0.4	1.0	0.6	0.1	1.0	0.2	0.2	0.0	0.4	0.2	0.0	1.8	2.3	0.1	0.0	0.0	0.0	0.0	9.5	0.8	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	44.0	0.0	2.5	0.0	3.5	0.0	0.7	0.0	0.1	0.0	3.2	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	10.2	6.8	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.4	0.1	1.8	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.0	0.0	9.5	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
CSTF2T	"CstF-64T, DKFZp434C1013, KIAA0689, tauCstF-64"	ENSG00000177613	"Cleavage stimulation factor subunit 2 tau variant"	Q9H0L4	10	51695487-51699591	"Predicted intracellular proteins"	"mRNA processing"	RNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039216, HPA062021"	Approved		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA039216: AB_10795462, HPA062021: "	"unprognostic (2.60e-2)"	"unprognostic (3.75e-2)"	"unprognostic (2.93e-2)"	"unprognostic (2.17e-1)"	"unprognostic (8.59e-2)"	"unprognostic (1.06e-1)"	"unprognostic (4.06e-3)"	"unprognostic (9.13e-2)"	"unprognostic (1.19e-1)"	"unprognostic (3.42e-1)"	"unprognostic (5.92e-2)"	"unprognostic (5.36e-2)"	"unprognostic (7.63e-2)"	"unprognostic (5.19e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.31e-1)"	"unprognostic (1.96e-1)"	20.2	23.5	16.5	20.0	21.6	14.0	15.2	16.2	24.0	14.8	13.5	29.6	9.9	14.3	16.8	13.4	13.1	19.0	12.7	17.4	18.4	16.6	15.5	15.4	11.9	21.7	21.3	16.5	23.3	16.3	30.2	14.1	14.6	23.5	15.8	13.5	12.6	13.4	12.5	25.0	13.3	16.8	16.8	28.0	24.6	17.7	11.6	20.1	31.9	17.0	12.6	22.9	17.0	13.2	4.6	5.5	5.5	5.1	13.9	6.8	3.2	8.3	10.0	15.1	15.8	21.3	14.6	1.0	11.9	11.1	13.8	13.5	13.2	12.3	24.2	6.9	10.4	13.2	11.3	12.5	12.6	14.0	12.8	13.9	10.6	2.4	10.3	5.3	12.8	21.0	9.7	12.1	14.1	10.3	14.9	13.8	11.9	7.1	21.8	8.6	5.5	21.6	17.4	30.4	5.1	10.6	7.0	12.7	16.3	9.9	10.4	10.6	19.4	10.0	10.9	8.8	12.1	8.1	14.8	17.6	6.5	17.4	18.4	12.6	7.6	3.7	5.0	5.5	4.9	5.1	6.8	2.3	3.6	3.8	5.5	4.6	6.2	5.3	1.5	13.9	3.4	3.5	5.7	3.2	16.5	21.6	16.2	24.0	18.4	16.6	21.3	16.5	23.5	20.1
CTAG2	"CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803"	ENSG00000126890	"Cancer/testis antigen 2"	O75638	X	154651972-154653579	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"heart muscle: 8.5;skeletal muscle: 5.7;testis: 11.9"	"Group enriched"	"Detected in some"	37	"K-562: 28.2;RPMI-8226: 62.9;SK-BR-3: 41.1;U-266/84: 71.2"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA071467, HPA076586"	Enhanced		Enhanced	"Nucleoplasm,Nuclear bodies,Vesicles"				"Nucleoplasm, Vesicles"	"Nuclear bodies"	"HPA071467: , HPA076586: "							"prognostic unfavourable (2.35e-4)"		"unprognostic (3.87e-1)"						"unprognostic (1.00e-1)"		"unprognostic (1.25e-2)"	0.2	1.0	0.4	0.0	0.0	0.2	0.1	0.2	0.5	0.0	0.2			0.0	0.0	0.0	1.0	2.9	0.0	8.5	0.0	0.0	0.1	0.8	0.2	0.0	0.2		0.8	3.6	0.0	0.4	4.4		0.2	0.0		0.1	0.0	5.7	0.2	0.0	0.0	0.0	0.3	0.6	11.9			0.0		0.0	0.0	0.6	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	62.9	0.0	0.0	0.0	0.0	0.0	41.1	0.0	0.0	0.1	0.0	1.3	0.0	0.1	0.0	0.5	71.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CTSA	"GSL, PPGB"	ENSG00000064601	"Cathepsin A"	P10619	20	45890144-45898820	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"		"Carboxypeptidase, Hydrolase, Protease"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 125.7"	"Cell line enhanced"	"Detected in all"		"ASC diff: 116.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB024930, HPA031068"	Enhanced		Enhanced	Vesicles	"Intracellular and membrane"		18000000	Vesicles		"CAB024930: , HPA031068: AB_10601205"	"unprognostic (8.61e-2)"	"unprognostic (3.37e-1)"	"unprognostic (4.30e-2)"	"unprognostic (2.13e-1)"	"unprognostic (6.42e-2)"	"unprognostic (2.21e-1)"	"prognostic unfavourable (1.95e-4)"	"unprognostic (6.33e-2)"	"unprognostic (9.53e-3)"	"unprognostic (7.19e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.85e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.09e-1)"	"unprognostic (6.05e-2)"	"unprognostic (1.71e-1)"	"unprognostic (8.40e-2)"	29.0	125.7	12.0	22.8	19.5	22.1	35.3	11.4	30.0	14.1	50.6	17.4	16.2	29.4	18.2	19.3	20.7	12.7	28.0	32.6	11.5	11.6	88.2	43.8	28.4	38.9	12.3	16.1	23.9	19.2	28.3	16.5	47.7	15.7	18.2	50.5	30.1	20.5	15.1	19.3	28.2	40.6	19.6	11.9	38.8	19.7	14.3	11.2	8.0	18.1	24.9	22.4	23.3	18.7	7.0	16.6	81.1	46.1	12.0	31.2	50.0	14.4	14.9	2.8	12.7	116.2	60.2	6.4	20.8	55.4	22.8	29.7	27.9	38.9	3.1	24.1	38.9	23.1	7.5	14.0	14.3	6.0	7.0	8.2	10.4	48.6	25.9	13.0	33.9	47.8	16.9	14.7	3.3	24.8	8.1	47.8	24.7	29.7	3.3	12.0	2.8	35.4	5.2	14.5	17.2	18.2	12.7	5.6	5.3	34.6	60.6	58.0	14.8	18.7	22.8	45.8	10.7	25.9	16.3	23.6	29.7	2.2	82.5	17.3	18.8	60.6	46.1	81.1	7.5	26.6	31.2	7.0	12.9	13.2	16.6	3.6	4.7	6.9	24.7	12.0	17.7	6.6	23.9	50.0	12.0	19.5	11.4	30.0	11.5	11.6	12.3	16.1	15.7	11.2
CYB5A	CYB5	ENSG00000166347	"Cytochrome b5 type A"	P00167	18	74250847-74292016	"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Transport"		"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 266.8"	"Cell line enhanced"	"Detected in many"		"ASC diff: 151.3;RT4: 66.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB006333, HPA047548, HPA058547"	Enhanced		Enhanced	Vesicles,Cytosol			780000	"Vesicles, Cytosol"		"CAB006333: , HPA047548: , HPA058547: "	"unprognostic (1.88e-1)"	"unprognostic (1.28e-1)"	"prognostic favourable (5.23e-4)"	"unprognostic (1.08e-2)"	"unprognostic (1.41e-1)"	"unprognostic (9.14e-2)"	"prognostic favourable (4.15e-4)"	"unprognostic (7.79e-3)"	"unprognostic (1.11e-1)"	"unprognostic (3.33e-2)"	"unprognostic (2.68e-2)"	"unprognostic (1.65e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.75e-1)"	"unprognostic (4.64e-2)"	"unprognostic (8.54e-2)"	25.0	13.2	4.3	11.0	5.8	1.5	39.4	6.9	5.9	7.5	68.2	4.3	38.5	37.7	4.9	16.0	8.3	7.0	34.8	14.5	4.1	3.7	76.2	266.8	67.0	9.2	6.5	3.4	25.1	75.3	10.1	6.5	7.2	5.2	13.5	9.0	6.2	7.6	54.9	4.3	11.4	70.7	21.2	11.5	10.3	18.0	12.2	5.5	4.6	4.6	7.9	4.3	21.6	18.8	34.9	16.9	2.1	12.9	10.2	38.0	13.5	9.8	16.8	8.8	0.0	151.3	26.9	11.7	6.8	14.7	14.5	21.8	19.8	10.7	12.0	4.8	12.4	22.0	0.0	9.3	11.6	22.4	11.7	4.4	9.2	52.5	23.5	8.4	5.8	45.0	7.4	8.2	4.2	7.9	7.1	4.5	12.1	17.7	4.7	10.0	3.9	10.9	11.7	2.8	0.2	14.4	66.0	25.1	10.4	6.6	18.0	8.0	35.6	8.0	7.4	0.0	11.4	3.5	8.6	3.2	13.0	3.7	8.9	2.3	8.4	1.1	9.6	2.1	16.7	10.8	38.0	28.5	18.7	19.6	16.9	34.9	18.4	23.1	1.1	10.2	12.9	14.8	14.4	13.5	4.3	5.8	6.9	5.9	4.1	3.7	6.5	3.4	5.2	5.5
CYP27C1	FLJ16008	ENSG00000186684	"Cytochrome P450 family 27 subfamily C member 1"	Q4G0S4	2	127184120-127220078	"Enzymes, Predicted intracellular proteins"		"Monooxygenase, Oxidoreductase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skin 1: 10.6"	"Cell line enhanced"	"Detected in many"		"HaCaT: 8.6;HDLM-2: 12.4;TIME: 12.5;U-138 MG: 12.7;U-251 MG: 8.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in some"			"HPA062460, HPA068731"			Enhanced	Vesicles				Vesicles		"HPA062460: , HPA068731: "	"unprognostic (1.90e-1)"	"unprognostic (4.07e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.38e-2)"	"unprognostic (3.03e-1)"	"unprognostic (7.75e-3)"	"unprognostic (3.48e-1)"	"unprognostic (2.31e-3)"	"unprognostic (4.38e-2)"	"unprognostic (3.15e-1)"	"unprognostic (1.81e-3)"	"unprognostic (1.11e-1)"	"unprognostic (6.29e-4)"	"unprognostic (3.49e-4)"	"unprognostic (1.83e-1)"	"unprognostic (4.27e-2)"	"unprognostic (8.64e-2)"	2.7	1.0	0.6	2.4	2.4	0.8	0.6	0.4	1.8	5.2	1.9	1.5	0.4	0.5	1.3	0.8	4.4	1.0	1.5	2.0	0.4	0.9	0.4	0.4	0.4	0.6	2.9	0.4	0.4	0.4	0.0	0.4	0.4	0.7	2.2	0.7	4.2	0.4	1.5	0.8	10.6	1.0	0.4	0.4	0.4	0.5	0.7	3.6	0.4	0.4	2.2	1.6	2.7	4.5	1.5	1.3	3.6	1.0	1.8	1.4	0.2	1.3	3.9	2.0	0.2	0.1	0.0	0.2	0.5	3.6	2.0	0.9	0.1	3.0	0.2	0.1	2.3	8.6	3.2	1.8	0.6	12.4	1.5	0.0	2.2	0.1	0.0	0.1	0.1	0.1	0.1	0.5	1.2	0.5	0.1	0.5	2.3	0.1	0.3	0.1	4.4	1.1	0.1	0.2	0.0	6.5	1.1	0.1	0.7	5.5	0.0	0.0	0.2	0.1	12.5	12.7	2.2	6.2	8.3	0.2	0.1	0.1	0.1	0.1	0.9	2.4	1.0	0.7	1.2	0.7	1.0	0.9	1.0	0.8	0.3	1.5	1.1	1.4	3.6	1.8	0.7	1.3	0.8	0.2	0.6	2.4	0.4	1.3	0.4	0.9	2.9	0.4	0.7	3.6
DAB1		ENSG00000173406	"DAB1, reelin adaptor protein"	O75553	1	56994778-58546734	"Disease related genes, Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 31.4;intestine: 20.8"	"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 29.3;HeLa: 10.5;NTERA-2: 13.0;RT4: 17.3;WM-115: 14.6"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"cerebellum: 31.4"	"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 5.5"	"Group enriched"	"Detected in many"	16	"granulocytes: 1.4;T-cells: 5.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB032329, HPA052033, HPA067495"	Enhanced		Enhanced	Vesicles				Vesicles		"CAB032329: AB_638973, HPA052033: , HPA067495: "	"unprognostic (7.88e-2)"	"unprognostic (1.02e-1)"	"unprognostic (8.54e-2)"	"unprognostic (2.09e-4)"	"unprognostic (1.21e-1)"	"unprognostic (1.18e-1)"	"unprognostic (7.30e-4)"	"unprognostic (3.90e-1)"	"unprognostic (3.07e-2)"	"unprognostic (1.47e-2)"	"unprognostic (2.06e-3)"	"unprognostic (1.27e-1)"	"unprognostic (2.00e-3)"	"unprognostic (1.78e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.44e-2)"	"unprognostic (5.67e-2)"	1.8	1.7	5.8	0.3	3.8	0.0	0.7	31.4	6.2	1.7	1.0	1.8	0.5	15.0	1.0	1.0	0.6	1.6	0.8	1.8	5.3	1.4	0.7	7.5	0.8	0.2	1.1	4.2	1.2	0.7	0.0	0.7	0.0	2.0	4.0	0.3	2.9	5.2	10.2	0.6	0.6	20.8	0.3	1.1	0.6	1.0	0.9	0.7	0.0	0.8	0.0	0.1	1.9	1.0	0.0	0.0	1.4	0.0	0.2	5.5	0.1	0.0	0.0	5.9	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	29.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	13.0	0.0	3.2	0.0	0.1	0.0	17.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	14.6	0.0	0.0	1.4	0.5	0.0	5.5	0.0	2.0	0.3	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.8	0.1	5.8	3.8	31.4	6.2	5.3	1.4	1.1	4.2	2.0	0.7
DAB2	DOC-2	ENSG00000153071	"DAB2, clathrin adaptor protein"	P98082	5	39371675-39462300	"Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Differentiation, Endocytosis, Protein transport, Transport, Wnt signaling pathway"	"Developmental protein"	"Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 194.4"	"Cell line enhanced"	"Detected in many"		"ASC diff: 42.2;ASC TERT1: 45.4;fHDF/TERT166: 65.6;TIME: 39.5;U-138 MG: 46.0"	"Cancer enhanced"	"Detected in all"		"renal cancer: 52.4"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	8	"plasmacytoid DC: 26.6"	"Lineage enriched"	"Detected in many"	10	"dendritic cells: 26.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009314, HPA028888"	Enhanced		Enhanced	"Nucleoli fibrillar center,Vesicles,Plasma membrane"				"Vesicles, Plasma membrane"	"Nucleoli fibrillar center"	"CAB009314: AB_638976, HPA028888: "	"unprognostic (1.24e-1)"	"unprognostic (7.28e-2)"	"unprognostic (2.16e-1)"	"unprognostic (1.25e-1)"	"unprognostic (5.37e-3)"	"unprognostic (7.01e-2)"	"prognostic unfavourable (7.38e-6)"	"unprognostic (3.11e-1)"	"unprognostic (2.82e-1)"	"unprognostic (2.78e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.87e-1)"	"unprognostic (3.16e-2)"	"prognostic unfavourable (9.67e-4)"	"unprognostic (1.27e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.20e-1)"	51.6	44.2	2.6	12.2	3.5	0.6	21.8	6.1	2.6	16.6	14.0	4.1	4.5	3.3	16.6	34.8	10.8	9.6	13.3	25.1	2.9	3.0	75.2	6.9	22.4	31.8	4.0	2.1	12.7	11.3	3.2	3.9	194.4	4.7	11.6	14.6	14.6	12.9	5.3	12.7	9.3	10.4	16.0	5.2	21.1	7.2	8.7	2.5	7.3	10.9	8.4	7.4	17.8	14.7	0.1	26.6	2.2	2.5	0.9	1.3	7.0	0.0	1.5	2.4	5.3	42.2	45.4	3.0	27.2	27.9	10.7	17.7	19.9	0.0	0.0	1.7	65.6	0.0	0.3	0.9	15.1	0.0	0.8	3.6	36.2	6.5	10.2	0.0	4.7	28.2	0.0	17.5	3.1	32.2	0.0	0.9	17.7	0.1	0.3	0.0	1.6	3.0	0.9	6.2	0.0	7.1	0.5	0.0	0.0	3.2	1.7	15.2	0.1	0.9	39.5	46.0	5.1	5.3	2.2	0.0	0.0	0.0	16.0	3.4	5.9	2.2	1.2	0.2	1.3	2.5	0.0	0.1	0.2	0.7	3.4	0.1	0.1	1.0	1.8	0.9	0.6	26.6	0.2	7.0	2.6	3.5	6.1	2.6	2.9	3.0	4.0	2.1	4.7	2.5
DBH	DBM	ENSG00000123454	"Dopamine beta-hydroxylase"	P09172	9	133636360-133659344	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Catecholamine biosynthesis"	"Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	9	"adrenal gland: 86.6;brain: 36.2;liver: 35.6"	"Cell line enriched"	"Detected in single"	340	"SH-SY5Y: 201.2"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	45	"pons and medulla: 36.2"	"Cell type enhanced"	"Detected in single"		"naive CD4 T-cell: 2.0"	"Lineage enriched"	"Detected in single"	21	"T-cells: 2.0"	"Region enriched"	"Detected in some"	6	"pons and medulla: 23.2"	"Region enriched"	"Detected in single"	37	"pons and medulla: 25.1"	"HPA002130, HPA005960, HPA070789"	Enhanced		Supported	"Endoplasmic reticulum,Vesicles"	"Intracellular and membrane"		2000000000	Vesicles	"Endoplasmic reticulum"	"HPA002130: AB_2666554, HPA005960: AB_1078628, HPA070789: AB_2686312"	"unprognostic (1.93e-3)"	"unprognostic (7.52e-3)"	"unprognostic (8.53e-2)"	"unprognostic (2.10e-2)"	"unprognostic (2.18e-3)"	"unprognostic (3.38e-3)"	"unprognostic (3.39e-3)"	"unprognostic (3.97e-2)"	"unprognostic (1.71e-1)"	"unprognostic (8.99e-2)"	"unprognostic (5.80e-2)"	"unprognostic (7.69e-2)"	"unprognostic (2.81e-7)"	"unprognostic (9.31e-2)"	"unprognostic (6.77e-2)"	"unprognostic (1.49e-2)"	"unprognostic (5.06e-3)"	0.7	86.6	0.1	0.3	0.1	0.0	0.0	0.1	0.8	0.3	0.0	1.9	0.7	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.5	35.6	0.3	0.6	0.0	0.0	0.1	1.3	0.0	0.6	0.4	36.2	0.8	0.0	1.0	0.2	5.9	0.0	0.0	0.2	0.0	1.4	0.4	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.8	0.5	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.5	0.5	0.0	0.0	0.2	201.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.8	0.0	0.1	0.0	0.0	36.2	0.0
DNAJA3	"hTid-1, TID1"	ENSG00000103423	"DnaJ heat shock protein family (Hsp40) member A3"	Q96EY1	16	4425805-4456775	"Predicted intracellular proteins"	Apoptosis	Chaperone		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016095, HPA040875, HPA044229"	Approved		Enhanced	Vesicles,Mitochondria				Mitochondria	Vesicles	"CAB016095: AB_668801, HPA040875: , HPA044229: "	"unprognostic (5.65e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.86e-3)"	"unprognostic (2.91e-2)"	"unprognostic (4.17e-1)"	"unprognostic (5.18e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.06e-1)"	"unprognostic (3.16e-3)"	"unprognostic (1.55e-1)"	"unprognostic (3.27e-2)"	"prognostic favourable (1.79e-4)"	"unprognostic (4.17e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.92e-1)"	10.8	26.6	10.7	11.3	15.5	6.2	13.0	15.3	20.8	10.0	14.0	13.9	11.1	17.3	11.3	8.7	15.6	12.6	12.5	28.8	13.9	12.6	19.0	44.8	9.1	13.4	13.0	13.0	13.2	18.1	21.6	12.1	13.7	14.2	11.5	13.4	10.6	14.4	13.4	46.7	12.8	13.2	11.4	12.6	11.4	12.8	15.1	11.1	13.6	16.1	16.2	13.3	13.4	11.2	10.4	6.5	2.2	7.0	7.8	11.9	7.9	8.9	17.9	6.3	11.8	7.9	6.9	11.7	11.8	8.9	16.5	13.6	14.9	12.6	17.6	11.0	7.6	13.6	20.4	14.0	9.6	12.1	17.6	9.0	15.5	14.3	19.5	15.6	8.6	8.4	16.8	14.5	24.3	7.9	23.1	14.6	9.3	20.4	14.6	11.3	13.7	16.6	18.2	10.0	32.9	12.3	9.6	15.5	6.7	12.9	29.6	19.5	16.9	13.1	7.4	12.3	8.4	29.6	14.7	15.1	20.2	24.0	6.6	15.1	14.4	0.7	4.6	2.2	9.5	7.0	11.0	10.4	9.1	8.9	6.5	8.9	11.9	9.2	0.5	7.8	5.2	4.6	7.4	7.9	10.7	15.5	15.3	20.8	13.9	12.6	13.0	13.0	14.2	11.1
DPP7	"DPP2, DPPII"	ENSG00000176978	"Dipeptidyl peptidase 7"	Q9UHL4	9	137110542-137115177	"Enzymes, Plasma proteins, Predicted intracellular proteins"		"Aminopeptidase, Hydrolase, Protease, Serine protease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RPMI-8226: 56.7;THP-1: 54.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA021282, CAB025541, HPA059381"	Supported		Supported	"Golgi apparatus,Vesicles"	"Intracellular and membrane"		1300000	"Golgi apparatus, Vesicles"		"CAB025541: , HPA021282: AB_1847673, HPA059381: "	"unprognostic (1.15e-1)"	"unprognostic (5.54e-2)"	"prognostic unfavourable (6.07e-6)"	"unprognostic (6.78e-3)"	"unprognostic (1.25e-1)"	"unprognostic (8.33e-2)"	"unprognostic (7.49e-2)"	"unprognostic (6.10e-2)"	"unprognostic (2.28e-2)"	"unprognostic (5.71e-3)"	"prognostic favourable (8.31e-5)"	"unprognostic (7.99e-2)"	"unprognostic (1.46e-2)"	"unprognostic (2.56e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.15e-1)"	"unprognostic (1.02e-1)"	28.1	45.2	23.7	23.4	35.3	31.8	20.8	23.5	27.5	21.5	22.0	24.9	40.7	23.2	17.5	35.8	19.1	27.0	30.2	44.7	24.6	29.2	21.0	29.9	25.6	34.8	29.7	25.9	14.3	55.4	23.3	42.5	21.9	24.2	28.8	6.9	32.8	73.1	41.6	25.3	26.9	17.8	22.8	21.7	29.1	24.4	30.9	26.8	18.9	41.2	17.5	24.7	21.3	16.6	20.0	60.8	12.2	43.1	19.2	36.8	38.2	6.8	10.9	0.9	0.9	13.5	10.8	1.4	10.4	17.0	6.9	4.5	10.3	5.7	13.6	11.4	6.8	14.9	8.0	2.0	0.3	13.3	0.5	6.2	15.0	0.3	30.2	16.8	34.9	13.3	8.3	3.0	6.2	9.0	13.6	10.6	4.6	19.0	8.4	16.0	3.7	10.7	12.4	0.1	56.7	11.0	7.7	17.4	12.1	12.0	31.6	29.4	11.3	54.5	10.9	17.7	6.0	11.2	7.2	13.0	7.4	3.6	21.2	10.2	7.9	6.8	43.1	12.2	34.4	37.6	35.5	19.7	31.1	29.6	41.7	20.0	28.1	25.1	2.6	19.2	22.6	60.8	36.8	38.2	23.7	35.3	23.5	27.5	24.6	29.2	29.7	25.9	24.2	26.8
DRAM2	"MGC54289, PRO180, RP5-1180E21.1, TMEM77, WWFQ154"	ENSG00000156171	"DNA damage regulated autophagy modulator 2"	Q6UX65	1	111117333-111140216	"Predicted membrane proteins"	"Apoptosis, Autophagy"		"Cone-rod dystrophy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"SK-MEL-30: 17.6;THP-1: 19.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018036, HPA061701"	Supported		Enhanced	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"HPA018036: AB_1858134, HPA061701: "	"unprognostic (9.38e-3)"	"unprognostic (1.58e-2)"	"unprognostic (2.16e-3)"	"unprognostic (5.22e-2)"	"unprognostic (1.12e-2)"	"unprognostic (2.65e-2)"	"prognostic unfavourable (3.45e-5)"	"unprognostic (6.57e-3)"	"prognostic unfavourable (6.43e-4)"	"unprognostic (2.69e-1)"	"unprognostic (4.37e-3)"	"unprognostic (2.66e-1)"	"prognostic unfavourable (7.45e-4)"	"unprognostic (1.10e-1)"	"unprognostic (1.63e-1)"	"unprognostic (2.29e-1)"	"unprognostic (1.77e-3)"	21.8	10.1	5.9	14.4	6.6	7.9	18.4	13.5	6.9	8.4	12.0	7.5	5.7	10.6	8.6	11.1	10.0	12.7	9.1	11.7	5.3	6.0	13.0	9.2	11.5	19.9	9.3	4.2	12.3	8.2	5.7	9.9	14.1	8.4	10.1	8.7	8.8	10.7	7.1	10.6	7.0	15.2	10.1	15.1	24.9	9.5	6.1	8.3	15.0	10.6	6.7	14.7	16.8	7.7	16.1	11.2	3.0	10.9	6.2	10.4	11.4	2.0	0.1	3.4	2.0	8.5	7.2	6.0	8.1	3.1	2.0	4.6	2.5	1.1	7.3	5.4	4.0	2.3	4.8	1.3	3.9	8.8	3.4	4.1	2.5	1.2	6.4	0.6	1.8	5.0	6.1	3.3	1.3	1.0	2.3	3.3	2.4	1.4	3.9	5.3	6.5	4.1	3.8	3.8	3.1	7.3	2.1	6.5	2.4	0.9	2.7	17.6	4.7	19.3	3.5	0.6	0.8	4.1	5.4	4.2	1.2	12.5	1.5	8.1	1.3	2.7	10.3	3.0	6.5	10.9	10.4	13.6	9.0	8.1	11.2	16.1	9.5	7.9	2.1	6.2	7.6	11.2	5.4	11.4	5.9	6.6	13.5	5.4	5.3	6.0	9.3	4.2	8.4	8.3
DYRK4		ENSG00000010219	"Dual specificity tyrosine phosphorylation regulated kinase 4"	Q9NR20	12	4562204-4615302	"Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in all"	9	"testis: 85.9"	"Cell line enhanced"	"Detected in many"		"HHSteC: 16.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA028065, HPA056073"	Enhanced		Enhanced	Vesicles				Vesicles		"HPA028065: AB_10601212, HPA056073: AB_2683028"	"unprognostic (2.50e-1)"	"unprognostic (1.55e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.56e-3)"	"unprognostic (2.62e-1)"	"unprognostic (4.07e-3)"	"unprognostic (2.03e-2)"	"unprognostic (4.69e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.13e-2)"	"unprognostic (1.22e-2)"	"unprognostic (2.46e-1)"	"prognostic unfavourable (6.52e-6)"	"unprognostic (1.86e-1)"	"unprognostic (9.71e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.98e-2)"	1.6	2.1	2.3	2.1	1.8	1.6	2.8	1.9	2.3	2.6	2.1	2.2	2.3	1.7	2.5	9.1	1.6	2.0	1.7	1.7	1.8	1.8	1.9	2.0	2.2	2.5	1.9	2.5	2.2	2.3	2.9	2.7	2.9	2.3	2.3	2.7	2.4	2.3	3.4	1.6	1.9	2.4	2.1	2.7	4.3	1.7	85.9	2.1	1.6	4.3	1.6	2.0	2.4	1.6	7.6	2.7	1.3	5.2	1.1	1.6	1.6	1.9	3.0	3.9	4.2	5.9	7.2	4.6	2.3	4.7	5.3	5.8	0.6	3.1	5.8	0.3	6.6	4.0	2.9	4.3	4.2	4.4	6.6	4.0	0.8	3.3	16.6	3.5	3.2	4.9	9.3	3.7	12.3	7.5	1.6	6.6	4.8	4.0	3.2	8.6	5.2	1.8	0.7	2.8	2.5	6.5	1.9	0.0	1.5	0.4	2.3	3.3	1.8	3.1	0.5	6.3	4.9	0.6	2.9	1.9	2.3	3.4	3.3	5.4	3.2	0.6	2.8	1.3	1.0	2.2	1.1	7.6	1.5	1.6	2.7	5.8	1.6	1.6	0.1	1.1	5.2	1.4	1.1	1.6	2.3	1.8	1.9	2.3	1.8	1.8	1.9	2.5	2.3	2.1
EDA	"ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2, EDA1, EDA2, HED, ODT1, XHED, XLHED"	ENSG00000158813	"Ectodysplasin A"	Q92838	X	69616067-70039469	"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	Differentiation	"Developmental protein"	"Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"EFO-21: 5.6;Hep G2: 18.2;Karpas-707: 5.1;RPMI-8226: 6.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 4.0"	"Group enriched"	"Detected in many"	6	"monocytes: 3.0;T-cells: 4.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA037972, HPA037973"			Supported	"Vesicles,Lipid droplets"	"Intracellular and membrane"			Vesicles	"Lipid droplets"	"HPA037972: , HPA037973: "	"unprognostic (3.76e-2)"	"unprognostic (8.29e-2)"	"unprognostic (1.59e-1)"	"unprognostic (3.59e-3)"	"unprognostic (7.85e-2)"	"unprognostic (1.25e-4)"	"unprognostic (4.33e-4)"	"unprognostic (5.03e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.01e-1)"	"prognostic favourable (1.04e-9)"	"unprognostic (8.63e-4)"	"unprognostic (7.64e-2)"	"unprognostic (9.85e-2)"	"unprognostic (2.79e-1)"	6.8	11.7	2.2	3.1	3.0	0.3	3.9	0.9	2.4	10.3	3.4	3.9	7.4	0.9	6.3	5.7	5.0	4.4	7.0	13.3	2.6	2.1	6.9	3.1	4.3	5.8	4.3	2.0	7.9	6.3	18.4	1.9	2.7	2.9	8.3	1.7	5.0	5.4	10.4	3.3	5.4	1.6	5.4	4.6	2.0	4.7	2.7	2.3	0.8	8.9	5.0	1.2	4.4	8.1	0.0	0.0	0.0	3.0	0.6	4.0	0.3	0.0	0.6	0.3	2.9	0.6	0.1	0.2	0.0	0.1	0.0	0.0	1.4	0.1	0.3	5.6	0.2	0.4	4.0	1.5	0.0	0.0	4.6	0.0	0.1	18.2	1.1	0.0	1.2	2.4	1.4	0.0	1.0	0.5	0.0	5.1	0.0	1.2	0.0	0.0	3.0	0.4	0.0	1.3	6.1	0.1	0.0	1.6	0.0	0.1	0.4	0.1	0.3	0.1	0.5	1.9	2.4	2.5	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.2	3.0	4.0	0.0	1.8	0.9	0.0	0.0	1.1	0.2	0.0	0.6	2.0	0.0	0.0	0.3	2.2	3.0	0.9	2.4	2.6	2.1	4.3	2.0	2.9	2.3
EIF4ENIF1	"2610509L04Rik, 4E-T, Clast4, FLJ21601"	ENSG00000184708	"Eukaryotic translation initiation factor 4E nuclear import factor 1"	Q9NRA8	22	31436977-31496108	"Plasma proteins, Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001619, HPA002078"	Enhanced		Enhanced	Vesicles				Vesicles		"HPA001619: AB_1078727, HPA002078: AB_1078728"	"unprognostic (1.16e-1)"	"unprognostic (1.63e-1)"	"unprognostic (2.40e-2)"	"unprognostic (3.01e-2)"	"unprognostic (1.53e-1)"	"unprognostic (6.72e-2)"	"unprognostic (2.28e-3)"	"unprognostic (1.30e-2)"	"unprognostic (4.95e-2)"	"unprognostic (9.92e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.80e-1)"	"prognostic favourable (1.57e-4)"	"unprognostic (2.30e-1)"	"unprognostic (1.92e-1)"	"unprognostic (7.32e-2)"	"unprognostic (2.45e-2)"	10.9	10.9	18.8	13.4	18.9	12.6	10.8	19.4	20.8	11.9	15.9	14.4	12.3	11.8	14.9	14.5	12.6	13.3	8.6	13.2	16.3	11.8	11.9	7.6	10.7	12.3	12.5	15.7	16.9	10.9	18.1	12.2	14.3	16.2	12.5	12.6	12.7	11.2	15.2	17.4	13.7	10.3	13.8	11.8	11.4	11.3	43.6	14.8	8.8	13.3	7.7	15.3	14.1	12.9	6.6	6.5	3.1	10.7	1.7	5.7	3.0	13.3	8.2	20.9	11.3	11.8	10.5	8.4	9.7	11.8	15.3	14.3	9.3	4.8	17.4	5.7	14.4	13.2	18.8	8.7	14.1	13.6	19.4	7.1	13.2	10.6	12.3	27.6	12.7	12.4	12.0	11.4	12.9	12.8	17.1	18.7	14.3	15.8	18.1	13.4	9.6	6.8	21.2	17.5	17.9	15.5	10.1	16.2	15.1	13.4	10.8	10.0	11.6	10.9	14.2	10.2	13.4	10.1	10.7	13.8	13.3	17.0	9.8	10.1	11.9	2.0	3.5	1.6	5.4	4.2	5.7	6.6	3.0	5.1	3.2	3.3	3.1	5.1	3.1	1.7	10.7	6.5	2.0	3.0	18.8	18.9	19.4	20.8	16.3	11.8	12.5	15.7	16.2	14.8
EPS15	"AF-1P, MLLT5"	ENSG00000085832	"Epidermal growth factor receptor pathway substrate 15"	P42566	1	51354263-51519328	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Endocytosis, Host-virus interaction, Protein transport, Transport"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008451, CAB010164, HPA061431"	Approved		Enhanced	Vesicles,Cytosol	"Intracellular and membrane"		67000	"Vesicles, Cytosol"		"CAB010164: AB_631445, HPA008451: AB_1848221, HPA061431: "	"unprognostic (1.45e-2)"	"prognostic unfavourable (6.44e-4)"	"unprognostic (1.05e-2)"	"unprognostic (7.72e-3)"	"unprognostic (3.99e-1)"	"unprognostic (1.42e-1)"	"unprognostic (4.96e-3)"	"unprognostic (9.26e-2)"	"unprognostic (4.13e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.41e-1)"	"unprognostic (5.36e-2)"	"unprognostic (8.73e-3)"	"unprognostic (2.13e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.24e-1)"	39.0	26.9	35.5	25.3	27.8	13.2	19.3	22.2	41.0	25.7	16.7	35.7	16.2	11.4	21.8	21.3	19.6	14.1	19.3	18.9	40.7	26.0	21.0	19.1	24.4	30.7	36.2	11.2	22.4	10.9	17.0	14.6	22.8	20.3	22.5	15.5	25.7	24.3	16.4	30.9	18.1	19.3	18.2	36.8	33.8	15.2	32.4	33.1	25.0	20.3	23.4	32.1	25.3	17.0	16.1	10.8	14.9	12.2	10.7	18.7	8.0	14.7	4.4	9.6	9.0	22.2	22.2	23.9	10.3	16.4	8.5	12.6	6.0	8.2	30.2	10.7	16.2	14.1	12.4	9.9	12.9	34.1	7.8	26.9	7.6	7.2	20.9	15.2	24.8	18.0	9.2	14.8	20.2	15.8	16.6	13.8	12.9	7.2	12.2	8.3	13.1	7.2	10.0	14.5	6.6	11.2	18.4	6.6	9.2	12.3	21.9	17.9	8.9	10.8	21.8	7.9	8.5	15.8	8.6	16.5	16.7	20.4	11.7	17.3	6.9	14.9	10.1	11.6	10.1	10.7	15.3	16.1	12.2	15.6	10.8	10.0	7.3	10.5	7.8	10.7	12.2	7.1	18.7	8.0	35.5	27.8	22.2	41.0	40.7	26.0	36.2	11.2	20.3	33.1
ERGIC1	"ERGIC-32, ERGIC32, KIAA1181, NET24"	ENSG00000113719	"Endoplasmic reticulum-golgi intermediate compartment 1"	Q969X5	5	172834275-172952685	"Predicted intracellular proteins, Predicted membrane proteins"	"ER-Golgi transport, Transport"		"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018666, HPA018900"	Enhanced		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"HPA018666: AB_1848241, HPA018900: AB_1848242"	"unprognostic (8.86e-2)"	"unprognostic (3.50e-2)"	"unprognostic (3.44e-2)"	"unprognostic (5.71e-2)"	"unprognostic (7.96e-2)"	"unprognostic (2.46e-2)"	"unprognostic (9.53e-3)"	"unprognostic (7.02e-3)"	"unprognostic (2.06e-1)"	"unprognostic (6.25e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.77e-1)"	"unprognostic (1.74e-2)"	"unprognostic (1.67e-1)"	"unprognostic (3.86e-2)"	"unprognostic (9.28e-2)"	"unprognostic (3.22e-2)"	30.2	56.5	14.2	20.6	13.8	12.0	44.6	25.5	18.1	42.9	30.5	12.3	35.6	24.6	26.4	24.9	22.6	23.7	30.3	20.7	14.2	11.4	36.4	120.8	28.6	29.3	14.5	11.4	22.5	55.5	15.6	18.9	25.5	13.5	48.1	32.9	19.2	51.5	29.3	27.1	16.7	32.6	22.0	10.8	30.8	36.5	15.8	13.2	29.1	41.5	20.9	25.8	21.3	45.8	6.6	4.2	20.8	9.2	8.5	3.8	3.0	20.3	19.5	16.8	37.3	64.3	48.1	9.3	41.6	31.5	18.8	17.6	27.7	21.0	19.7	29.8	70.2	7.5	12.3	55.2	22.1	15.6	12.1	12.1	28.7	14.8	47.1	5.6	3.9	40.8	23.1	27.7	26.0	30.1	7.2	27.6	31.1	25.5	16.1	9.7	10.0	18.1	55.6	11.2	60.4	43.9	11.9	9.5	17.1	14.5	41.5	20.8	17.2	6.4	22.9	30.7	12.6	29.4	16.9	44.0	49.0	8.2	42.7	13.5	13.4	2.1	4.9	12.1	2.3	7.1	3.8	6.6	1.2	1.5	4.2	4.9	1.0	1.6	20.8	8.5	9.2	2.1	0.7	3.0	14.2	13.8	25.5	18.1	14.2	11.4	14.5	11.4	13.5	13.2
FYCO1	"FLJ13335, ZFYVE7"	ENSG00000163820	"FYVE and coiled-coil domain containing 1"	Q9BQS8	3	45917899-45995824	"Disease related genes, Predicted intracellular proteins"			"Cataract, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 105.8"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035526, HPA057966"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA035526: AB_10672867, HPA057966: "	"unprognostic (2.45e-1)"	"unprognostic (6.62e-2)"	"unprognostic (6.97e-3)"	"unprognostic (1.14e-3)"	"unprognostic (7.65e-2)"	"unprognostic (1.23e-2)"	"unprognostic (1.57e-2)"	"unprognostic (4.53e-3)"	"unprognostic (5.85e-2)"	"unprognostic (8.85e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.98e-1)"	"prognostic favourable (3.33e-11)"	"unprognostic (2.90e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.89e-2)"	"unprognostic (6.99e-2)"	11.6	7.8	4.1	11.4	4.7	3.1	11.6	1.4	3.5	13.5	20.2	7.3	11.4	4.2	19.8	11.1	12.6	7.9	22.0	29.1	4.2	2.7	5.7	6.2	7.9	5.0	4.7	3.5	14.8	15.9	11.4	4.9	4.3	6.1	14.5	5.6	16.2	9.5	11.6	105.8	9.9	7.7	39.9	6.4	6.4	11.6	5.0	5.3	8.5	10.4	25.5	9.5	23.3	27.0	0.6	2.8	1.1	1.1	3.0	6.0	1.3	6.3	6.2	1.8	8.0	17.6	13.9	3.0	6.2	14.4	8.3	9.1	3.4	5.6	4.8	3.5	8.7	4.8	5.2	10.4	9.8	2.0	5.5	6.7	5.1	3.7	12.0	5.1	4.9	15.4	10.4	13.0	12.9	16.3	4.4	6.9	5.8	3.9	5.2	3.2	2.8	5.9	1.8	5.1	2.6	9.9	22.5	1.3	2.1	3.9	12.3	10.7	6.0	3.4	12.5	3.1	3.7	10.5	3.4	3.9	2.5	1.6	10.8	6.6	5.8	1.1	1.0	0.6	4.4	1.1	6.0	0.6	2.6	4.6	0.4	0.6	1.1	1.8	0.9	3.0	0.7	2.8	2.6	1.3	4.1	4.7	1.4	3.5	4.2	2.7	4.7	3.5	6.1	5.3
GPRC5A	"PEIG-1, RAI3, RAIG1, TIG1"	ENSG00000013588	"G protein-coupled receptor class C group 5 member A"	Q8NFJ5	12	12890782-12917937	"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 155.0"	"Cell line enhanced"	"Detected in many"		"A-431: 41.8;CAPAN-2: 161.0;HaCaT: 42.2;SiHa: 59.2"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	5	"pons and medulla: 3.1"	"Cell type enhanced"	"Detected in some"		"basophil: 3.1"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 3.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA007928, HPA046526"	Enhanced		Enhanced	"Vesicles,Plasma membrane"				"Vesicles, Plasma membrane"		"HPA007928: AB_1849318, HPA046526: "	"unprognostic (4.79e-2)"	"unprognostic (8.35e-2)"	"unprognostic (4.21e-2)"	"unprognostic (1.64e-1)"	"unprognostic (4.65e-3)"	"unprognostic (1.73e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.89e-2)"	"unprognostic (3.48e-1)"	"unprognostic (8.69e-3)"	"prognostic unfavourable (4.63e-6)"	"unprognostic (3.81e-1)"	"prognostic unfavourable (9.02e-5)"	"unprognostic (9.30e-2)"	"unprognostic (4.34e-1)"	"unprognostic (1.62e-2)"	"unprognostic (2.49e-1)"	9.8	1.4	0.2	6.0	0.6	0.4	5.4	0.1	0.3	12.1	19.8	0.5	2.0	6.2	4.3	1.9	9.1	3.0	15.5	7.1	0.1	0.2	5.1	0.6	155.0	0.1	0.5	0.1	18.5	1.1	0.0	0.9	20.1	3.1	10.4	16.9	4.8	9.6	1.5	1.1	2.0	36.9	14.2	1.1	0.1	11.4	4.8	0.3	0.1	54.2	14.9	11.5	32.1	14.0	0.6	0.6	3.1	0.3	0.5	0.4	0.0	41.8	33.5	0.0	0.1	0.4	0.2	2.1	12.6	4.8	8.2	6.3	5.8	161.0	0.0	1.0	10.0	42.2	0.1	6.1	12.6	0.0	0.5	0.0	13.8	0.2	3.0	0.0	0.0	0.2	8.2	3.4	0.8	5.0	0.0	0.0	0.3	29.3	0.0	0.0	0.1	5.2	0.0	0.9	0.0	16.3	8.3	0.0	0.0	59.2	4.5	1.9	1.3	0.1	0.5	0.3	10.7	19.2	0.5	0.0	0.0	0.0	4.3	0.0	0.2	3.1	0.3	0.4	0.3	0.2	0.3	0.3	0.2	0.3	0.1	0.6	0.4	0.4	1.3	0.5	0.2	0.6	0.3	0.0	0.2	0.6	0.1	0.3	0.1	0.2	0.5	0.1	3.1	0.3
GTPBP2		ENSG00000172432	"GTP binding protein 2"	Q9BX10	6	43605316-43629162	"Predicted intracellular proteins"			"Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTERT-HME1: 55.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031418, HPA031419"	Approved		Enhanced	Vesicles				Vesicles		"HPA031418: , HPA031419: AB_10600709"	"unprognostic (1.35e-1)"	"unprognostic (1.01e-1)"	"unprognostic (8.94e-2)"	"unprognostic (1.08e-3)"	"unprognostic (2.56e-1)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (1.08e-6)"	"unprognostic (4.71e-2)"	"unprognostic (2.58e-3)"	"unprognostic (6.47e-2)"	"unprognostic (8.31e-2)"	"unprognostic (6.15e-3)"	"prognostic unfavourable (1.44e-15)"	"unprognostic (1.13e-1)"	"unprognostic (3.36e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.89e-3)"	26.8	19.8	21.4	28.0	19.7	27.9	23.5	27.5	26.1	20.1	22.4	19.9	29.6	22.7	19.0	20.5	38.2	14.5	18.6	20.5	19.1	10.8	20.5	22.5	29.1	21.4	15.0	17.4	20.4	26.2	30.9	26.8	24.1	17.9	20.7	20.7	19.9	29.0	25.3	19.2	19.8	21.9	21.0	17.0	28.8	23.8	17.2	20.1	28.2	30.0	13.3	29.6	25.7	25.2	3.0	2.8	7.0	2.5	1.2	3.4	4.4	17.5	4.6	12.3	8.3	9.5	10.3	14.2	16.7	18.0	19.6	22.5	5.3	7.4	6.3	7.1	8.9	9.5	4.6	6.7	13.5	17.3	10.0	15.6	11.7	4.7	38.1	10.1	17.4	12.1	47.5	21.6	55.7	10.1	21.8	32.5	9.7	6.0	7.5	14.6	3.7	5.4	6.5	8.9	7.1	9.1	10.7	10.6	11.0	5.6	5.2	21.3	10.0	15.7	11.1	9.9	11.1	6.2	11.1	22.2	10.5	8.6	14.2	9.3	10.3	7.0	2.5	5.0	3.4	1.4	2.0	1.7	0.9	3.0	1.3	3.0	2.4	2.8	3.7	1.2	2.0	2.8	1.5	4.4	21.4	19.7	27.5	26.1	19.1	10.8	15.0	17.4	17.9	20.1
HDHD3	"C9orf158, MGC12904"	ENSG00000119431	"Haloacid dehalogenase like hydrolase domain containing 3"	Q9BSH5	9	113373419-113376999	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 54.7"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020427, HPA024158, HPA024585"	Enhanced		Enhanced	Nucleoli,Vesicles				Nucleoli	Vesicles	"HPA020427: AB_1850561, HPA024158: AB_1850563, HPA024585: AB_1850565"	"unprognostic (1.30e-1)"	"prognostic favourable (2.72e-4)"	"unprognostic (3.01e-2)"	"unprognostic (1.31e-2)"	"unprognostic (8.24e-3)"	"unprognostic (1.57e-2)"	"unprognostic (6.66e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.76e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.92e-2)"	"unprognostic (5.87e-2)"	"prognostic favourable (3.54e-7)"	"unprognostic (2.16e-2)"	"unprognostic (1.84e-1)"	"unprognostic (4.68e-1)"	"unprognostic (1.19e-3)"	4.9	54.7	5.1	10.1	8.4	3.3	12.7	6.2	8.5	6.0	29.8	5.6	10.6	38.2	6.4	15.5	13.8	5.8	18.1	9.1	4.6	5.3	17.7	36.6	4.4	6.3	4.5	9.4	7.2	23.7	20.5	9.1	6.5	7.3	10.6	16.8	8.3	24.4	12.5	2.8	11.4	47.1	8.0	4.8	6.0	17.7	4.5	4.0	8.0	18.2	6.1	6.8	7.0	6.9	12.1	10.6	5.9	2.9	5.6	12.3	5.8	3.6	10.5	2.3	6.3	5.7	2.5	19.2	2.7	5.2	4.4	4.9	19.2	18.4	8.1	3.4	1.5	14.4	3.6	4.2	1.5	11.3	8.2	11.2	5.7	11.9	6.6	0.6	8.6	3.9	9.0	3.6	10.3	2.3	8.8	2.0	2.1	23.9	5.1	3.2	5.1	8.2	4.2	0.0	6.5	5.6	7.7	5.7	3.6	4.7	20.3	6.8	12.7	2.3	2.3	0.9	0.0	0.7	0.9	5.0	9.7	3.3	1.1	0.0	0.6	0.1	2.9	5.9	9.9	1.6	11.2	11.3	11.5	9.0	4.5	12.1	12.0	8.9	1.9	5.6	0.2	10.6	12.3	5.8	5.1	8.4	6.2	8.5	4.6	5.3	4.5	9.4	7.3	4.0
HEXIM1	"CLP-1, EDG1, HIS1, MAQ1"	ENSG00000186834	"Hexamethylene bisacetamide inducible 1"	O94992	17	45148502-45152101	"Predicted intracellular proteins"	"Immunity, Innate immunity, Transcription, Transcription regulation"	Repressor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA008926, CAB011625"	Supported		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"CAB011625: AB_2233058, HPA008926: AB_1079048"	"unprognostic (2.82e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.15e-1)"	"unprognostic (2.72e-2)"	"unprognostic (2.39e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.34e-2)"	"unprognostic (4.74e-2)"	"unprognostic (1.44e-1)"	"unprognostic (2.32e-2)"	"unprognostic (1.20e-2)"	"unprognostic (1.83e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.58e-1)"	"unprognostic (2.89e-3)"	"unprognostic (1.26e-2)"	14.8	25.3	30.0	12.6	25.3	30.4	13.7	41.4	37.4	16.2	21.0	10.7	18.5	17.8	17.0	17.2	18.6	18.2	18.6	16.0	31.1	15.6	20.9	19.0	15.8	11.8	24.9	19.2	14.8	15.6	12.2	24.4	56.7	27.5	19.9	10.8	12.6	16.4	25.2	29.7	22.6	20.2	19.5	31.4	20.7	17.3	17.1	21.7	8.9	17.2	14.3	12.3	17.8	30.6	3.7	3.4	15.9	6.7	3.8	4.6	2.3	12.9	41.2	8.6	12.4	14.3	7.7	21.1	11.5	10.4	9.5	10.7	19.3	18.4	5.6	35.6	12.1	10.5	5.2	11.3	7.7	11.6	12.3	17.6	22.7	23.5	12.5	10.9	23.4	8.9	9.7	7.0	3.1	4.7	7.7	13.8	7.1	17.3	11.4	12.7	7.9	12.5	4.8	7.5	6.9	25.0	23.0	4.6	3.5	17.3	19.6	18.6	20.4	8.6	9.0	9.6	13.3	5.5	21.3	12.6	4.0	3.7	8.8	10.3	10.9	15.9	4.3	6.6	4.5	6.1	2.7	3.3	4.6	4.0	3.3	3.7	4.2	4.4	10.5	3.8	6.7	3.4	3.9	2.3	30.0	25.3	41.4	37.4	31.1	15.6	24.9	19.2	27.5	21.7
HIP1	ILWEQ	ENSG00000127946	"Huntingtin interacting protein 1"	O00291	7	75533300-75738962	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Differentiation, Endocytosis, Transcription, Transcription regulation"	"Actin-binding, Activator"	"Cancer-related genes, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A549: 27.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013606, CAB015334, CAB016402, HPA017964"	Enhanced		Enhanced	Vesicles				Vesicles		"CAB015334: AB_2117565, CAB016402: AB_627725, HPA013606: AB_1850717, HPA017964: AB_1850719"	"unprognostic (8.23e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.20e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.59e-1)"	"unprognostic (2.73e-3)"	"unprognostic (1.03e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.02e-2)"	"unprognostic (2.70e-2)"	"unprognostic (7.98e-2)"	"unprognostic (1.73e-3)"	"unprognostic (9.67e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.00e-2)"	"unprognostic (1.09e-1)"	16.5	8.7	14.6	7.2	25.9	5.1	13.5	13.2	20.8	13.2	5.3	34.4	4.9	2.9	13.4	10.1	5.7	13.8	8.7	9.2	17.5	11.9	14.6	9.6	17.7	4.6	27.2	11.8	8.1	4.0	4.9	3.6	20.0	16.1	6.8	4.5	9.9	4.0	12.4	3.9	10.8	4.6	12.6	24.8	10.8	4.6	18.5	29.7	1.6	15.8	5.7	4.6	9.7	8.8	0.5	4.0	8.8	1.1	3.3	1.5	0.3	2.5	27.3	18.6	17.5	7.9	10.7	5.6	4.8	3.1	3.1	2.3	1.5	2.4	1.8	5.6	11.8	3.1	18.8	3.9	4.2	1.5	3.5	1.4	3.2	2.5	7.8	0.4	7.4	8.2	2.4	10.2	2.1	13.0	1.9	1.8	5.0	10.4	1.2	10.6	20.2	3.3	2.1	7.8	0.1	2.4	9.7	0.9	8.2	4.4	2.8	6.3	17.2	6.7	4.6	9.2	7.1	3.1	6.6	2.0	0.2	4.4	9.2	3.9	6.2	8.8	1.1	7.6	1.1	1.1	1.0	0.4	0.2	0.9	1.6	0.5	0.1	0.7	7.7	3.3	0.8	4.0	1.5	0.3	14.6	25.9	13.2	16.9	17.5	11.9	27.2	11.8	16.1	29.7
IGF2R	"CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI"	ENSG00000197081	"Insulin like growth factor 2 receptor"	P11717	6	159969099-160113507	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HBEC3-KT: 59.6;hTERT-HME1: 60.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 13.3"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009661, HPA011332"	Supported		Enhanced	"Golgi apparatus,Vesicles"			150000000	"Golgi apparatus, Vesicles"		"CAB009661: AB_2122795, HPA011332: AB_1846276"	"prognostic unfavourable (3.01e-4)"	"prognostic unfavourable (2.92e-5)"	"unprognostic (5.83e-2)"	"unprognostic (1.72e-1)"	"unprognostic (4.15e-1)"	"unprognostic (3.25e-1)"	"unprognostic (7.32e-3)"	"unprognostic (2.32e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.07e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.45e-1)"	"unprognostic (5.74e-3)"	"unprognostic (1.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.85e-1)"	"prognostic unfavourable (6.08e-4)"	28.0	22.2	6.8	13.5	8.1	16.7	39.4	6.4	8.2	14.9	17.3	9.5	13.0	9.4	19.6	16.0	16.7	13.1	17.9	27.9	6.7	6.2	20.6	26.6	32.6	44.7	12.3	3.6	18.0	19.6	23.5	13.6	15.5	10.0	14.1	13.3	13.9	18.2	13.5	62.0	15.9	15.4	16.5	7.6	30.2	14.4	13.8	9.0	37.9	18.5	17.3	14.1	16.3	26.9	0.4	2.9	13.3	2.0	1.0	3.6	0.9	7.7	7.0	12.4	17.4	45.3	25.0	16.8	12.2	26.4	10.1	17.4	10.6	12.2	3.2	13.7	13.4	10.4	9.3	59.6	17.0	16.8	6.6	1.4	12.2	19.1	26.8	7.4	12.1	19.9	19.1	21.0	60.7	6.5	13.9	17.4	15.9	5.7	3.4	7.4	5.5	7.5	8.0	8.5	16.3	14.3	7.8	4.1	9.1	16.5	14.8	16.5	6.2	21.0	9.8	9.8	10.3	21.1	22.3	10.3	14.4	3.3	18.9	10.2	15.1	0.1	2.0	1.1	3.6	0.8	1.4	0.3	1.2	1.7	0.3	0.4	1.0	2.4	13.3	1.0	1.4	2.9	0.7	0.9	6.8	8.1	6.4	8.2	6.7	6.2	12.3	3.6	10.0	9.0
ITCH	AIP4	ENSG00000078747	"Itchy E3 ubiquitin protein ligase"	Q96J02	20	34363235-34511393	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Antiviral defense, Apoptosis, Host-virus interaction, Immunity, Innate immunity, Ubl conjugation pathway"	Transferase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA021126, HPA049032, CAB072824, CAB072825"	Supported		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"CAB072824: , CAB072825: , HPA021126: AB_1851941, HPA049032: "	"unprognostic (2.51e-1)"	"unprognostic (6.95e-2)"	"unprognostic (1.25e-3)"	"unprognostic (3.22e-2)"	"unprognostic (1.77e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.78e-1)"	"unprognostic (9.29e-3)"	"unprognostic (1.94e-1)"	"unprognostic (3.89e-3)"	"unprognostic (1.28e-3)"	"unprognostic (1.42e-1)"	"unprognostic (1.84e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.24e-1)"	"unprognostic (3.23e-2)"	"unprognostic (2.21e-1)"	20.7	16.7	18.9	15.4	26.9	20.5	17.5	19.8	26.7	23.9	18.2	37.9	15.2	16.9	18.4	15.1	35.9	14.5	14.5	17.9	20.4	15.9	21.1	46.5	18.5	16.8	29.2	16.5	19.3	17.1	21.6	26.3	26.9	29.0	17.5	20.4	16.7	20.1	18.4	24.0	19.2	20.3	19.8	30.4	17.3	17.3	34.8	32.3	22.3	22.7	13.0	23.6	19.6	21.0	7.3	11.4	19.6	6.2	6.2	11.4	2.7	20.0	13.2	13.5	9.7	14.9	21.3	16.2	16.3	18.7	20.4	20.0	37.2	30.9	9.8	15.8	20.8	25.4	20.5	32.9	24.9	7.4	6.6	28.4	11.2	22.2	15.6	11.6	12.9	10.8	16.8	17.2	27.0	15.3	16.1	17.0	15.9	10.0	17.0	6.2	6.5	15.7	14.3	28.5	22.6	12.1	34.8	8.3	6.1	30.5	11.9	18.3	14.3	10.5	14.8	24.4	14.7	15.9	12.0	13.5	14.1	14.3	15.1	7.5	14.3	3.6	5.8	6.1	10.8	6.2	11.4	7.3	3.8	5.7	4.5	6.9	3.3	4.9	19.6	6.2	3.8	11.4	4.8	2.7	18.9	26.9	19.8	26.7	20.4	15.9	29.2	16.5	29.0	32.3
ITM2B	"BRI, BRI2, BRICD2B, E25B, E3-16"	ENSG00000136156	"Integral membrane protein 2B"	Q9Y287	13	48233158-48270357	"Disease related genes, Predicted membrane proteins"			"Amyloidosis, Deafness, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"epididymis: 346.2"	"Cell line enhanced"	"Detected in many"		"HMC-1: 108.7;RPTEC TERT1: 154.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 236.4"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 236.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029292, HPA071992"	Approved		Enhanced	"Golgi apparatus,Vesicles"	"Intracellular and membrane"		2600000	"Golgi apparatus, Vesicles"		"HPA029292: AB_10601917, HPA071992: "	"unprognostic (4.66e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.03e-2)"	"unprognostic (1.00e-1)"	"unprognostic (4.41e-2)"	"unprognostic (6.84e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.29e-1)"	"unprognostic (9.88e-2)"	"unprognostic (2.42e-1)"	"unprognostic (5.89e-2)"	"unprognostic (2.87e-2)"	"prognostic favourable (3.73e-5)"	"unprognostic (4.38e-2)"	"unprognostic (4.09e-2)"	"unprognostic (6.00e-2)"	"unprognostic (1.22e-1)"	89.3	79.6	60.6	41.3	61.6	25.0	79.6	87.2	65.8	72.6	58.3	64.9	93.4	83.4	61.2	346.2	71.5	53.2	59.4	86.9	75.9	61.4	198.7	65.1	80.2	75.9	71.7	49.8	100.7	48.5	27.0	63.1	132.0	50.2	66.5	36.0	80.8	75.1	99.8	30.9	73.5	81.0	53.1	90.0	78.5	64.5	44.7	48.3	35.0	73.1	63.0	47.7	63.3	74.5	13.3	23.3	236.4	46.6	17.2	31.7	73.7	8.6	7.5	12.7	23.8	48.5	29.4	18.9	22.9	29.0	11.5	14.6	5.3	41.5	2.3	19.5	16.7	35.3	6.8	16.5	9.7	6.7	16.1	16.4	6.1	14.6	20.9	16.1	108.7	17.6	14.8	6.7	7.5	14.8	4.2	19.9	14.0	5.8	25.9	35.6	34.8	10.2	11.7	12.6	11.7	154.6	40.9	4.3	17.1	20.3	16.7	11.8	10.9	17.1	23.8	9.6	9.6	12.5	11.1	7.8	7.2	0.3	14.0	9.4	21.4	136.9	46.6	141.3	21.3	35.7	28.1	12.0	29.8	26.5	23.3	13.3	31.7	26.5	236.4	17.2	35.5	10.3	28.7	73.7	60.6	61.6	87.2	58.0	75.9	61.4	71.7	49.8	50.2	48.3
KLRG1	"2F1, CLEC15A, MAFA, MAFA-L"	ENSG00000139187	"Killer cell lectin like receptor G1"	Q96E93	12	8950044-9010760	"Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 83.1"	"Group enriched"	"Detected in many"	5	"HEL: 23.0;HUVEC TERT2: 8.1;NTERA-2: 15.8;U-937: 14.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 71.3;MAIT T-cell: 83.1"	"Lineage enriched"	"Detected in many"	28	"T-cells: 83.1"	"Low region specificity"	"Detected in some"							"HPA051403, HPA076494"	Approved		Enhanced	Vesicles				Vesicles		"HPA051403: , HPA076494: "	"unprognostic (1.54e-2)"	"unprognostic (8.42e-4)"	"unprognostic (1.06e-1)"	"unprognostic (1.28e-1)"	"unprognostic (2.94e-1)"	"unprognostic (1.53e-4)"	"unprognostic (3.05e-1)"	"unprognostic (2.27e-3)"	"unprognostic (2.23e-2)"	"unprognostic (1.01e-2)"	"unprognostic (3.45e-3)"	"unprognostic (6.88e-2)"	"unprognostic (1.71e-2)"	"unprognostic (2.05e-2)"	"unprognostic (4.17e-2)"	"unprognostic (4.96e-2)"	"unprognostic (7.86e-2)"	15.4	3.9	4.4	7.3	5.8	5.6	5.7	12.3	5.0	3.2	3.5	7.1	0.8	1.7	5.6	4.2	2.2	2.6	7.7	5.1	4.4	5.8	3.2	6.4	5.5	17.3	8.3	3.4	2.7	1.9	1.5	5.6	1.5	5.5	4.8	4.7	5.6	3.5	1.8	3.1	2.2	5.0	3.9	5.5	19.0	3.6	2.2	6.8	6.8	2.9	2.3	11.1	8.3	2.6	0.5	1.3	2.4	0.6	2.9	83.1	14.0	0.1	2.2	1.2	1.7	2.0	0.4	1.1	0.3	0.3	0.2	0.7	0.7	0.7	3.1	0.1	0.3	0.2	2.8	0.3	0.3	2.2	1.4	23.0	0.3	1.2	0.5	0.7	1.2	1.4	0.3	0.3	0.0	8.1	1.0	0.3	0.1	0.5	0.5	1.6	15.8	1.5	0.9	0.7	0.0	0.3	0.3	0.3	3.1	0.7	0.4	0.9	0.2	1.0	0.5	0.5	0.7	0.4	1.0	1.0	2.7	1.7	1.4	14.5	0.2	2.4	0.3	0.2	71.3	0.4	83.1	0.5	15.8	43.4	1.3	0.5	4.3	29.9	0.9	2.9	0.6	0.5	1.2	14.0	4.4	5.8	12.3	5.0	4.4	5.8	8.3	3.4	5.5	6.8
LAMP3	"CD208, DC-LAMP, DCLAMP, LAMP, TSC403"	ENSG00000078081	"Lysosomal associated membrane protein 3"	Q9UQV4	3	183122213-183163839	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"lung: 123.9"	"Group enriched"	"Detected in some"	6	"EFO-21: 57.2;HDLM-2: 14.5;HHSteC: 21.2;hTCEpi: 19.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"eosinophil: 7.6"	"Group enriched"	"Detected in many"	8	"granulocytes: 7.6;T-cells: 6.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB025133, HPA051467"	Enhanced		Enhanced	Vesicles			47000	Vesicles		"CAB025133: , HPA051467: "	"unprognostic (1.43e-3)"	"unprognostic (2.06e-2)"	"unprognostic (1.70e-1)"	"unprognostic (2.99e-3)"	"unprognostic (1.30e-2)"	"unprognostic (2.15e-1)"	"unprognostic (7.67e-2)"	"unprognostic (8.64e-2)"	"unprognostic (4.95e-2)"	"prognostic favourable (9.90e-4)"	"unprognostic (1.80e-3)"	"unprognostic (5.80e-2)"	"prognostic unfavourable (1.89e-7)"	"unprognostic (3.12e-1)"	"unprognostic (4.13e-2)"	"unprognostic (8.35e-2)"	"unprognostic (1.29e-1)"	0.5	0.7	0.4	14.1	0.4	0.0	0.5	0.3	0.4	1.0	0.6	0.1	0.6	0.4	0.4	1.0	2.5	0.5	0.8	0.4	0.4	0.4	0.8	0.6	123.9	11.2	0.4	0.1	0.4	8.3	0.0	0.6	1.0	0.6	1.0	1.7	0.2	6.8	1.9	0.4	1.9	1.4	0.8	0.5	2.0	0.8	8.4	0.0	21.3	8.3	3.1	11.3	3.3	0.9	0.4	0.0	7.6	0.1	0.8	6.6	1.1	3.4	0.1	0.0	0.5	0.0	0.0	2.8	0.0	0.9	0.6	0.1	0.8	1.8	0.0	57.2	0.2	0.5	1.2	2.1	0.1	14.5	1.7	0.0	0.1	0.1	21.2	0.0	0.5	0.3	19.4	0.0	2.5	2.6	0.1	3.4	0.1	0.0	0.8	0.1	0.1	0.8	0.0	0.0	0.2	0.0	1.1	0.2	0.1	0.2	0.1	1.5	1.1	0.1	2.7	0.0	1.0	0.1	0.0	1.2	4.3	0.1	0.0	0.0	0.0	0.4	0.1	7.6	0.4	0.0	3.2	0.1	2.7	1.7	0.0	0.4	3.5	2.0	1.9	0.8	0.1	0.0	6.6	1.1	0.4	0.4	0.3	0.4	0.4	0.4	0.4	0.1	0.6	0.0
MBD1	"CXXC3, PCM1"	ENSG00000141644	"Methyl-CpG binding domain protein 1"	Q9UIS9	18	50266882-50281774	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009017, CAB036003, HPA068850"	Approved		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB009017: AB_2095559, CAB036003: , HPA068850: "	"unprognostic (2.12e-2)"	"unprognostic (5.05e-2)"	"unprognostic (6.88e-2)"	"unprognostic (5.01e-3)"	"unprognostic (9.20e-2)"	"unprognostic (6.85e-2)"	"prognostic unfavourable (5.08e-6)"	"unprognostic (5.91e-2)"	"unprognostic (2.61e-2)"	"unprognostic (4.65e-2)"	"unprognostic (1.96e-3)"	"prognostic unfavourable (1.70e-6)"	"unprognostic (7.06e-3)"	"unprognostic (7.70e-2)"	"unprognostic (7.05e-2)"	"unprognostic (4.61e-2)"	"unprognostic (1.31e-1)"	14.7	21.7	18.0	18.8	20.8	29.4	15.7	27.1	29.4	15.3	17.2	18.8	16.2	18.7	18.4	16.6	21.1	16.4	16.8	19.7	19.2	14.0	17.4	18.9	16.0	20.9	21.8	23.1	20.7	19.7	28.2	24.2	19.4	18.2	18.0	13.9	15.0	19.6	19.5	25.9	24.2	18.3	18.3	15.2	22.6	18.0	72.3	21.5	19.1	19.9	20.0	18.2	19.1	20.0	13.1	11.7	22.2	11.6	14.3	17.4	12.1	10.2	9.7	11.0	12.4	11.8	9.7	11.8	12.4	14.3	17.2	13.3	7.3	8.2	16.3	9.0	12.0	18.6	12.5	21.7	10.0	18.2	8.0	10.3	13.8	7.7	22.9	24.8	21.8	11.3	35.1	19.6	45.0	14.1	12.9	25.6	13.2	9.5	20.8	13.0	10.3	7.8	19.3	8.1	17.7	8.5	4.7	14.5	13.8	9.2	8.8	11.3	11.2	22.8	15.2	18.7	8.6	6.0	12.5	47.6	20.1	17.2	12.1	19.1	16.9	15.2	11.6	22.2	17.4	10.1	16.4	13.0	15.2	14.4	11.7	13.1	15.9	12.8	15.6	14.3	7.9	10.7	13.9	12.1	18.0	20.8	27.1	29.4	19.2	14.0	21.8	23.1	18.2	21.5
MEF2D		ENSG00000116604	"Myocyte enhancer factor 2D"	Q14814	1	156463727-156500828	"Predicted intracellular proteins, Transcription factors"	"Apoptosis, Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 97.8"	"Cell line enhanced"	"Detected in all"		"THP-1: 53.9;U-266/70: 47.4;U-266/84: 48.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004807, HPA007114"	Enhanced		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA004807: AB_1079354, HPA007114: AB_1079353"	"unprognostic (3.17e-2)"	"unprognostic (7.31e-2)"	"unprognostic (3.35e-2)"	"unprognostic (3.45e-2)"	"unprognostic (1.95e-1)"	"unprognostic (8.99e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.29e-1)"	"unprognostic (9.96e-2)"	"unprognostic (1.96e-2)"	"unprognostic (1.97e-1)"	"unprognostic (2.50e-1)"	"prognostic unfavourable (7.53e-4)"	"unprognostic (9.27e-2)"	"unprognostic (1.66e-1)"	"unprognostic (8.09e-3)"	"unprognostic (1.45e-1)"	18.1	19.6	14.9	15.7	27.5	47.6	15.5	27.0	40.3	23.8	21.1	12.1	10.5	11.0	28.6	12.9	13.8	19.5	16.6	26.3	11.8	9.6	10.4	10.6	20.0	13.9	8.6	21.1	26.7	22.4	21.4	15.0	16.2	11.6	17.2	10.6	22.3	11.3	18.8	97.8	17.5	14.8	22.0	8.4	17.2	16.1	9.9	9.9	17.2	14.7	19.4	15.6	21.9	19.3	1.7	8.5	8.1	2.0	1.5	2.3	0.8	4.5	8.5	1.8	2.7	4.3	6.0	2.7	6.0	7.8	3.2	3.4	2.7	6.2	10.6	6.9	8.0	4.5	2.1	3.4	1.9	14.4	2.8	2.5	10.4	1.5	5.3	6.2	8.4	6.7	5.8	5.5	7.5	6.0	1.8	18.7	5.0	4.3	4.1	14.3	2.6	4.3	20.4	3.9	12.2	2.7	2.2	2.9	4.6	5.8	12.6	10.0	3.4	53.9	10.0	7.5	7.1	5.5	4.4	47.4	48.8	20.3	6.4	4.9	4.0	1.3	2.0	2.3	1.9	1.1	2.3	1.7	1.4	1.7	1.4	1.7	0.7	1.3	8.1	1.5	1.9	8.5	1.6	0.8	14.9	27.5	27.0	40.3	11.8	9.6	8.6	21.1	11.6	9.9
MIA3	"FLJ39207, KIAA0268, TANGO, TANGO1, UNQ6077"	ENSG00000154305	"MIA family member 3, ER export factor"	Q5JRA6	1	222618086-222668012	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"ER-Golgi transport, Exocytosis, Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA055922, HPA056816"	Supported		Enhanced	Vesicles	"Intracellular and membrane"		750000	Vesicles		"HPA055922: , HPA056816: "	"unprognostic (1.24e-1)"	"unprognostic (7.42e-2)"	"unprognostic (1.43e-1)"	"unprognostic (6.60e-2)"	"unprognostic (1.86e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.28e-3)"	"unprognostic (5.41e-2)"	"unprognostic (2.56e-1)"	"unprognostic (5.65e-2)"	"unprognostic (6.73e-2)"	"unprognostic (1.39e-2)"	"prognostic unfavourable (3.73e-4)"	"unprognostic (3.57e-2)"	"unprognostic (1.83e-1)"	"unprognostic (8.62e-3)"	"unprognostic (3.26e-1)"	20.5	24.1	21.4	17.4	23.7	25.8	25.0	32.8	25.0	23.3	19.3	10.0	26.2	18.7	23.5	24.4	15.7	18.1	18.5	19.5	18.4	17.4	19.5	63.7	18.4	19.0	17.0	18.8	23.4	34.1	30.2	34.7	22.7	25.6	30.1	23.1	9.9	32.8	31.7	25.5	16.5	23.2	21.3	22.9	23.0	36.6	29.3	19.6	19.5	25.6	19.5	19.3	26.8	19.8	18.6	14.9	29.4	20.1	22.0	18.3	11.1	11.8	9.0	14.0	21.3	44.5	22.4	23.5	17.0	25.5	18.9	22.5	9.3	12.3	9.7	16.3	19.3	20.3	14.9	15.7	19.4	16.8	9.3	13.4	9.3	14.5	40.8	23.0	16.3	20.5	15.1	18.0	31.9	19.7	17.2	23.9	14.2	7.1	17.9	14.9	15.5	12.9	12.2	38.0	23.5	9.7	11.8	15.2	16.0	17.5	15.9	14.2	17.0	15.1	14.3	12.8	9.8	21.6	18.1	27.3	17.3	12.2	16.0	11.1	16.8	23.6	14.6	29.4	17.4	19.5	18.3	18.3	15.0	17.0	10.4	18.6	17.8	17.4	24.8	22.0	20.1	14.9	16.0	11.1	21.4	23.7	32.8	25.0	18.4	17.4	17.0	18.8	25.6	19.6
MITD1	LOC129531	ENSG00000158411	"Microtubule interacting and trafficking domain containing 1"	Q8WV92	2	99161427-99181058	"Predicted intracellular proteins"	"Cell cycle, Cell division, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036162, HPA036163"	Approved		Enhanced	Vesicles				Vesicles		"HPA036162: AB_10672236, HPA036163: "	"prognostic favourable (5.96e-4)"	"unprognostic (1.67e-2)"	"unprognostic (3.09e-1)"	"unprognostic (2.79e-1)"	"unprognostic (2.02e-1)"	"unprognostic (8.96e-2)"	"prognostic unfavourable (1.47e-6)"	"unprognostic (1.39e-1)"	"unprognostic (5.35e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.09e-1)"	"unprognostic (6.31e-3)"	"prognostic unfavourable (1.32e-11)"	"unprognostic (2.38e-1)"	"unprognostic (2.40e-1)"	"unprognostic (6.91e-2)"	"prognostic favourable (5.46e-8)"	18.8	19.1	19.6	26.3	34.2	11.7	18.8	20.6	30.2	16.6	17.6	13.5	14.4	15.6	17.7	15.5	20.0	16.6	14.2	13.6	21.1	12.5	17.9	17.1	15.2	33.6	29.0	12.5	18.4	13.8	6.6	28.9	16.8	21.6	14.9	21.0	12.7	15.5	13.4	12.8	15.9	18.9	17.8	30.2	25.9	17.4	7.0	33.1	20.2	17.7	14.0	28.4	16.5	26.7	25.0	24.0	22.9	20.8	19.2	21.5	10.3	24.6	6.6	13.5	5.1	16.0	20.8	18.6	11.8	16.7	16.6	22.7	8.1	20.9	17.2	13.7	9.6	18.7	13.2	13.1	27.9	24.4	9.0	15.1	9.9	17.2	23.9	25.4	9.0	16.4	11.3	14.6	14.1	18.7	12.4	10.6	15.0	5.9	24.3	37.7	11.4	13.2	13.7	19.5	14.7	20.9	13.9	4.4	6.6	11.6	10.7	14.6	5.6	20.3	14.0	10.3	13.5	10.8	14.5	12.6	9.8	23.4	18.8	21.6	10.2	12.9	20.8	14.3	15.2	18.1	17.0	25.0	21.5	18.0	17.6	24.9	20.9	16.7	22.9	19.2	16.2	24.0	18.2	10.3	19.6	34.2	20.6	30.2	21.1	12.5	29.0	12.5	21.6	33.1
NACC1	"BEND8, BTBD14B, BTBD30, NAC-1, NAC1"	ENSG00000160877	"Nucleus accumbens associated 1"	Q96RE7	19	13118103-13141141	"Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Repressor	"Disease mutation, Epilepsy, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA021238, HPA062245, CAB069927"	Enhanced		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"CAB069927: AB_1082966, HPA021238: AB_1845475, HPA062245: "	"unprognostic (2.19e-1)"	"unprognostic (9.20e-3)"	"unprognostic (2.67e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.62e-1)"	"unprognostic (7.75e-2)"	"unprognostic (8.46e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.93e-1)"	"unprognostic (8.46e-2)"	"unprognostic (2.40e-2)"	"unprognostic (3.04e-2)"	"unprognostic (7.35e-2)"	"unprognostic (2.80e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.97e-1)"	"unprognostic (9.74e-2)"	12.5	13.7	27.2	18.2	22.3	10.0	6.7	19.8	38.7	10.8	16.6	20.1	11.7	16.6	12.8	10.0	17.9	10.5	9.4	13.2	23.6	14.2	10.8	15.6	11.3	14.9	17.1	14.2	7.8	16.8	10.5	10.6	15.4	16.0	11.9	8.4	7.8	15.3	15.6	17.6	10.9	18.3	9.2	17.2	15.2	16.1	18.8	15.4	10.7	9.8	9.6	9.9	13.2	7.9	0.7	0.9	1.8	0.8	0.6	1.3	0.5	27.9	34.0	7.9	17.6	4.5	5.6	21.6	13.7	10.3	13.3	10.4	34.3	12.0	14.0	30.8	11.4	14.0	10.2	25.0	4.9	24.8	16.2	8.9	27.8	24.0	10.7	14.0	25.2	8.5	8.3	13.0	7.1	15.1	19.5	5.6	6.5	57.8	22.5	11.1	35.3	31.5	13.9	9.1	14.0	8.1	30.7	17.2	10.8	13.3	19.6	12.1	17.4	12.9	21.5	28.3	17.7	20.8	24.1	15.5	24.2	11.6	30.3	14.1	17.6	0.1	0.5	0.0	0.8	0.8	0.6	0.7	1.3	0.8	0.9	0.4	0.4	0.7	1.8	0.6	0.6	0.8	0.2	0.5	27.2	22.3	19.8	38.7	23.6	14.2	17.1	14.2	16.0	15.4
NMRK2	"ITGB1BP3, MIBP, NRK2"	ENSG00000077009	"Nicotinamide riboside kinase 2"	Q9NPI5	19	3933103-3942416	"Enzymes, Predicted intracellular proteins"	"Pyridine nucleotide biosynthesis"	"Kinase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	10	"heart muscle: 271.6;skeletal muscle: 103.2"	"Group enriched"	"Detected in some"	7	"BEWO: 22.4;NTERA-2: 18.5"	"Cancer enhanced"	"Detected in some"		"renal cancer: 32.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA049909, HPA054792, HPA072450"	Approved		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA049909: , HPA054792: , HPA072450: "				"unprognostic (3.61e-1)"	"unprognostic (5.92e-2)"	"unprognostic (1.18e-2)"		"unprognostic (2.54e-1)"	"unprognostic (1.03e-1)"	"unprognostic (7.61e-2)"		"unprognostic (3.30e-2)"	"prognostic favourable (1.19e-4)"	"unprognostic (1.72e-1)"	"unprognostic (3.29e-2)"	"unprognostic (5.38e-1)"		0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	1.0	0.0	0.0	271.6	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.4	0.0	1.0	1.9	0.1	103.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.4	18.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.5	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
NOV	"CCN3, IGFBP9"	ENSG00000136999	"Nephroblastoma overexpressed"	P48745	8	119416306-119424353	"Plasma proteins, Predicted secreted proteins, Transporters"		"Growth factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"adrenal gland: 236.7"	"Group enriched"	"Detected in many"	5	"BJ hTERT+: 43.0;U-2197: 44.5"	"Cancer enhanced"	"Detected in all"		"melanoma: 62.7"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	113	"eosinophil: 28.1;neutrophil: 14.0"	"Lineage enriched"	"Detected in single"	151	"granulocytes: 28.1"	"Group enriched"	"Detected in many"	7	"amygdala: 134.6;basal ganglia: 51.6;cerebral cortex: 101.0;hippocampal formation: 166.1"	"Low region specificity"	"Detected in many"			"HPA018449, HPA019684, CAB034423"	Enhanced		Enhanced	Vesicles	"Secreted to blood"	269030000	2900000	Vesicles		"CAB034423: AB_2151387, HPA018449: AB_1846189, HPA019684: AB_1846190"	"unprognostic (5.04e-2)"	"unprognostic (1.01e-1)"	"unprognostic (7.36e-3)"	"unprognostic (1.30e-3)"	"unprognostic (9.35e-3)"	"unprognostic (4.92e-1)"	"unprognostic (8.10e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.79e-2)"	"unprognostic (9.17e-2)"	"unprognostic (1.67e-1)"	"unprognostic (3.10e-1)"	"unprognostic (2.66e-1)"	"unprognostic (8.74e-3)"	"unprognostic (1.51e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.72e-2)"	6.3	236.7	2.2	1.4	7.9	1.0	5.6	3.1	12.3	5.0	2.0	3.6	3.6	1.5	5.8	2.9	1.9	3.0	2.0	5.7	3.5	1.9	4.9	0.9	2.9	1.1	2.1	15.1	1.8	2.7	2.1	13.4	0.8	7.4	5.6	2.2	1.2	1.2	5.0	1.6	3.6	1.5	2.5	2.5	1.0	1.6	2.6	0.0	0.0	6.9	4.8	1.1	3.3	2.5	0.0	0.1	28.1	0.1	0.0	0.0	0.0	0.0	1.0	0.6	0.0	3.9	1.0	0.0	5.7	43.0	5.2	3.0	0.0	0.1	0.0	4.5	7.2	3.6	0.2	0.0	1.7	0.0	0.1	0.0	3.3	0.0	0.1	0.0	0.0	0.2	0.0	2.0	0.2	0.1	0.0	0.0	0.2	0.2	0.0	0.0	0.0	8.6	0.0	0.0	0.0	5.5	0.0	1.3	0.0	2.1	0.0	8.0	0.0	0.0	0.0	3.7	5.7	44.5	1.1	0.0	0.0	0.0	5.9	1.8	4.3	0.0	0.1	28.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	14.0	0.0	0.0	0.0	0.0	0.0	2.2	7.9	3.1	12.3	3.5	1.9	2.1	15.1	7.4	0.0
OSBPL5	"KIAA1534, ORP5"	ENSG00000021762	"Oxysterol binding protein like 5"	Q9H0X9	11	3087116-3166739	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Lipid transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NB-4: 36.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 3.1;gdT-cell: 9.3;intermediate monocyte: 4.4;memory CD8 T-cell: 3.4;myeloid DC: 2.7;naive CD8 T-cell: 3.6;NK-cell: 10.0;non-classical monocyte: 10.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038335, HPA038712, HPA058727"	Approved		Enhanced	Vesicles				Vesicles		"HPA038335: , HPA038712: AB_10675949, HPA058727: AB_2683799"	"unprognostic (6.02e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.68e-1)"	"unprognostic (3.69e-2)"	"unprognostic (8.22e-3)"	"unprognostic (1.71e-1)"	"unprognostic (1.25e-1)"	"unprognostic (4.03e-3)"	"unprognostic (1.29e-1)"	"unprognostic (3.49e-3)"	"unprognostic (2.16e-3)"	"unprognostic (9.44e-2)"	"unprognostic (2.78e-2)"	"unprognostic (1.22e-1)"	"unprognostic (6.50e-2)"	"unprognostic (7.67e-2)"	"unprognostic (2.60e-1)"	17.6	7.0	4.2	10.3	6.2	17.8	20.7	4.4	8.8	24.7	15.6	7.5	24.0	9.0	17.1	15.9	8.1	12.6	13.8	10.0	4.6	6.5	8.1	2.7	12.9	10.5	6.9	6.4	9.6	8.4	2.4	6.5	7.8	9.8	15.9	5.2	9.0	17.1	17.5	28.0	17.8	9.6	20.1	11.9	20.3	10.2	4.4	6.3	36.5	9.3	9.6	3.8	14.3	17.7	0.0	2.7	1.0	10.1	10.0	9.3	3.9	1.7	2.7	3.2	3.7	9.7	4.5	0.0	8.8	4.3	3.5	2.5	0.0	5.1	0.0	2.7	4.9	6.5	0.6	2.4	0.5	1.7	2.5	7.3	8.7	0.0	7.9	6.5	1.1	7.0	2.9	1.2	1.3	2.4	2.5	0.0	1.7	4.9	14.2	36.3	2.3	5.7	7.4	4.4	1.0	1.4	1.6	5.4	0.6	3.6	12.9	3.3	5.3	17.3	8.0	4.5	6.1	10.6	1.5	1.8	0.0	0.2	4.7	12.3	5.6	0.2	3.1	1.0	9.3	4.4	1.2	0.0	1.0	3.4	2.7	0.0	0.6	3.6	0.4	10.0	10.1	1.2	0.1	3.9	4.2	6.2	4.4	8.8	4.6	6.5	6.9	6.4	9.8	6.3
P4HA2	C-P4Halpha(II)	ENSG00000072682	"Prolyl 4-hydroxylase subunit alpha 2"	O15460	5	132191838-132295315	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"		"Dioxygenase, Oxidoreductase"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HHSteC: 61.3;U-87 MG: 59.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA016997, HPA027824, CAB062557"	Enhanced		Enhanced	"Endoplasmic reticulum,Vesicles"	"Intracellular and membrane"			"Endoplasmic reticulum, Vesicles"		"CAB062557: , HPA016997: AB_2669501, HPA027824: AB_2672402"	"unprognostic (1.30e-3)"	"prognostic unfavourable (1.24e-5)"	"unprognostic (2.56e-3)"	"unprognostic (1.28e-3)"	"unprognostic (2.08e-3)"	"unprognostic (1.62e-3)"	"unprognostic (1.16e-3)"	"unprognostic (1.93e-3)"	"unprognostic (2.83e-2)"	"unprognostic (1.92e-1)"	"unprognostic (8.98e-2)"	"unprognostic (1.91e-1)"	"prognostic unfavourable (2.77e-7)"	"unprognostic (2.50e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.23e-1)"	"prognostic unfavourable (3.12e-4)"	10.2	5.6	7.1	6.5	5.4	0.8	12.2	9.5	7.8	14.4	12.5	4.6	6.1	9.8	20.0	35.3	11.6	13.7	9.7	26.1	6.6	7.0	34.4	6.3	16.0	4.3	6.3	4.2	6.7	42.5	6.7	15.8	15.1	9.5	9.3	14.6	15.1	21.1	8.4	7.1	9.3	17.1	23.3	5.1	6.3	12.6	5.1	4.4	4.1	12.2	10.8	5.4	11.3	34.5	0.2	1.0	3.1	1.3	2.6	2.6	0.7	10.1	6.2	2.0	9.9	27.9	33.3	11.3	47.5	40.6	20.2	50.0	14.0	8.9	0.2	14.0	50.8	12.8	6.2	24.8	32.0	7.5	2.1	0.0	9.1	8.4	61.3	0.0	6.1	20.1	36.7	23.9	22.0	10.6	3.6	0.6	24.7	4.0	0.0	0.0	0.5	5.1	0.1	0.6	1.5	5.6	1.9	1.0	2.8	12.1	4.0	8.0	5.0	0.7	16.3	30.7	12.0	9.3	10.2	4.3	4.6	2.0	59.2	0.0	8.5	0.0	1.3	0.0	2.6	1.1	2.4	0.0	1.4	0.4	0.6	0.2	0.0	0.4	3.1	2.6	0.2	1.0	0.0	0.7	7.1	5.4	9.5	7.8	6.6	7.0	6.3	4.2	9.5	4.4
PDCD6IP	"AIP1, Alix, Hp95"	ENSG00000170248	"Programmed cell death 6 interacting protein"	Q8WUM4	3	33798352-33869707	"Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Host-virus interaction, Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011905, CAB016212, HPA051604"	Approved		Enhanced	Vesicles	"Intracellular and membrane"		6200000	Vesicles		"CAB016212: AB_673819, HPA011905: AB_1855111, HPA051604: "	"unprognostic (1.53e-1)"	"unprognostic (2.63e-1)"	"prognostic favourable (1.16e-4)"	"unprognostic (2.17e-1)"	"unprognostic (2.75e-1)"	"unprognostic (5.12e-2)"	"unprognostic (7.76e-3)"	"unprognostic (1.23e-2)"	"unprognostic (3.29e-1)"	"unprognostic (2.86e-1)"	"unprognostic (3.88e-3)"	"unprognostic (4.49e-2)"	"prognostic favourable (3.90e-9)"	"unprognostic (9.61e-2)"	"unprognostic (1.89e-1)"	"unprognostic (4.78e-1)"	"unprognostic (1.11e-1)"	39.1	26.8	18.6	26.2	27.2	16.0	27.0	24.0	31.5	33.8	36.8	26.3	16.5	28.6	33.7	22.7	45.2	27.1	26.2	29.6	20.7	19.7	42.8	41.5	29.9	24.8	22.7	18.1	33.0	21.2	34.9	26.3	43.2	48.9	26.6	34.0	23.0	27.4	20.4	29.5	31.7	57.9	25.9	24.8	32.2	29.1	24.2	16.8	35.9	35.1	25.6	37.3	28.6	31.6	11.8	12.3	10.8	18.2	12.0	9.7	8.9	17.7	18.6	12.0	10.0	31.5	32.5	13.2	22.7	21.8	20.3	21.2	12.8	17.5	25.4	14.2	29.9	15.7	18.6	23.8	23.2	10.6	15.5	21.8	15.3	10.6	21.0	21.7	22.6	25.3	27.7	22.9	27.4	30.1	19.6	10.6	29.4	9.2	13.3	13.1	11.6	23.1	12.7	14.8	16.5	25.3	15.2	5.9	10.6	22.3	26.7	12.0	25.9	20.9	37.2	24.1	12.1	20.0	18.8	10.7	14.3	21.3	22.7	23.9	11.8	6.3	13.4	10.8	8.7	18.2	9.3	11.8	9.6	8.6	12.3	10.1	8.5	8.2	8.1	12.0	17.2	5.7	9.7	8.9	18.6	27.2	24.0	31.5	20.7	19.7	22.7	18.1	48.9	16.8
PDXDC1	KIAA0251	ENSG00000179889	"Pyridoxal dependent decarboxylase domain containing 1"	Q6P996	16	14974591-15139339	"Predicted intracellular proteins"		"Decarboxylase, Lyase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 91.1"	"Cell line enhanced"	"Detected in all"		"T-47d: 46.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047369, HPA049121, HPA051484"	Approved		Enhanced	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"HPA047369: , HPA049121: , HPA051484: "	"unprognostic (3.67e-2)"	"unprognostic (4.99e-1)"	"unprognostic (1.97e-3)"	"unprognostic (1.84e-1)"	"unprognostic (9.08e-2)"	"unprognostic (2.18e-1)"	"unprognostic (6.47e-3)"	"unprognostic (4.97e-2)"	"unprognostic (2.43e-1)"	"unprognostic (2.74e-1)"	"unprognostic (7.61e-2)"	"unprognostic (1.32e-1)"	"prognostic favourable (3.13e-4)"	"unprognostic (4.58e-2)"	"unprognostic (8.11e-2)"	"unprognostic (2.15e-1)"	"unprognostic (2.88e-1)"	10.5	13.2	11.0	11.7	10.7	6.0	27.8	15.4	16.9	13.8	21.6	9.0	11.8	27.7	10.9	16.5	14.2	11.0	16.6	15.5	11.5	8.1	21.9	33.8	11.2	12.7	10.2	10.0	11.2	37.4	17.2	26.0	19.6	12.8	19.6	25.3	13.7	25.2	14.7	22.1	8.8	30.9	13.1	14.9	10.6	24.6	91.1	8.7	6.9	16.3	8.2	9.5	13.4	11.1	11.0	12.8	12.0	8.3	7.7	12.6	7.8	7.8	11.6	12.0	10.0	6.7	8.1	19.8	7.4	6.6	5.5	7.7	14.2	17.2	15.1	16.3	9.9	12.9	8.4	7.6	8.0	9.2	11.5	9.1	19.5	37.2	17.5	7.2	21.8	8.5	7.9	9.6	8.1	5.8	6.7	9.9	13.0	19.3	4.7	3.8	5.8	4.4	7.3	4.9	18.0	8.8	12.8	12.3	8.8	20.0	11.5	19.0	46.4	11.2	9.0	4.3	3.9	4.7	9.5	9.3	9.0	14.6	8.8	6.1	13.6	3.2	8.0	12.0	11.0	8.3	12.6	9.2	8.0	8.9	12.8	11.0	10.0	9.4	1.1	7.7	6.6	5.9	7.0	7.8	11.0	10.7	15.4	16.9	11.5	8.1	10.2	10.0	12.8	8.7
PICALM	"CALM, CLTH"	ENSG00000073921	"Phosphatidylinositol binding clathrin assembly protein"	Q13492	11	85957684-86069882	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	Endocytosis		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 25.8"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019053, HPA019061"	Enhanced		Enhanced	Vesicles			28000	Vesicles		"HPA019053: AB_1855361, HPA019061: AB_1855362"	"unprognostic (9.27e-3)"	"unprognostic (7.29e-2)"	"unprognostic (3.51e-1)"	"unprognostic (6.83e-2)"	"unprognostic (5.13e-2)"	"unprognostic (1.93e-1)"	"unprognostic (5.36e-3)"	"unprognostic (9.02e-3)"	"unprognostic (9.80e-2)"	"unprognostic (6.27e-3)"	"prognostic unfavourable (6.61e-4)"	"unprognostic (4.31e-1)"	"prognostic favourable (2.02e-6)"	"unprognostic (1.26e-2)"	"unprognostic (5.21e-3)"	"unprognostic (2.52e-1)"	"unprognostic (1.02e-1)"	72.9	24.2	35.6	43.1	51.4	37.1	51.3	30.2	39.7	38.7	35.9	60.0	27.7	39.6	41.6	26.0	41.3	31.5	48.1	41.4	43.7	34.2	63.9	53.8	45.1	35.2	52.0	33.5	38.2	29.7	70.6	23.8	76.7	50.7	29.9	32.0	26.7	31.8	37.0	35.5	35.0	45.3	49.9	70.7	49.5	30.7	22.9	55.1	31.0	30.8	28.5	34.8	44.0	49.2	2.1	7.1	25.8	8.5	3.9	5.3	3.1	28.9	13.8	21.9	15.3	33.6	35.3	41.4	37.3	48.5	29.5	26.1	54.4	39.5	22.6	38.5	59.8	24.0	22.9	27.2	42.7	6.7	8.2	64.2	18.8	17.3	34.3	15.0	28.9	30.6	29.5	55.3	46.1	32.0	41.1	18.7	55.5	17.0	17.6	13.8	12.0	7.9	12.2	33.2	16.0	57.3	24.5	13.3	10.8	45.8	15.5	12.3	21.0	12.2	34.6	54.6	19.0	64.4	29.7	6.7	17.5	20.7	12.9	11.9	36.8	3.6	8.5	4.2	3.9	7.2	3.3	2.1	2.9	5.3	7.1	1.4	3.0	2.7	25.8	3.9	7.2	2.5	3.8	3.1	35.6	51.4	30.2	39.7	43.7	34.2	52.0	33.5	50.7	55.1
PLCH1	"DKFZp434C1372, KIAA1069, MGC117152, PLCeta1, PLCL3"	ENSG00000114805	"Phospholipase C eta 1"	Q4KWH8	3	155375580-155745067	"Enzymes, Predicted intracellular proteins"	"Lipid degradation, Lipid metabolism"	"Hydrolase, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 14.7;testis: 15.8"	"Cell line enhanced"	"Detected in some"		"A549: 8.2;AF22: 26.6;NTERA-2: 14.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"MAIT T-cell: 1.2"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA036176, HPA057978"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA036176: AB_10671837, HPA057978: "	"unprognostic (1.08e-2)"	"unprognostic (3.68e-1)"	"unprognostic (2.17e-2)"	"unprognostic (1.55e-2)"	"unprognostic (3.50e-4)"	"unprognostic (6.41e-2)"	"unprognostic (2.94e-5)"	"unprognostic (5.04e-2)"	"unprognostic (2.41e-1)"	"unprognostic (2.24e-3)"	"unprognostic (4.84e-2)"	"unprognostic (1.76e-2)"	"prognostic favourable (3.03e-5)"	"unprognostic (3.28e-2)"	"unprognostic (1.62e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.37e-2)"	0.3	0.3	3.9	0.7	14.1	0.5	3.9	7.4	14.7	2.1	3.9	5.7	4.1	3.9	1.4	12.9	0.5	12.4	2.4	2.5	4.5	3.6	2.1	0.4	6.1	0.3	3.4	7.3	0.5	2.5	0.8	3.2	0.8	6.5	0.8	3.9	5.6	2.3	3.4	0.6	0.5	3.9	0.5	1.9	0.3	5.8	15.8	2.9	0.0	8.9	0.0	0.4	1.3	0.4	0.1	0.3	0.7	0.0	0.0	1.2	0.9	0.0	8.2	26.6	1.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	1.5	6.6	0.0	0.5	0.0	0.0	4.7	0.0	0.0	0.0	2.4	6.6	0.0	0.9	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.8	1.5	6.1	14.1	1.1	0.6	0.0	0.0	1.6	0.1	2.5	0.6	0.0	6.4	0.0	2.8	0.0	0.0	0.0	0.1	0.0	1.1	0.3	0.0	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.0	1.2	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.3	0.0	0.9	3.9	14.1	7.4	14.7	4.5	3.6	3.4	7.3	6.5	2.9
POU2F2	"OCT2, OTF2"	ENSG00000028277	"POU class 2 homeobox 2"	P09086	19	42086110-42196585	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 33.1;brain: 12.0;intestine: 10.8;lymphoid tissue: 43.1"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 18.1;Daudi: 38.2;hTEC/SVTERT24-B: 15.0;U-266/70: 26.6;U-266/84: 25.7;U-698: 30.3;U-87 MG: 14.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 33.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002513, HPA049056, HPA062096, HPA064404"	Enhanced		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB002513: AB_442118, HPA049056: , HPA062096: , HPA064404: "	"unprognostic (2.07e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.16e-2)"	"unprognostic (8.89e-2)"	"unprognostic (6.77e-2)"	"unprognostic (1.44e-2)"	"unprognostic (1.62e-2)"	"unprognostic (3.34e-1)"	"unprognostic (8.39e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.52e-1)"	"unprognostic (8.56e-2)"	"prognostic unfavourable (7.57e-11)"	"unprognostic (2.31e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.61e-2)"	"unprognostic (1.54e-1)"	1.9	2.0	5.6	43.1	7.4	4.8	1.2	12.0	5.7	0.9	3.2	2.5	0.0	2.1	0.9	1.7	1.4	1.5	2.3	4.8	5.7	5.9	1.6	1.4	3.1	31.4	6.8	1.5	0.7	1.6	0.4	2.1	2.5	6.6	2.5	2.1	1.4	2.1	2.3	0.7	1.2	10.8	1.9	6.5	22.7	3.1	6.0	6.2	1.9	1.3	0.6	30.0	4.3	1.0	13.9	8.0	1.7	33.1	0.6	2.7	4.5	0.3	0.5	0.6	0.0	0.0	1.0	0.1	2.8	18.1	1.8	3.5	0.1	0.5	38.2	1.0	1.0	0.3	0.2	2.9	8.2	0.1	0.1	0.9	0.1	0.0	0.2	0.3	0.7	0.8	0.5	15.0	1.0	1.1	0.4	8.8	0.4	0.2	0.1	2.0	0.1	0.2	0.4	0.0	0.1	0.0	0.2	0.6	0.3	0.1	0.2	0.2	0.0	4.8	1.4	7.8	0.8	0.0	0.3	26.6	25.7	30.3	14.6	0.9	1.0	1.0	10.7	0.1	1.2	19.3	1.1	11.0	1.8	1.6	8.0	13.9	0.9	1.3	1.7	0.6	33.1	1.3	2.7	4.5	5.6	7.4	12.0	5.7	5.7	5.9	6.8	1.5	6.6	6.2
PPARG	"NR1C3, PPARG1, PPARG2, PPARgamma"	ENSG00000132170	"Peroxisome proliferator activated receptor gamma"	P37231	3	12287368-12434356	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 97.6;breast: 102.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 47.4;ASC TERT1: 27.0;BEWO: 55.9;CAPAN-2: 25.0;HSkMC: 27.8;PC-3: 24.9;RT4: 34.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 33.5"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.8;intermediate monocyte: 2.3"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB004282, HPA051239, HPA063663"	Approved		Enhanced	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB004282: AB_628115, HPA051239: , HPA063663: "	"unprognostic (7.35e-3)"	"unprognostic (3.27e-2)"	"unprognostic (4.05e-2)"	"unprognostic (8.37e-2)"	"unprognostic (2.41e-2)"	"unprognostic (5.27e-3)"	"prognostic unfavourable (3.41e-5)"	"unprognostic (9.13e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.77e-1)"	"prognostic favourable (1.59e-8)"	"unprognostic (1.51e-2)"	"unprognostic (1.46e-1)"	"unprognostic (9.68e-3)"	"prognostic favourable (5.52e-5)"	97.6	1.6	1.9	17.1	1.2	0.7	102.1	1.5	1.3	3.1	24.9	0.8	2.1	7.5	3.5	2.2	2.8	2.4	8.7	12.5	1.4	0.9	6.7	5.9	24.8	11.4	1.1	0.9	6.7	1.2	2.8	0.3	26.8	0.9	10.4	13.9	1.1	5.8	1.5	5.0	2.7	9.6	7.4	1.2	7.0	11.9	3.5	0.6	0.9	6.2	4.3	2.1	30.2	14.1	0.0	0.4	0.0	2.3	0.0	0.7	0.3	9.6	8.6	0.0	0.0	47.4	27.0	55.9	0.9	10.4	1.3	0.5	1.8	25.0	0.0	0.0	0.9	3.9	3.4	0.1	0.2	23.2	4.8	0.0	1.9	2.3	12.6	0.0	0.0	27.8	2.3	2.3	9.0	0.1	0.0	0.0	2.0	2.4	0.0	0.1	0.1	24.9	0.0	0.0	0.0	7.1	34.1	0.0	0.2	4.0	1.5	0.5	0.0	7.7	7.8	1.8	2.6	1.0	0.0	0.0	0.0	0.0	0.8	0.1	0.2	0.0	1.8	0.0	0.0	2.3	0.0	0.0	0.7	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.3	1.9	1.2	1.5	1.3	1.4	0.9	1.1	0.9	0.9	0.6
PPOX	"PPO, VP"	ENSG00000143224	"Protoporphyrinogen oxidase"	P50336	1	161166410-161178013	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Heme biosynthesis, Porphyrin biosynthesis"	Oxidoreductase	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA030123, HPA054287"	Uncertain		Supported	"Golgi apparatus,Vesicles"				Vesicles	"Golgi apparatus"	"HPA030123: AB_10603987, HPA054287: "	"unprognostic (1.17e-1)"	"unprognostic (4.73e-2)"	"unprognostic (9.88e-2)"	"unprognostic (2.13e-2)"	"unprognostic (3.24e-1)"	"unprognostic (1.64e-2)"	"unprognostic (9.58e-3)"	"unprognostic (1.79e-2)"	"unprognostic (9.17e-2)"	"unprognostic (1.17e-1)"	"unprognostic (2.18e-3)"	"unprognostic (7.12e-3)"	"prognostic unfavourable (9.89e-4)"	"unprognostic (6.12e-2)"	"unprognostic (2.23e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.80e-2)"	7.3	14.8	11.6	9.1	12.1	31.7	10.2	23.5	16.5	11.0	9.9	13.2	8.5	6.0	11.7	13.5	7.5	33.2	9.5	9.5	11.5	12.5	12.0	9.1	10.2	11.2	14.2	16.1	13.0	13.1	10.5	12.3	10.1	12.1	11.0	6.7	14.4	11.3	14.6	8.5	15.9	7.1	10.0	10.6	12.0	8.2	6.9	13.7	9.2	11.0	6.1	8.7	8.7	8.2	9.8	11.5	6.9	7.7	12.3	16.7	8.9	7.0	6.5	9.8	6.4	7.4	7.9	3.3	4.9	5.7	6.0	8.1	7.7	6.8	5.5	11.8	3.4	4.9	7.5	7.9	5.5	3.8	14.9	6.7	14.7	17.5	7.9	2.2	3.7	6.3	7.9	5.9	8.3	11.4	19.7	8.6	4.4	6.6	8.9	7.0	7.0	14.0	10.8	6.8	13.1	11.4	3.1	7.8	12.5	5.9	8.7	9.8	15.6	10.4	4.0	5.6	6.2	4.8	6.2	15.4	11.2	8.5	5.7	4.9	4.3	6.9	7.7	5.5	12.7	7.7	8.4	9.8	9.8	8.8	11.5	8.6	8.6	8.8	1.6	12.3	5.3	7.2	16.7	8.9	11.6	12.1	23.5	16.5	11.5	12.5	14.2	16.1	12.1	13.7
PUSL1	FLJ90811	ENSG00000169972	"Pseudouridylate synthase-like 1"	Q8N0Z8	1	1308567-1311677	"Predicted intracellular proteins"	"tRNA processing"	Isomerase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HEK 293: 33.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA032057, HPA039999"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA032057: AB_10601251, HPA039999: "	"unprognostic (2.04e-2)"	"unprognostic (1.60e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.80e-1)"	"unprognostic (3.91e-1)"	"prognostic unfavourable (1.33e-4)"	"unprognostic (7.55e-2)"	"unprognostic (4.35e-2)"	"unprognostic (1.47e-1)"	"unprognostic (2.44e-2)"	"unprognostic (3.91e-2)"	"prognostic unfavourable (1.62e-5)"	"unprognostic (3.05e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.44e-1)"	7.6	11.7	8.0	8.8	6.8	8.8	9.1	9.4	9.2	13.6	9.2	9.8	15.4	9.9	11.2	14.4	17.1	9.1	10.3	9.2	7.9	6.0	9.5	16.2	7.1	7.8	12.2	6.8	11.4	19.5	6.2	13.2	8.0	6.6	12.4	5.0	9.5	23.3	13.7	11.0	17.0	9.6	7.5	6.5	8.8	11.4	8.3	7.7	9.0	10.6	16.7	11.9	10.9	9.8	9.0	11.3	5.8	16.6	8.1	13.4	7.8	10.0	4.5	4.6	7.8	2.2	3.6	6.3	9.1	5.0	9.0	6.1	15.6	6.6	6.1	7.4	4.4	8.2	5.1	8.3	1.6	6.8	33.4	8.5	8.2	9.3	8.5	10.1	8.2	3.5	4.3	4.9	3.8	4.0	10.8	2.8	4.1	8.2	9.5	13.1	6.2	20.0	8.8	3.5	14.5	6.9	3.8	21.3	7.7	7.1	21.3	7.2	5.9	6.7	4.7	5.8	6.0	9.4	8.6	11.2	3.5	26.1	7.2	9.1	3.4	3.6	12.3	5.8	10.6	16.6	10.6	8.9	11.6	8.7	11.3	9.0	7.7	7.7	4.9	8.1	14.0	7.1	13.4	7.8	8.0	6.8	9.4	9.2	7.9	6.0	12.2	6.8	6.6	7.7
RAB11A	YL8	ENSG00000103769	"RAB11A, member RAS oncogene family"	P62491	15	65726054-65891991	"Predicted intracellular proteins"	"Cell cycle, Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013097, HPA051697, HPA060686"	Approved		Enhanced	"Vesicles,Centriolar satellite"				"Vesicles, Centriolar satellite"		"CAB013097: AB_2533987, HPA051697: , HPA060686: "	"unprognostic (4.15e-2)"	"unprognostic (5.86e-2)"	"unprognostic (1.22e-1)"	"unprognostic (8.74e-3)"	"unprognostic (6.85e-2)"	"unprognostic (6.07e-2)"	"unprognostic (3.17e-2)"	"unprognostic (7.12e-2)"	"unprognostic (8.60e-2)"	"unprognostic (4.83e-2)"	"prognostic unfavourable (4.37e-4)"	"unprognostic (4.29e-2)"	"prognostic favourable (1.46e-5)"	"unprognostic (9.93e-2)"	"unprognostic (1.83e-2)"	"unprognostic (5.23e-3)"	"unprognostic (1.21e-1)"	43.3	64.1	32.4	27.0	49.6	25.1	35.4	34.9	57.3	41.3	49.9	27.7	30.5	31.4	36.4	31.7	131.6	34.2	42.8	34.5	35.0	40.5	52.4	28.7	38.1	32.8	34.3	36.6	35.6	24.5	32.3	36.6	60.5	60.5	35.8	52.2	33.7	58.3	31.2	27.3	79.8	35.2	34.3	33.1	55.3	47.9	47.4	25.1	32.4	46.2	60.7	62.1	51.7	60.6	18.1	31.5	54.0	33.3	15.1	24.5	59.5	42.0	49.9	51.0	36.9	46.7	43.9	66.7	45.0	45.9	41.1	49.1	45.8	75.8	55.3	46.0	51.5	65.2	80.2	59.6	38.8	36.0	47.9	66.2	36.1	40.5	35.6	31.0	39.4	44.7	67.9	40.3	33.6	90.9	53.1	33.0	57.9	41.8	30.6	24.6	42.5	28.4	26.1	38.7	51.2	110.3	110.6	36.8	39.1	32.4	51.6	41.7	68.2	36.3	68.6	32.6	46.5	31.3	39.7	17.4	41.3	43.0	30.2	52.7	34.9	32.4	32.1	51.8	14.0	29.8	14.3	18.1	21.0	16.6	31.5	14.1	19.8	15.5	54.0	15.1	33.3	20.3	24.5	59.5	32.4	49.6	34.9	57.3	35.0	40.5	34.3	36.6	60.5	25.1
RAB11FIP1	"FLJ22524, FLJ22622, Rab11-FIP1, RCP"	ENSG00000156675	"RAB11 family interacting protein 1"	Q6WKZ4	8	37858618-37899467	"Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 90.6"	"Cell line enhanced"	"Detected in many"		"K-562: 29.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 39.0"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 39.0"	"Low region specificity"	"Detected in single"							"CAB017037, HPA023904, HPA024010, HPA025960"	Enhanced		Enhanced	Vesicles				Vesicles		"CAB017037: , HPA023904: AB_1855990, HPA024010: AB_1855991, HPA025960: AB_1855992"	"unprognostic (1.62e-2)"	"unprognostic (3.47e-2)"	"unprognostic (3.22e-3)"	"unprognostic (2.87e-1)"	"unprognostic (1.06e-1)"	"prognostic favourable (6.61e-4)"	"unprognostic (4.32e-1)"	"unprognostic (4.50e-3)"	"unprognostic (1.58e-1)"	"unprognostic (4.72e-2)"	"unprognostic (2.82e-3)"	"unprognostic (2.73e-2)"	"prognostic favourable (1.14e-6)"	"unprognostic (4.94e-2)"	"unprognostic (8.41e-2)"	"unprognostic (9.99e-2)"	"unprognostic (1.50e-1)"	6.9	3.2	1.3	16.8	1.0	17.8	7.4	1.8	1.3	8.9	37.1	1.9	17.8	13.8	2.9	8.8	30.9	5.6	31.5	5.9	1.1	1.3	8.4	4.1	64.5	8.4	1.1	0.6	4.7	31.5	3.9	12.9	26.0	6.9	7.0	16.4	9.9	20.9	21.3	3.4	13.8	90.6	5.3	1.3	10.9	15.2	5.4	0.9	16.4	8.5	14.9	34.1	9.6	9.6	2.3	6.9	39.0	7.7	4.1	4.0	3.3	17.2	7.6	0.8	3.4	0.2	0.0	23.5	1.8	2.8	3.3	4.2	17.0	9.9	7.0	5.5	2.1	13.4	6.2	3.9	4.9	18.2	5.8	1.3	4.0	4.9	9.3	3.0	15.7	2.2	5.3	1.2	3.4	0.0	29.7	3.5	1.7	4.1	5.0	4.4	5.1	2.3	1.6	4.2	5.4	17.0	17.7	3.2	3.7	4.5	22.5	5.5	15.2	5.8	0.2	0.1	10.2	0.2	0.3	7.1	8.3	1.9	0.1	4.1	2.4	6.9	7.7	13.7	1.8	3.7	4.0	2.3	1.3	1.2	6.9	1.7	0.8	0.9	39.0	4.1	6.9	4.2	2.9	3.3	1.3	1.0	1.8	1.3	1.1	1.3	1.1	0.6	6.9	0.9
RAB11FIP5	"GAF1, KIAA0857, pp75, RIP11"	ENSG00000135631	"RAB11 family interacting protein 5"	Q9BXF6	2	73073382-73156721	"Plasma proteins, Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 46.4"	"Cell line enhanced"	"Detected in many"		"TIME: 25.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.6"	"Lineage enriched"	"Detected in single"	18	"T-cells: 2.6"					"Low region specificity"	"Detected in all"			"HPA036406, HPA036407"	Enhanced		Enhanced	"Vesicles,Centriolar satellite"				"Vesicles, Centriolar satellite"		"HPA036406: , HPA036407: AB_10669778"	"unprognostic (1.49e-1)"	"unprognostic (4.40e-3)"	"unprognostic (1.41e-2)"	"unprognostic (2.45e-3)"	"unprognostic (1.67e-3)"	"unprognostic (3.26e-2)"	"unprognostic (1.58e-3)"	"unprognostic (4.08e-3)"	"unprognostic (2.27e-1)"	"prognostic unfavourable (3.87e-4)"	"unprognostic (3.23e-3)"	"unprognostic (1.45e-1)"	"prognostic favourable (2.26e-5)"	"unprognostic (1.17e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.83e-1)"	"unprognostic (9.66e-3)"	8.4	5.4	5.3	3.8	9.3	1.5	6.3	9.5	16.7	5.2	4.2	2.8	4.6	3.5	7.9	7.3	5.3	5.6	8.2	7.2	4.9	6.3	14.9	2.3	4.8	2.1	5.6	6.5	6.7	8.4	22.3	4.3	11.4	16.0	5.3	2.1	5.1	9.5	5.9	9.0	5.8	2.6	5.2	2.9	18.9	4.9	46.4	2.5	0.0	3.9	4.7	2.7	5.3	7.4	0.1	0.0	0.0	0.0	0.0	2.6	0.5	12.0	5.4	0.4	3.8	4.0	4.8	7.0	18.2	10.0	6.2	4.8	3.9	3.0	0.0	9.6	9.2	4.9	2.3	5.6	2.8	20.9	6.7	4.4	2.3	2.5	4.9	0.0	0.8	5.8	5.3	7.6	5.0	8.5	3.4	2.4	4.4	0.3	0.0	0.1	2.9	8.6	4.1	4.9	10.2	5.4	1.5	1.8	1.9	6.0	2.5	2.7	1.4	0.2	25.0	15.1	8.8	11.2	9.5	7.9	2.3	0.0	11.8	4.7	1.4	0.0	0.0	0.0	2.6	0.0	0.5	0.0	1.2	1.9	0.0	0.1	0.2	1.5	0.0	0.0	0.0	0.0	0.8	0.5	5.3	9.3	9.5	16.7	4.9	6.3	5.6	6.5	16.0	2.5
RAB20	FLJ20429	ENSG00000139832	"RAB20, member RAS oncogene family"	Q9NX57	13	110523066-110561733	"Plasma proteins, Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CACO-2: 19.5;SK-BR-3: 35.9;T-47d: 22.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA003621, HPA052111, HPA068647"	Uncertain		Enhanced	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"HPA003621: , HPA052111: , HPA068647: "	"unprognostic (5.59e-3)"	"unprognostic (1.30e-1)"	"unprognostic (3.48e-1)"	"unprognostic (1.42e-3)"	"unprognostic (1.30e-1)"	"unprognostic (3.82e-2)"	"unprognostic (1.14e-2)"	"unprognostic (5.99e-2)"	"unprognostic (9.43e-2)"	"unprognostic (2.06e-2)"	"unprognostic (9.41e-2)"	"unprognostic (2.65e-1)"	"prognostic favourable (8.57e-4)"	"unprognostic (6.96e-2)"	"unprognostic (4.32e-2)"	"unprognostic (2.28e-2)"	"prognostic favourable (4.48e-4)"	30.9	23.5	3.7	11.9	5.3	11.9	27.5	1.3	4.0	6.9	20.2	5.2	3.0	15.7	6.0	8.8	4.1	6.8	17.8	17.0	5.3	2.5	15.9	38.2	27.8	21.9	7.1	1.8	17.0	14.5	3.2	5.8	12.6	9.1	9.4	8.3	8.5	10.9	3.2	8.8	2.6	23.8	5.0	13.4	32.9	15.0	6.3	3.6	2.5	13.6	1.9	4.2	13.2	13.6	1.9	8.3	13.4	19.4	0.0	3.6	5.6	8.0	1.2	0.8	1.6	5.3	1.4	13.1	0.7	2.5	3.4	5.3	19.5	16.5	0.0	5.8	0.7	3.1	1.6	5.0	1.8	9.0	1.2	8.0	1.5	9.0	3.3	1.1	2.4	2.9	0.8	1.8	0.5	1.3	1.5	0.0	0.7	9.7	0.0	11.6	1.7	3.5	0.7	0.0	3.6	5.9	10.7	0.2	0.9	1.5	35.9	10.9	22.6	12.4	0.9	0.8	1.8	0.0	1.1	0.0	0.0	0.0	11.7	15.8	1.7	2.8	19.4	3.5	0.6	17.0	0.7	1.9	1.6	0.5	8.3	1.2	3.6	1.2	13.4	0.0	12.7	0.4	0.4	5.6	3.7	5.3	1.3	4.0	5.3	2.5	7.1	1.8	9.1	3.6
RAB30		ENSG00000137502	"RAB30, member RAS oncogene family"	Q15771	11	82973133-83071923	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 21.6;HDLM-2: 19.3;U-698: 58.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"memory B-cell: 23.2;naive B-cell: 25.1"	"Lineage enriched"	"Detected in many"	5	"B-cells: 25.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054514, HPA060565"	Approved		Enhanced	Vesicles				Vesicles		"HPA054514: , HPA060565: "	"unprognostic (3.21e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.82e-1)"	"unprognostic (5.18e-2)"	"unprognostic (7.21e-2)"	"unprognostic (8.06e-2)"	"unprognostic (2.91e-2)"	"unprognostic (3.14e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.53e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.64e-2)"	"unprognostic (2.37e-1)"	"unprognostic (2.42e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.85e-1)"	12.2	17.3	15.8	14.5	21.6	12.7	13.8	19.9	22.5	10.3	12.6	30.6	2.2	16.7	10.3	6.7	7.0	7.2	6.5	9.9	17.2	12.2	4.5	8.5	7.4	21.1	27.9	15.0	15.5	4.9	6.0	10.0	10.0	22.8	8.6	14.3	10.9	8.8	6.7	19.8	11.8	20.0	11.6	29.3	10.9	11.2	4.2	29.2	3.3	7.2	5.0	29.0	11.0	8.3	25.1	2.6	0.5	0.4	0.9	5.4	2.7	1.4	1.9	2.0	1.3	4.6	6.6	2.4	3.3	3.4	6.5	3.2	3.5	0.6	21.6	4.1	5.0	1.8	3.0	2.2	4.2	19.3	0.6	5.3	6.2	1.7	1.1	0.6	0.9	4.2	1.5	3.2	2.2	5.3	0.6	5.4	3.9	2.7	0.7	0.1	2.7	3.6	1.5	5.6	8.1	3.8	1.3	2.6	1.7	9.4	2.0	1.0	4.5	0.0	6.5	3.1	6.9	3.1	1.0	8.5	4.5	58.4	1.2	0.5	2.2	0.5	0.3	0.5	2.3	0.1	1.6	23.2	2.2	2.2	0.8	25.1	5.4	4.6	0.5	0.9	0.4	2.6	4.1	2.7	15.8	21.6	19.9	22.5	17.2	12.2	27.9	15.0	22.8	29.2
RALY	"HNRPCL2, P542"	ENSG00000125970	"RALY heterogeneous nuclear ribonucleoprotein"	Q9UKM9	20	33993646-34108308	"Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Ribonucleoprotein, RNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA040971, HPA043614"	Enhanced		Enhanced	Nucleoplasm,Vesicles			12000	Nucleoplasm	Vesicles	"HPA040971: AB_2677230, HPA043614: AB_2678581"	"unprognostic (2.06e-1)"	"unprognostic (9.54e-3)"	"unprognostic (3.72e-2)"	"unprognostic (2.28e-1)"	"unprognostic (4.68e-2)"	"unprognostic (1.01e-1)"	"prognostic unfavourable (3.60e-4)"	"unprognostic (3.06e-1)"	"unprognostic (1.27e-1)"	"unprognostic (3.66e-1)"	"unprognostic (4.20e-2)"	"unprognostic (8.59e-2)"	"unprognostic (3.29e-2)"	"unprognostic (2.88e-2)"	"unprognostic (8.61e-3)"	"unprognostic (1.64e-2)"	"unprognostic (8.80e-2)"	37.7	23.4	26.3	39.9	30.7	65.2	55.4	22.4	33.9	35.0	43.7	37.6	35.1	41.9	36.4	31.0	41.6	35.2	38.9	51.9	27.3	24.4	39.3	30.3	40.9	53.9	33.0	23.4	38.3	38.5	21.9	20.7	41.9	26.5	34.9	34.9	32.0	38.7	32.7	62.0	39.8	48.8	41.7	40.9	40.4	36.0	56.8	28.9	76.0	76.7	43.6	42.6	33.5	49.7	30.8	40.9	61.6	54.1	54.1	48.4	40.4	36.3	25.2	40.8	31.1	18.3	19.5	33.1	25.5	21.2	34.3	29.6	67.8	33.1	28.7	37.6	21.2	41.1	19.2	39.8	19.5	18.8	19.9	68.0	14.8	67.7	25.4	35.0	34.7	20.7	24.3	25.3	26.0	33.2	28.1	49.2	21.8	35.3	87.1	56.6	21.1	48.7	51.6	55.8	39.0	20.9	23.1	38.9	43.6	42.6	40.8	57.9	41.6	37.3	26.0	70.9	42.9	34.4	31.8	49.3	41.3	51.1	35.6	26.6	32.5	32.9	32.4	61.6	44.3	39.9	33.1	30.8	40.1	48.4	40.9	30.7	35.6	33.6	52.9	54.1	54.1	33.8	42.0	40.4	26.3	30.7	22.4	33.9	27.3	24.4	33.0	23.4	26.5	28.9
RANBP2	"ADANE, ANE1, NUP358"	ENSG00000153201	"RAN binding protein 2"	P49792	2	108719481-108785811	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"mRNA transport, Protein transport, Translocation, Transport, Ubl conjugation pathway"	"RNA-binding, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564"	Supported		Enhanced	"Nuclear membrane,Vesicles"				"Nuclear membrane, Vesicles"		"CAB034063: AB_2176784, HPA018437: AB_2620151, HPA023960: , HPA049497: , HPA051675: , HPA067564: "	"unprognostic (2.51e-1)"	"unprognostic (3.99e-2)"	"unprognostic (1.22e-1)"	"unprognostic (4.37e-2)"	"unprognostic (1.28e-2)"	"unprognostic (9.30e-2)"	"unprognostic (5.47e-2)"	"unprognostic (2.91e-1)"	"unprognostic (4.02e-2)"	"unprognostic (2.54e-1)"	"unprognostic (4.23e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.62e-2)"	"unprognostic (8.74e-2)"	"unprognostic (3.08e-1)"	"unprognostic (3.40e-2)"	"unprognostic (2.53e-1)"	20.5	24.3	14.4	17.0	18.6	35.5	24.4	23.1	22.2	19.8	17.1	12.8	25.5	13.3	19.9	21.5	17.0	19.1	14.8	20.2	12.9	12.5	18.9	19.5	17.7	19.2	15.1	17.0	32.4	24.1	48.5	37.5	18.8	16.5	21.8	15.8	14.3	20.0	31.6	37.5	17.3	17.4	23.2	17.8	16.3	20.9	20.6	15.9	26.6	28.7	18.0	17.5	20.5	19.7	5.6	5.1	8.3	6.3	4.2	8.7	2.3	18.2	11.2	16.1	14.6	18.8	16.9	15.6	16.5	13.1	13.6	12.0	27.8	8.8	28.8	12.8	17.1	15.4	27.5	17.1	19.9	17.5	13.3	30.0	13.9	19.6	11.0	35.0	10.1	14.1	13.1	21.3	16.6	20.8	32.1	16.0	18.0	10.1	15.5	14.3	20.3	13.4	14.6	24.8	13.9	12.1	22.9	23.5	10.8	14.6	12.6	16.0	8.0	16.1	24.8	14.3	18.9	10.0	18.4	13.3	19.6	26.2	11.1	15.8	11.0	8.3	5.3	5.1	7.6	3.4	8.7	5.5	6.3	6.9	4.2	5.6	6.2	6.7	8.3	4.2	6.3	5.1	5.1	2.3	14.4	18.6	23.1	22.2	12.9	12.5	15.1	17.0	16.5	15.9
RANGAP1	"Fug1, KIAA1835, SD"	ENSG00000100401	"Ran GTPase activating protein 1"	P46060	22	41245611-41286251	"Plasma proteins, Predicted intracellular proteins, Transporters"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004293, HPA050110, HPA062034"	Supported		Enhanced	"Nuclear membrane,Vesicles,Cytosol"				"Nuclear membrane"	"Vesicles, Cytosol"	"CAB004293: AB_2176987, HPA050110: AB_2681018, HPA062034: AB_2684667"	"unprognostic (1.30e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.66e-1)"	"unprognostic (7.97e-2)"	"unprognostic (2.57e-1)"	"unprognostic (2.54e-1)"	"prognostic unfavourable (1.08e-4)"	"unprognostic (8.28e-3)"	"unprognostic (8.09e-2)"	"unprognostic (9.87e-2)"	"unprognostic (5.84e-2)"	"unprognostic (7.56e-2)"	"unprognostic (7.07e-3)"	"prognostic favourable (5.39e-4)"	"unprognostic (2.06e-1)"	"unprognostic (2.74e-1)"	"unprognostic (2.68e-1)"	12.2	30.7	23.5	16.9	28.4	28.5	16.1	17.6	41.1	8.5	11.8	23.1	7.3	12.7	9.5	9.4	26.1	11.5	13.7	11.5	26.9	30.4	12.0	25.1	11.5	19.5	31.7	28.6	10.6	20.2	11.0	17.7	16.1	28.1	11.4	9.6	7.1	16.3	13.3	12.5	51.6	12.8	12.3	22.0	14.2	16.0	64.3	28.3	22.1	12.7	14.4	21.7	13.3	29.2	8.7	7.6	8.2	14.8	7.1	13.1	9.7	58.7	30.9	20.1	21.0	10.9	9.0	24.5	51.0	27.9	51.4	27.0	37.5	19.4	31.7	41.1	37.3	54.7	36.6	40.1	31.1	25.6	56.8	26.8	30.1	29.2	13.6	43.3	20.2	8.7	19.1	36.6	32.5	26.9	34.4	22.6	29.2	50.4	25.2	35.2	22.0	36.8	31.0	19.9	33.4	20.1	33.7	18.3	12.2	36.2	32.1	18.6	18.9	17.5	41.6	39.4	37.8	21.7	41.8	16.8	22.4	30.2	27.5	30.8	22.7	2.8	9.5	8.2	11.2	11.2	13.1	7.9	11.3	10.3	7.1	8.7	10.5	8.0	2.7	7.1	14.8	7.6	11.6	9.7	23.5	28.4	17.6	41.1	26.9	30.4	31.7	28.6	28.1	28.3
RC3H2	"FLJ20301, FLJ20713, MNAB, RNF164"	ENSG00000056586	"Ring finger and CCCH-type domains 2"	Q9HBD1	9	122844556-122905341	"Enzymes, Predicted intracellular proteins, Transcription factors"	"Ubl conjugation pathway"	"Repressor, RNA-binding, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA042863, HPA062144"	Approved		Enhanced	Vesicles				Vesicles		"HPA042863: , HPA062144: "	"unprognostic (6.05e-2)"	"unprognostic (7.87e-2)"	"unprognostic (7.24e-2)"	"unprognostic (1.66e-1)"	"unprognostic (4.08e-3)"	"unprognostic (2.37e-1)"	"unprognostic (2.43e-2)"	"unprognostic (3.92e-2)"	"unprognostic (1.99e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.21e-1)"	"prognostic favourable (5.50e-4)"	"unprognostic (1.36e-1)"	"unprognostic (1.68e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.26e-1)"	16.4	10.7	25.4	14.1	28.8	30.6	14.1	18.7	27.6	17.1	13.0	10.5	14.4	11.0	14.6	9.7	16.5	12.2	12.6	15.7	18.1	11.2	15.0	14.8	16.2	19.2	12.3	25.3	14.7	9.7	19.0	16.2	16.3	12.6	11.5	13.1	9.4	13.2	13.9	16.1	13.8	13.0	16.3	14.4	15.2	12.8	12.8	13.2	18.9	15.0	11.5	18.8	14.1	13.7	8.6	9.6	12.4	10.4	4.9	8.9	3.7	9.8	14.3	19.1	10.3	10.2	12.1	10.6	12.6	13.8	14.9	13.0	17.3	10.4	16.5	10.3	16.8	23.1	20.4	14.8	16.4	7.6	8.1	9.4	25.8	11.4	13.4	11.1	15.1	11.6	14.4	14.5	20.6	20.4	13.2	12.1	18.8	13.2	10.9	7.8	9.5	13.3	11.0	31.6	10.6	14.5	7.8	22.5	15.6	22.3	13.8	11.4	16.6	9.4	20.2	11.5	9.6	15.6	22.4	8.5	13.8	18.0	13.1	9.9	12.9	12.4	6.6	8.5	8.9	10.4	7.3	6.5	7.3	8.9	5.8	8.6	7.0	6.8	11.8	4.9	9.3	9.6	7.1	3.7	25.4	28.8	18.7	27.6	18.1	11.2	12.3	25.3	12.6	13.2
RUNX1	"AML1, AMLCR1, CBFA2, PEBP2A2"	ENSG00000159216	"Runt related transcription factor 1"	Q01196	21	34787801-36004667	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 54.3;lymphoid tissue: 58.6"	"Cell line enhanced"	"Detected in many"		"HEL: 65.0;HMC-1: 39.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 17.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA004176, HPA037912"	Enhanced		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA004176: AB_1078412, HPA037912: "	"unprognostic (4.06e-3)"	"unprognostic (2.35e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.15e-3)"	"unprognostic (2.62e-1)"	"unprognostic (5.87e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.12e-3)"	"unprognostic (2.33e-2)"	"unprognostic (3.47e-2)"	"prognostic unfavourable (3.44e-15)"	"unprognostic (1.48e-1)"	"unprognostic (1.50e-1)"	"unprognostic (6.17e-2)"	"unprognostic (5.47e-2)"	11.5	3.2	5.2	14.8	7.3	29.8	54.3	1.0	4.3	12.5	4.7	3.8	4.0	3.8	2.9	7.4	6.5	4.6	12.4	7.6	6.1	2.0	4.2	6.7	17.9	13.9	8.5	1.1	6.5	5.8	1.6	5.5	6.4	6.0	9.9	5.1	3.5	29.8	8.8	14.4	8.3	5.1	6.8	12.3	10.6	12.7	2.9	6.6	58.6	4.6	5.7	14.2	11.0	9.1	3.2	3.4	17.0	3.9	1.3	4.8	2.0	13.0	1.0	0.0	0.1	3.4	4.4	8.6	7.4	7.5	4.1	3.1	0.6	10.0	6.4	0.5	6.5	11.8	0.8	8.8	6.0	9.9	1.0	65.0	2.6	3.0	6.3	7.5	39.2	8.5	5.3	12.5	12.4	2.3	4.4	3.8	8.7	2.8	30.3	11.9	0.6	3.8	30.7	22.8	3.9	5.5	5.2	0.3	0.0	7.6	1.9	2.7	3.9	17.6	9.7	6.8	8.8	10.1	11.1	12.5	5.1	6.1	8.5	16.5	9.9	17.0	3.2	6.3	3.4	1.4	3.3	3.2	3.1	3.2	0.9	3.1	4.8	3.8	3.5	1.3	3.9	3.4	4.0	2.0	5.2	7.3	1.0	4.3	6.1	2.0	8.5	1.1	6.0	6.6
SAMD9	"C7orf5, FLJ20073, KIAA2004"	ENSG00000205413	"Sterile alpha motif domain containing 9"	Q5K651	7	93099513-93118023	"Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 34.6;lymphoid tissue: 35.4"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+ SV40 Large T+ RasG12V: 30.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA021318, HPA021319"	Approved		Enhanced	Vesicles,Cytosol				"Vesicles, Cytosol"		"HPA021318: AB_2183383, HPA021319: AB_1856554"	"unprognostic (3.66e-2)"	"unprognostic (5.35e-1)"	"unprognostic (8.60e-2)"	"prognostic unfavourable (3.14e-4)"	"unprognostic (8.96e-2)"	"unprognostic (1.38e-1)"	"unprognostic (7.48e-2)"	"prognostic unfavourable (2.93e-4)"	"unprognostic (4.76e-2)"	"unprognostic (3.37e-2)"	"prognostic unfavourable (8.31e-5)"	"unprognostic (6.00e-2)"	"prognostic unfavourable (8.40e-7)"	"unprognostic (5.91e-2)"	"unprognostic (1.37e-2)"	"unprognostic (2.18e-2)"	"unprognostic (3.64e-1)"	9.6	4.0	2.3	9.2	2.4	5.2	2.6	1.0	1.6	9.3	6.8	0.6	0.9	4.3	2.8	3.0	34.6	2.7	4.3	2.5	1.3	1.5	6.3	3.5	7.8	10.8	2.5	1.1	6.3	2.3	0.1	6.4	11.3	3.1	5.3	7.0	0.7	5.7	1.6	2.4	1.5	12.7	2.2	2.5	21.7	6.3	2.5	1.7	35.4	3.3	9.9	9.5	4.8	9.7	5.5	3.0	15.6	9.8	7.4	7.6	2.6	12.2	1.6	0.4	0.1	5.5	7.0	0.1	4.8	20.1	23.0	30.5	0.1	13.6	5.1	7.6	11.8	14.5	0.0	4.4	7.8	17.4	0.6	7.4	8.2	0.0	2.5	8.3	10.4	3.1	6.4	7.6	2.1	3.4	0.5	12.8	4.8	0.0	12.3	6.8	0.0	3.5	4.1	4.1	5.8	0.1	1.5	2.0	0.2	3.7	1.4	3.9	0.4	4.1	14.8	5.4	1.9	16.1	2.6	7.6	1.4	4.7	5.6	4.9	5.3	15.6	3.6	12.7	7.6	7.0	7.3	5.0	5.9	6.5	3.0	5.5	6.3	5.7	15.5	7.4	9.8	2.1	7.2	2.6	2.3	2.4	1.0	1.6	1.3	1.5	2.5	1.1	3.1	1.7
SEC23IP	p125	ENSG00000107651	"SEC23 interacting protein"	Q9Y6Y8	10	119892711-119944658	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038403, HPA043305"	Approved		Enhanced	Vesicles				Vesicles		"HPA038403: AB_10675796, HPA043305: AB_2678416"	"unprognostic (4.05e-2)"	"unprognostic (5.01e-2)"	"unprognostic (8.70e-2)"	"unprognostic (1.35e-1)"	"unprognostic (3.12e-1)"	"unprognostic (1.07e-1)"	"unprognostic (9.52e-3)"	"unprognostic (1.78e-1)"	"unprognostic (3.36e-1)"	"unprognostic (2.33e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.00e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.23e-1)"	"unprognostic (6.81e-3)"	"unprognostic (3.43e-2)"	21.6	22.4	11.7	26.3	15.9	21.3	22.0	18.2	16.1	21.3	19.4	19.2	22.8	15.5	25.7	25.7	21.1	20.4	22.0	18.2	18.7	11.4	19.0	32.9	20.0	25.5	10.4	13.0	23.2	21.6	19.3	23.2	21.2	16.8	21.0	21.9	19.1	23.3	27.0	24.3	20.9	20.4	26.0	12.4	20.2	27.5	30.9	11.1	23.3	22.2	15.2	25.4	21.6	18.7	14.3	14.3	15.1	20.6	14.6	17.6	11.1	19.3	23.7	16.2	23.2	16.0	21.0	13.9	19.4	32.2	20.4	24.2	22.8	18.8	21.6	9.0	27.8	16.7	23.6	22.0	30.3	16.9	20.9	17.7	12.5	18.1	21.9	19.9	21.6	24.1	12.0	26.2	24.5	26.2	14.5	16.2	19.8	12.3	18.6	14.0	19.2	17.1	16.7	32.4	11.9	15.1	19.2	7.5	17.4	18.1	12.8	15.4	14.1	12.7	23.2	12.6	12.2	18.6	22.4	21.3	19.1	25.9	20.5	23.9	10.9	15.1	12.3	12.2	14.0	19.3	17.6	14.3	13.9	15.7	14.3	12.1	14.8	13.9	5.0	14.6	20.6	9.0	14.4	11.1	11.7	15.9	18.2	16.1	18.7	11.4	10.4	13.0	16.8	11.1
SERPINA1	"A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1"	ENSG00000197249	"Serpin family A member 1"	P01009	14	94376747-94390693	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Blood coagulation, Hemostasis"	"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	16	"liver: 3314.2"	"Cell line enriched"	"Detected in some"	8	"Hep G2: 318.5"	"Cancer enriched"	"Detected in all"	10	"liver cancer: 3850.6"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	5	"classical monocyte: 110.2;intermediate monocyte: 165.9;neutrophil: 139.3;non-classical monocyte: 203.0"	"Group enriched"	"Detected in many"	5	"granulocytes: 139.3;monocytes: 203.0"					"Region enriched"	"Detected in many"	6	"cerebellum: 334.2"	"HPA000927, HPA001292, CAB013211, CAB016648, CAB073396"	Enhanced		Enhanced	Vesicles	"Secreted to blood"	1663100000000	210000000000	Vesicles		"CAB013211: , CAB016648: AB_1611888, CAB073396: , HPA000927: AB_1844761, HPA001292: AB_1844762"	"prognostic favourable (1.61e-5)"	"unprognostic (3.37e-1)"	"prognostic favourable (5.86e-4)"	"unprognostic (1.38e-2)"	"unprognostic (1.98e-2)"	"unprognostic (5.50e-3)"	"unprognostic (3.81e-2)"	"unprognostic (6.78e-2)"	"unprognostic (2.54e-2)"	"unprognostic (7.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.54e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.30e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.96e-1)"	0.9	0.4	0.7	4.9	1.4	3.0	2.4	0.2	0.7	2.6	7.5	0.5	3.1	6.3	0.8	8.6	0.4	0.7	14.2	1.0	0.4	0.5	74.1	3314.2	13.6	5.3	1.0	0.2	0.6	7.4	0.0	0.4	0.8	0.8	0.6	4.1	0.6	0.9	3.6	0.2	0.3	36.2	1.4	1.3	8.9	7.0	0.8	0.8	0.5	0.8	0.2	0.9	0.5	0.6	0.3	33.5	139.3	203.0	0.2	0.3	100.0	2.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	12.6	40.1	0.1	1.1	0.0	0.1	0.0	0.8	0.0	4.9	0.0	0.2	0.1	318.5	0.0	1.1	0.1	0.2	0.4	0.0	1.4	0.0	0.2	0.0	0.0	0.0	0.0	0.7	0.1	0.5	0.1	1.1	0.1	21.5	0.2	0.0	0.0	0.4	0.1	0.1	18.9	0.1	0.1	0.1	5.0	0.1	0.6	0.2	0.1	0.4	0.3	2.8	0.0	0.4	110.2	29.1	0.2	165.9	0.3	0.3	0.1	0.2	33.5	0.1	0.2	0.1	139.3	0.2	203.0	0.7	0.2	100.0	0.7	1.4	0.2	0.7	0.4	0.5	1.0	0.2	0.8	0.8
SERTM1	C13orf36	ENSG00000180440	"Serine rich and transmembrane domain containing 1"	A2A2V5	13	36673912-36697839	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"brain: 30.2;endometrium 1: 30.9;fallopian tube: 25.3"	"Group enriched"	"Detected in some"	5	"HAP1: 2.6;HEK 293: 3.1;NTERA-2: 7.9;SH-SY5Y: 4.6"	"Cancer enhanced"	"Detected in some"		"ovarian cancer: 3.7"	"Group enriched"	"Detected in many"	7	"amygdala: 13.9;basal ganglia: 10.1;cerebral cortex: 21.6;hippocampal formation: 26.5;olfactory region: 11.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA054814, HPA070485"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA054814: , HPA070485: "	"unprognostic (8.71e-2)"	"unprognostic (2.11e-1)"		"unprognostic (5.58e-3)"	"unprognostic (4.66e-3)"			"unprognostic (4.05e-3)"		"unprognostic (5.06e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.00e-8)"	"unprognostic (2.51e-2)"	"unprognostic (5.60e-2)"	"unprognostic (4.44e-2)"		5.0	1.8	13.9	0.5	10.1	0.5	1.2	0.3	30.2	16.4	0.7	1.3	1.8	0.6	30.9	13.5	0.5	25.3	0.5	0.6	26.5	2.0	0.6	0.5	5.6	0.5	1.5	11.6	14.5	0.8	1.0	11.2	0.5	2.4	0.9	0.5	8.2	0.5	1.2	0.5	0.6	0.6	17.4	0.9	0.5	0.9	1.5	0.0	0.0	9.3	0.0	0.5	1.1	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	3.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.0	0.0	0.0	0.3	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.9	10.1	0.3	21.6	26.5	2.0	1.5	11.6	2.4	0.0
SPINK5	"DKFZp686K19184, FLJ21544, FLJ97536, FLJ97596, FLJ99794, LEKTI, LETKI, NETS, NS, VAKTI"	ENSG00000133710	"Serine peptidase inhibitor, Kazal type 5"	Q9NQ38	5	148025683-148137289	"Disease related genes, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Hypotrichosis, Ichthyosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix, uterine: 101.6;esophagus: 313.0;tongue: 97.4"	"Cell line enhanced"	"Detected in some"		"HaCaT: 12.1;HeLa: 17.9;Karpas-707: 15.8"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 45.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA009067, HPA011351, CAB015347"	Enhanced		Enhanced	Vesicles	"Secreted in other tissues"		28000000	Vesicles		"CAB015347: AB_2196138, HPA009067: AB_1080084, HPA011351: AB_1857447"	"unprognostic (9.66e-3)"	"unprognostic (1.42e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.17e-1)"	"unprognostic (3.25e-2)"	"unprognostic (1.42e-3)"	"unprognostic (2.45e-2)"	"unprognostic (6.85e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.28e-2)"	"unprognostic (4.92e-3)"	"unprognostic (4.56e-1)"	"unprognostic (2.44e-1)"	"unprognostic (7.91e-2)"	"unprognostic (2.82e-1)"	"unprognostic (6.87e-2)"	"unprognostic (2.59e-1)"	0.1	0.0	0.2	0.1	0.1	0.0	2.8	0.1	0.2	101.6	0.7	0.2	0.1	0.0	3.2	0.2	313.0	0.0	0.2	0.2	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.2	0.3	0.1	0.2	1.7	0.2	18.1	0.1	0.2	48.6	0.1	0.1	0.1	0.1	0.7	0.2	0.1	3.6	0.3	97.4	65.3	0.3	64.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.2	1.5	0.0	12.1	0.0	1.0	0.0	0.0	0.0	0.0	17.9	0.0	0.0	0.2	0.0	0.0	3.4	0.0	0.0	0.2	0.7	15.8	0.0	1.7	0.0	0.0	2.1	0.2	0.0	0.0	0.0	0.0	4.6	2.4	0.0	0.5	0.0	0.0	3.8	0.0	0.0	0.0	0.1	0.0	0.0	4.1	1.5	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1
SQSTM1	"A170, OSIL, p60, p62, p62B, PDB3"	ENSG00000161011	"Sequestosome 1"	Q13501	5	179806398-179838078	"Disease related genes, Predicted intracellular proteins"	"Apoptosis, Autophagy, Differentiation, Immunity"		"Amyotrophic lateral sclerosis, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 196.4;HHSteC: 135.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004587, HPA064165, HPA068843"	Supported		Enhanced	Vesicles,Cytosol				"Vesicles, Cytosol"		"CAB004587: AB_628279, HPA064165: , HPA068843: "	"unprognostic (1.08e-1)"	"unprognostic (1.39e-1)"	"unprognostic (3.19e-1)"	"unprognostic (9.45e-2)"	"unprognostic (1.47e-2)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (2.31e-5)"	"unprognostic (1.34e-1)"	"unprognostic (2.34e-1)"	"unprognostic (5.65e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.70e-1)"	"unprognostic (9.52e-2)"	"unprognostic (3.21e-1)"	"unprognostic (8.68e-3)"	"unprognostic (4.41e-2)"	"unprognostic (2.01e-1)"	47.8	74.5	12.4	21.6	16.0	19.5	60.4	26.2	23.4	25.2	31.7	20.9	39.8	22.9	29.4	27.7	30.8	23.1	45.2	51.9	13.9	12.8	38.6	88.3	33.3	33.4	23.2	16.3	32.3	51.8	22.7	33.6	72.7	15.6	36.2	15.2	28.9	39.0	36.2	102.8	15.3	22.0	36.3	15.5	25.6	40.0	18.9	17.9	18.8	60.4	45.3	17.5	47.9	64.0	27.8	34.2	100.4	58.3	28.2	38.7	52.4	13.9	79.8	3.8	11.4	56.5	39.0	57.4	20.4	61.0	16.2	20.8	15.6	57.7	2.2	56.7	31.2	17.3	7.5	17.2	7.6	196.4	11.7	6.6	28.9	24.4	135.4	6.7	36.3	32.7	21.9	30.3	46.9	16.6	7.0	46.9	34.6	11.0	2.6	6.5	9.4	24.9	5.2	8.4	21.8	24.0	61.1	8.4	7.4	30.2	29.5	72.8	14.7	11.6	36.9	28.4	12.6	26.9	26.1	70.2	73.5	7.3	64.7	11.4	31.5	90.0	58.3	59.9	32.7	39.6	38.7	27.8	28.9	29.2	34.2	27.1	24.0	24.0	100.4	28.2	36.6	14.8	38.7	52.4	12.4	16.0	26.2	23.4	13.9	12.8	23.2	16.3	15.6	17.9
STK11IP	"KIAA1898, LIP1, LKB1IP, STK11IP1"	ENSG00000144589	"Serine/threonine kinase 11 interacting protein"		2	219597860-219616451	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"				"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"plasmacytoid DC: 14.8"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036837, HPA036838, HPA053192"	Approved		Enhanced	Vesicles				Vesicles		"HPA036837: AB_10969754, HPA036838: AB_10672100, HPA053192: "	"unprognostic (3.37e-1)"	"unprognostic (1.33e-1)"	"unprognostic (3.51e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.15e-1)"	"unprognostic (3.33e-3)"	"unprognostic (1.22e-3)"	"unprognostic (8.36e-2)"	"unprognostic (9.36e-2)"	"unprognostic (1.87e-2)"	"prognostic favourable (1.63e-4)"	"unprognostic (9.51e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.80e-3)"	"unprognostic (9.44e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.51e-2)"	5.7	8.4	10.1	11.9	10.7	15.2	6.4	15.0	9.5	5.8	8.2	6.7	6.7	8.1	9.2	14.3	8.2	9.1	9.5	6.2	7.0	6.5	7.2	5.6	7.4	11.4	5.1	7.5	17.0	9.9	7.0	21.2	12.1	7.0	8.2	7.2	6.2	5.8	6.3	5.1	16.3	7.9	7.5	5.9	10.6	6.4	27.7	6.4	26.5	8.9	7.1	9.6	5.9	6.3	1.7	14.8	5.0	6.1	3.4	2.7	2.1	6.9	10.8	11.6	7.8	4.1	7.4	11.9	6.2	5.4	10.1	8.6	9.9	11.8	4.0	6.3	5.9	17.3	5.5	13.2	7.5	5.9	8.3	10.4	11.0	8.0	5.4	10.8	27.7	7.1	11.9	8.4	4.3	6.1	7.8	6.1	5.6	13.6	6.3	13.5	11.6	6.0	12.0	4.2	3.1	10.0	11.0	7.6	12.1	4.0	9.9	8.1	6.3	10.6	4.6	11.0	9.3	10.4	6.0	6.8	3.0	7.2	8.3	6.0	6.8	1.5	3.9	5.0	2.7	5.7	2.4	1.7	1.3	2.2	7.6	1.5	1.1	1.1	1.3	3.4	6.1	14.8	2.1	2.1	10.1	10.7	15.0	9.5	7.0	6.5	5.1	7.5	7.0	6.4
STX16	"hsyn16, SYN16"	ENSG00000124222	"Syntaxin 16"	O14662	20	58651253-58679526	"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA041019, HPA042033"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA041019: AB_10964273, HPA042033: AB_10963935"	"unprognostic (7.52e-2)"	"unprognostic (1.91e-1)"	"unprognostic (7.96e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.12e-1)"	"prognostic unfavourable (4.18e-4)"	"unprognostic (7.32e-2)"	"unprognostic (5.11e-2)"	"unprognostic (3.51e-2)"	"unprognostic (2.80e-3)"	"unprognostic (2.41e-2)"	"prognostic unfavourable (1.11e-16)"	"unprognostic (3.35e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.56e-1)"	"unprognostic (5.89e-2)"	22.1	24.5	41.9	25.3	46.7	36.7	22.3	54.5	43.2	21.9	23.3	35.0	35.9	20.3	30.3	36.9	18.8	26.7	23.4	17.3	36.8	22.4	18.6	20.0	20.5	32.8	43.0	32.8	29.2	23.1	18.5	33.0	20.5	34.0	24.6	21.1	20.9	27.9	28.5	25.9	41.5	23.6	29.4	33.0	31.0	21.7	22.2	42.9	16.6	23.7	15.7	24.7	24.2	24.3	4.7	4.3	14.1	6.2	5.6	6.1	4.0	14.4	8.5	11.2	10.9	20.7	22.1	15.6	18.0	12.2	18.5	11.5	16.5	21.2	16.7	25.2	12.8	21.5	10.2	21.4	15.4	7.8	10.8	10.4	22.3	19.9	20.6	14.8	23.6	24.5	32.9	12.4	18.9	18.6	12.0	14.9	14.9	33.8	11.4	17.9	4.5	14.5	10.6	10.5	11.4	14.1	10.8	7.4	11.3	19.0	33.6	32.3	13.4	19.7	19.7	30.6	14.8	11.6	19.7	30.9	14.3	9.3	22.5	11.5	12.7	14.1	6.2	5.2	5.0	5.6	5.6	2.6	4.5	3.5	4.1	4.7	6.1	5.5	14.0	5.6	4.1	4.3	4.8	4.0	41.9	46.7	54.5	43.2	36.8	22.4	43.0	32.8	34.0	42.9
SYNDIG1	"C20orf39, FLJ14220, IFITMD5, SynDIG1, TMEM90B"	ENSG00000101463	"Synapse differentiation inducing 1"	Q9H7V2	20	24469199-24666616	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 23.3;heart muscle: 28.2"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 8.0;RH-30: 22.8;RPMI-8226: 21.6;SCLC-21H: 5.3;U-87 MG: 13.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA044271, HPA059267"			Enhanced	Vesicles				Vesicles		"HPA044271: , HPA059267: "	"unprognostic (9.33e-2)"	"unprognostic (1.83e-2)"	"unprognostic (2.17e-1)"	"unprognostic (9.56e-2)"	"unprognostic (5.03e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.62e-1)"	"unprognostic (4.69e-2)"	"unprognostic (4.23e-1)"	"unprognostic (3.71e-2)"	"unprognostic (1.94e-2)"	"unprognostic (7.75e-3)"	"unprognostic (2.21e-1)"	"prognostic unfavourable (6.16e-6)"	"unprognostic (1.40e-3)"	2.6	1.7	12.5	2.1	12.0	0.7	0.8	21.3	22.7	4.5	1.5	23.3	0.3	1.9	2.6	1.5	0.9	5.1	10.0	28.2	12.8	8.8	6.2	0.7	1.1	2.5	14.5	12.9	1.3	1.4	0.9	0.6	0.9	11.5	3.2	1.6	0.5	0.8	14.8	0.6	0.8	2.8	3.1	22.4	1.4	2.2	1.3	16.6	0.1	5.1	0.0	3.1	2.7	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.3	0.0	0.4	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.0	0.0	0.4	0.0	0.0	1.4	0.0	0.0	22.8	21.6	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.0	13.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.5	12.0	21.3	19.7	12.8	8.8	14.5	12.9	11.5	16.6
SYNPO2	MYOPODIN	ENSG00000172403	"Synaptopodin 2"	Q9UMS6	4	118850688-119061247	"Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 185.8"	"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 25.8;LHCN-M2: 9.2;SH-SY5Y: 39.3"	"Cancer enhanced"	"Detected in all"		"stomach cancer: 27.0"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Region enriched"	"Detected in many"	5	"thalamus: 64.1"	"Low region specificity"	"Detected in all"			"HPA030665, CAB037231, HPA049707, HPA068563"	Enhanced		Enhanced	"Vesicles,Actin filaments"				"Vesicles, Actin filaments"		"CAB037231: AB_262098, HPA030665: AB_10696210, HPA049707: , HPA068563: "	"unprognostic (1.50e-2)"	"unprognostic (1.73e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.39e-1)"	"unprognostic (5.71e-4)"	"unprognostic (2.18e-1)"	"unprognostic (3.07e-1)"	"unprognostic (3.52e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.66e-1)"	"prognostic unfavourable (5.67e-5)"	"unprognostic (1.82e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.26e-1)"	"prognostic unfavourable (3.91e-4)"	11.4	2.3	1.8	9.6	3.9	0.0	7.3	1.0	5.6	26.5	56.0	4.4	20.5	6.5	37.5	23.9	37.0	14.2	19.4	29.0	2.6	1.5	2.4	1.7	3.7	5.7	1.9	5.2	27.9	1.4	0.9	2.6	3.8	3.8	35.9	11.1	21.2	4.1	58.8	185.8	3.7	14.5	88.7	4.0	6.1	29.5	9.6	3.1	3.0	3.7	12.8	2.1	50.7	15.5	1.8	0.2	2.0	0.4	1.2	2.3	0.4	0.1	1.8	0.1	0.0	5.5	1.8	0.3	5.7	6.3	0.2	0.2	0.0	0.3	0.6	0.0	25.8	0.1	0.1	0.1	0.3	2.4	0.0	0.3	0.4	0.0	1.3	0.0	0.1	6.6	0.1	1.8	0.1	0.0	0.0	0.3	9.2	0.1	0.3	3.5	0.6	0.0	0.2	0.6	0.1	0.1	0.1	0.2	39.3	0.2	0.1	0.0	0.0	3.3	0.1	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.2	0.0	1.9	0.3	2.0	1.2	0.1	1.9	1.3	2.0	1.2	0.1	1.8	2.1	1.3	0.9	1.2	0.4	0.2	2.3	0.4	1.8	3.9	1.0	5.6	2.6	1.5	1.9	5.2	3.8	3.1
TBK1	NAK	ENSG00000183735	"TANK binding kinase 1"	Q9UHD2	12	64451880-64502108	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Antiviral defense, Host-virus interaction, Immunity, Innate immunity"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Amyotrophic lateral sclerosis, Disease mutation, Glaucoma, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045797, HPA060211"	Uncertain		Enhanced	Nucleoplasm,Vesicles				Nucleoplasm	Vesicles	"HPA045797: , HPA060211: "	"unprognostic (4.73e-2)"	"unprognostic (8.46e-2)"	"unprognostic (6.07e-3)"	"unprognostic (1.90e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.28e-1)"	"prognostic unfavourable (3.30e-4)"	"unprognostic (1.26e-1)"	"prognostic unfavourable (3.48e-4)"	"unprognostic (1.69e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.24e-2)"	"prognostic unfavourable (4.20e-6)"	"unprognostic (4.35e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.26e-2)"	"unprognostic (9.56e-3)"	19.1	23.3	13.7	16.8	17.1	32.3	19.1	17.8	20.5	14.9	18.3	10.0	14.1	18.0	17.0	15.1	15.3	13.8	15.6	11.7	14.7	15.6	15.4	20.8	17.8	18.3	20.2	13.6	15.6	11.1	13.1	27.2	40.6	21.1	16.3	12.9	10.1	15.0	18.3	24.8	12.1	21.4	17.2	18.8	24.6	14.5	27.9	16.9	3.4	13.3	12.6	16.7	18.4	19.6	9.7	8.2	22.5	11.9	16.3	11.8	5.9	13.4	15.5	8.8	12.9	15.8	16.0	19.5	14.8	21.5	13.9	13.3	8.7	8.2	18.9	12.9	16.0	12.7	11.4	12.4	16.5	17.3	10.8	20.2	11.2	12.0	17.4	20.6	25.3	12.0	11.4	13.9	13.4	18.5	15.5	27.5	17.9	16.5	0.6	16.2	17.7	9.1	9.6	9.8	18.2	15.2	24.5	7.4	10.7	19.5	20.0	14.3	20.5	15.0	17.1	12.6	12.2	10.1	14.4	17.4	30.3	18.4	15.9	11.4	16.2	22.5	7.3	16.6	11.0	11.9	11.8	9.7	8.0	11.0	8.2	7.6	2.8	7.1	15.1	16.3	10.6	1.9	9.5	5.9	13.7	17.1	17.8	20.5	14.7	15.6	20.2	13.6	21.1	16.9
TMEM63A	KIAA0792	ENSG00000196187	"Transmembrane protein 63A"	O94886	1	225845536-225882369	"Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 91.4"	"Cell line enhanced"	"Detected in many"		"RPMI-8226: 37.7;SK-BR-3: 42.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA066504, HPA066936, HPA068918"			Enhanced	"Vesicles,Centriolar satellite"			96000	"Vesicles, Centriolar satellite"		"HPA066504: , HPA066936: , HPA068918: "	"unprognostic (5.31e-2)"	"unprognostic (3.46e-2)"	"unprognostic (2.14e-2)"	"prognostic favourable (8.79e-4)"	"unprognostic (2.05e-1)"	"unprognostic (7.16e-3)"	"unprognostic (2.52e-2)"	"unprognostic (1.76e-2)"	"unprognostic (2.57e-1)"	"unprognostic (1.27e-1)"	"unprognostic (6.55e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.14e-2)"	"unprognostic (1.62e-1)"	"unprognostic (3.35e-1)"	"unprognostic (2.92e-2)"	10.5	7.4	14.7	11.6	38.8	18.6	12.2	4.1	23.2	14.3	14.0	91.4	17.3	12.2	12.2	11.2	6.6	13.9	12.9	8.5	30.2	15.1	14.3	15.1	12.6	15.4	59.3	16.4	13.1	22.4	11.6	5.3	11.3	34.9	22.3	17.8	5.7	55.8	19.1	6.9	9.9	13.3	8.8	71.0	14.0	22.9	3.0	49.6	11.2	8.0	4.5	12.4	13.3	9.6	5.4	10.0	5.5	4.1	8.7	16.6	5.7	9.3	2.8	2.4	7.1	19.6	6.8	16.9	7.1	7.7	8.0	8.1	10.2	6.9	2.6	13.2	8.7	14.4	2.6	4.3	3.7	8.7	4.7	11.3	6.5	6.1	4.5	4.2	29.9	7.1	2.7	4.7	2.9	5.1	9.4	2.2	6.3	5.9	3.7	4.3	13.3	4.6	3.7	7.5	37.7	12.2	24.7	0.2	1.3	5.2	42.0	5.1	9.7	4.0	6.1	4.6	3.2	4.2	6.4	0.9	3.4	0.6	4.2	2.4	8.4	5.5	3.2	3.0	9.4	2.7	10.6	5.2	12.1	8.9	2.5	5.4	10.9	6.3	5.1	8.7	4.1	10.0	16.6	5.7	14.7	38.8	4.1	23.0	30.2	15.1	59.3	16.4	34.9	49.6
TNPO3	"IPO12, LGMD1F, MTR10A, TRN-SR, TRN-SR2"	ENSG00000064419	"Transportin 3"	Q9Y5L0	7	128954180-129055173	"Disease related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Disease mutation, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039555, HPA041537"	Approved		Enhanced	Vesicles				Vesicles		"HPA039555: AB_10672000, HPA041537: "	"unprognostic (5.76e-2)"	"unprognostic (1.72e-2)"	"unprognostic (1.97e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.05e-1)"	"unprognostic (1.74e-1)"	"prognostic unfavourable (3.29e-5)"	"unprognostic (1.86e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.93e-2)"	"unprognostic (2.27e-2)"	"unprognostic (2.34e-2)"	"unprognostic (3.26e-2)"	"unprognostic (4.70e-2)"	"unprognostic (2.93e-1)"	"unprognostic (2.04e-1)"	"unprognostic (4.24e-2)"	17.8	24.0	22.6	23.8	20.5	28.9	16.2	29.6	21.4	15.2	18.4	15.8	30.1	15.5	19.7	17.9	26.3	16.1	12.9	16.1	16.6	17.7	19.1	21.6	15.4	20.5	17.7	15.5	20.7	19.8	21.7	19.2	13.9	18.4	16.7	19.7	15.6	19.0	20.4	41.4	19.2	17.8	18.9	16.2	17.2	21.9	36.3	15.1	29.5	22.3	15.9	26.4	22.6	18.1	16.6	15.9	20.9	21.7	14.4	17.4	10.5	20.1	22.8	17.8	30.0	17.3	15.0	15.2	18.1	15.9	17.0	20.1	18.6	18.6	25.3	8.5	19.4	14.9	35.9	17.5	24.5	20.9	15.9	18.6	19.0	14.5	16.5	33.9	15.9	14.0	17.8	20.7	18.6	21.1	42.1	18.2	21.7	14.9	29.3	25.1	50.8	21.1	20.9	16.6	20.6	17.2	19.0	22.1	17.5	19.3	9.1	20.4	10.3	21.2	15.8	21.6	10.7	25.4	24.7	23.5	18.2	35.0	31.3	34.9	37.5	20.6	13.6	20.9	17.4	17.2	15.5	16.6	14.2	15.4	15.9	15.5	14.1	16.1	15.9	14.4	21.7	7.7	14.5	10.5	22.6	20.5	29.6	21.4	16.6	17.7	17.7	15.5	18.4	15.1
TYR	"OCA1, OCA1A, OCAIA"	ENSG00000077498	Tyrosinase	P14679	11	89177452-89295759	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Melanin biosynthesis"	"Monooxygenase, Oxidoreductase, Tumor antigen"	"Albinism, Deafness, Disease mutation, FDA approved drug targets, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	70	"retina: 82.0;skin 1: 25.2"	"Cell line enriched"	"Detected in single"	844	"SK-MEL-30: 84.3"	"Cancer enriched"	"Detected in single"	1755	"melanoma: 351.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000079, HPA043241, HPA050889, HPA064583"	Enhanced		Enhanced	Vesicles				Vesicles		"CAB000079: AB_564045, HPA043241: , HPA050889: , HPA064583: "	"unprognostic (1.16e-1)"								"unprognostic (1.01e-1)"		"unprognostic (1.85e-3)"		"unprognostic (9.75e-3)"					0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	82.0	0.7	0.0	0.0	25.2	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	84.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0
VAC14	"ArPIKfyve, FLJ10305, TAX1BP2"	ENSG00000103043	"Vac14, PIKFYVE complex component"	Q08AM6	16	70687439-70801161	"Disease related genes, Predicted intracellular proteins"	"Host-virus interaction"		"Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA027766, HPA075382"	Approved		Supported	Vesicles,Cytosol				Vesicles	Cytosol	"HPA027766: AB_1848651, HPA075382: "	"unprognostic (9.25e-2)"	"prognostic favourable (8.33e-5)"	"unprognostic (2.83e-2)"	"unprognostic (1.51e-1)"	"unprognostic (8.94e-2)"	"unprognostic (2.72e-1)"	"unprognostic (2.21e-2)"	"unprognostic (8.93e-3)"	"unprognostic (1.03e-1)"	"unprognostic (1.34e-2)"	"unprognostic (7.20e-2)"	"unprognostic (3.26e-1)"	"prognostic favourable (1.56e-6)"	"unprognostic (1.61e-1)"	"unprognostic (1.10e-1)"	"unprognostic (5.05e-2)"	"unprognostic (1.80e-1)"	26.3	26.6	22.9	22.8	21.8	16.3	17.4	15.6	34.9	17.9	18.4	27.0	18.5	19.8	18.8	15.8	21.0	20.9	17.0	22.2	22.9	23.5	25.7	27.1	20.1	34.9	22.3	20.8	19.2	27.8	33.7	21.4	20.1	25.8	17.9	14.1	22.9	24.3	19.4	23.3	24.6	21.6	19.2	22.2	29.0	20.0	21.7	20.6	31.2	26.0	16.3	22.9	21.0	16.3	5.5	9.7	6.6	5.9	3.7	5.5	1.9	11.2	11.2	9.5	10.6	13.8	10.1	14.5	8.2	13.0	15.7	7.3	13.8	18.3	14.5	10.7	9.8	14.3	12.4	13.3	7.4	4.4	13.0	7.3	8.5	17.0	35.7	12.5	15.4	16.7	14.0	23.2	21.2	14.9	12.8	6.6	13.7	16.3	11.6	20.9	16.7	10.6	14.0	6.9	21.4	7.5	7.8	11.3	12.3	27.2	8.3	18.7	12.3	11.8	11.8	20.9	12.0	13.3	8.8	9.5	11.6	27.8	34.9	11.2	9.5	1.3	4.8	6.6	2.9	5.9	2.5	4.0	3.7	5.5	9.7	5.5	3.5	3.1	1.6	3.7	5.4	5.1	2.3	1.9	22.9	21.8	15.6	34.9	22.9	23.5	22.3	20.8	25.8	20.6
VTI1B	VTI2	ENSG00000100568	"Vesicle transport through interaction with t-SNAREs 1B"	Q9UEU0	14	67647075-67674831	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA044121, HPA048150, HPA060118"	Approved		Enhanced	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"HPA044121: , HPA048150: , HPA060118: "	"unprognostic (2.26e-1)"	"unprognostic (4.83e-2)"	"unprognostic (8.09e-2)"	"unprognostic (2.24e-1)"	"unprognostic (3.00e-2)"	"unprognostic (2.36e-3)"	"unprognostic (3.25e-3)"	"unprognostic (9.12e-2)"	"unprognostic (1.90e-2)"	"unprognostic (3.86e-1)"	"unprognostic (2.60e-1)"	"unprognostic (2.11e-2)"	"prognostic favourable (3.53e-12)"	"unprognostic (8.35e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.43e-1)"	"unprognostic (8.02e-3)"	37.5	21.4	49.3	14.9	39.3	14.3	32.1	12.6	32.9	11.3	22.8	16.8	16.1	21.3	12.5	42.5	34.1	14.6	22.0	49.6	36.9	30.4	39.0	30.5	14.8	16.3	38.1	20.5	12.7	27.9	20.3	11.3	21.0	24.2	16.2	27.4	15.4	25.7	18.8	31.0	21.8	20.2	22.9	37.1	15.6	20.7	15.4	20.2	8.2	25.9	18.8	19.5	19.4	24.2	18.7	22.4	52.1	29.6	20.1	21.7	18.9	38.3	19.4	11.3	6.5	22.6	13.5	16.4	17.0	10.6	8.2	8.5	9.6	13.8	11.5	14.5	18.9	10.9	12.9	12.9	13.4	11.8	8.2	11.6	11.7	12.3	9.7	7.2	8.4	13.1	14.0	9.1	9.4	9.5	7.6	9.0	12.0	45.5	9.0	26.7	7.3	31.3	10.9	12.8	4.2	12.2	23.1	6.3	13.1	12.0	16.3	24.1	15.2	20.3	13.6	22.9	34.2	18.4	15.7	8.5	9.1	17.7	19.3	13.5	10.5	28.6	23.4	52.1	19.8	29.6	16.9	18.7	17.5	20.2	22.4	16.4	16.7	20.4	10.6	20.1	24.7	14.7	21.7	18.9	49.3	39.3	12.6	32.9	36.9	30.4	38.1	20.5	24.2	20.2
ZDHHC13	"FLJ10852, FLJ10941, HIP14L"	ENSG00000177054	"Zinc finger DHHC-type containing 13"	Q8IUH4	11	19117099-19176422	"Enzymes, Predicted membrane proteins, Transporters"		"Acyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HUVEC TERT2: 53.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016759, HPA018791"	Uncertain		Enhanced	Vesicles				Vesicles		"HPA016759: AB_1858993, HPA018791: AB_1858992"	"unprognostic (1.43e-2)"	"unprognostic (4.00e-3)"	"unprognostic (1.08e-1)"	"unprognostic (1.11e-3)"	"unprognostic (2.95e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.55e-2)"	"unprognostic (1.57e-1)"	"unprognostic (3.57e-3)"	"unprognostic (3.03e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.16e-1)"	"unprognostic (6.95e-3)"	"unprognostic (1.15e-1)"	"unprognostic (7.93e-2)"	"unprognostic (2.17e-1)"	"unprognostic (2.76e-2)"	4.7	5.2	6.3	9.3	8.0	6.8	7.3	13.2	9.7	8.8	13.2	5.8	7.1	8.7	6.4	5.6	36.4	10.5	6.9	7.7	6.2	7.1	10.8	2.3	4.7	6.9	5.4	5.2	5.8	14.0	10.9	20.1	9.4	9.4	7.1	14.7	6.4	11.2	5.9	2.1	14.9	12.3	4.9	4.7	6.3	14.4	11.2	4.8	15.0	7.7	18.2	27.5	15.3	14.5	6.3	4.3	23.4	5.8	4.3	7.5	3.5	15.8	7.5	7.2	6.1	2.6	3.0	6.9	7.6	7.0	8.5	9.9	4.5	3.8	8.1	5.3	6.3	24.2	10.3	5.0	9.4	10.0	9.0	4.2	4.8	3.6	6.0	5.7	7.3	3.4	5.9	3.6	5.0	53.8	4.0	4.1	8.8	5.1	7.3	4.7	6.0	7.0	8.2	10.0	1.9	8.8	10.5	12.6	9.2	9.1	11.1	4.1	5.2	6.7	15.4	7.6	5.4	11.6	6.1	3.5	10.7	7.5	9.1	5.9	13.2	7.4	3.5	23.4	6.8	5.8	6.1	6.3	5.3	7.5	4.3	4.2	5.1	6.5	4.4	4.3	4.6	4.2	6.8	3.5	6.3	8.0	13.2	9.7	6.2	7.1	5.4	5.2	9.4	4.8
ZFYVE16	"KIAA0305, PPP1R69"	ENSG00000039319	"Zinc finger FYVE-type containing 16"	Q7Z3T8	5	80408013-80479350	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 41.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 17.3"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 17.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035935, HPA035936"	Supported		Enhanced	Vesicles,Cytosol				"Vesicles, Cytosol"		"HPA035935: AB_10672076, HPA035936: AB_10669662"	"unprognostic (1.11e-1)"	"unprognostic (3.98e-2)"	"unprognostic (1.78e-2)"	"unprognostic (3.26e-1)"	"unprognostic (7.19e-2)"	"unprognostic (2.57e-2)"	"unprognostic (7.25e-3)"	"unprognostic (6.91e-2)"	"unprognostic (4.00e-1)"	"unprognostic (8.83e-2)"	"unprognostic (1.29e-1)"	"unprognostic (2.15e-1)"	"unprognostic (3.04e-1)"	"unprognostic (4.64e-2)"	"unprognostic (4.95e-2)"	"unprognostic (6.91e-2)"	"unprognostic (4.23e-2)"	10.7	11.9	11.0	10.1	28.9	6.1	11.6	14.9	19.2	21.2	9.0	33.2	7.7	6.7	17.0	6.6	9.6	9.7	14.6	17.6	11.7	9.5	13.1	13.3	11.6	6.8	25.7	16.8	16.8	7.1	13.4	15.0	16.5	37.3	11.5	8.4	9.0	8.6	9.3	12.7	6.4	8.7	12.8	26.9	11.2	8.4	11.7	21.2	3.8	12.6	4.6	5.8	12.8	10.8	2.5	2.3	17.3	3.9	2.4	1.5	0.3	5.6	6.7	11.9	11.5	7.2	7.5	8.0	8.8	7.6	7.9	10.7	4.9	6.6	3.9	6.4	7.2	5.9	8.5	7.2	8.7	2.5	5.6	4.2	9.1	5.5	6.1	1.2	3.2	8.2	4.0	6.6	6.3	9.0	4.1	6.1	8.5	7.2	2.7	1.2	2.8	3.1	5.7	24.8	4.1	6.8	11.1	4.5	10.4	12.6	6.0	41.5	8.4	3.9	7.9	4.8	5.5	7.3	7.3	1.8	3.5	3.9	6.3	3.9	10.6	11.5	3.7	1.8	1.5	2.3	0.8	2.5	0.7	1.3	1.4	2.5	0.6	0.7	17.3	2.4	3.9	2.3	0.8	0.3	11.0	28.9	14.9	19.2	11.7	9.5	25.7	16.8	37.3	21.2
ZFYVE9	"MADHIP, PPP1R173, SARA, SMADIP"	ENSG00000157077	"Zinc finger FYVE-type containing 9"	O95405	1	52142094-52346686	"Predicted intracellular proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 2.1"	"Lineage enriched"	"Detected in single"	5	"T-cells: 2.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017702, HPA065852, HPA065862"	Approved		Enhanced	Vesicles,Cytosol				"Vesicles, Cytosol"		"CAB017702: AB_1128462, HPA065852: , HPA065862: "	"unprognostic (5.05e-2)"	"unprognostic (4.78e-2)"	"unprognostic (2.58e-2)"	"unprognostic (1.51e-1)"	"unprognostic (7.15e-2)"	"unprognostic (3.87e-1)"	"unprognostic (2.87e-3)"	"unprognostic (6.11e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.47e-2)"	"unprognostic (5.36e-2)"	"unprognostic (1.17e-3)"	"unprognostic (2.14e-1)"	"unprognostic (3.69e-1)"	"unprognostic (1.99e-3)"	"unprognostic (1.73e-2)"	10.2	10.0	13.6	3.8	18.4	1.0	13.0	28.4	27.7	15.5	8.0	9.5	10.1	6.8	14.1	9.1	10.8	12.2	8.1	10.4	13.8	15.7	15.2	10.7	11.3	4.1	13.8	15.8	19.5	16.9	32.3	14.6	7.4	18.7	13.6	9.9	9.6	9.8	13.8	25.5	12.3	7.4	13.3	11.6	4.2	8.6	14.9	8.0	1.5	19.5	8.8	4.2	10.9	13.8	0.4	0.0	0.0	0.0	0.2	2.1	0.4	9.8	4.7	6.8	8.6	16.6	15.0	11.1	8.0	11.1	9.6	11.1	5.4	0.8	0.0	5.0	11.4	3.6	12.0	13.0	14.8	0.0	8.1	2.8	5.4	6.5	11.0	2.5	1.7	10.0	14.7	8.4	19.1	13.9	4.3	1.8	12.8	2.2	3.5	1.8	8.8	8.3	3.1	11.6	0.9	5.5	22.1	5.7	5.8	9.0	7.7	10.4	3.5	3.3	12.8	9.7	3.9	7.4	4.8	2.5	1.5	1.2	6.9	3.1	3.9	0.0	0.0	0.0	0.3	0.0	2.1	0.3	1.6	0.4	0.0	0.4	1.3	0.7	0.0	0.2	0.0	0.0	0.0	0.4	13.6	18.4	28.4	27.7	13.8	15.7	13.8	15.8	18.7	8.0
ZNF266	HZF1	ENSG00000174652	"Zinc finger protein 266"	Q14584	19	9412598-9435578	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NB-4: 45.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA026836, HPA054110"	Uncertain		Supported	"Nucleoplasm,Vesicles,Rods & Rings"				Vesicles	"Nucleoplasm, Rods & Rings"	"HPA026836: , HPA054110: "	"unprognostic (2.50e-2)"	"prognostic favourable (1.41e-4)"	"unprognostic (2.27e-2)"	"unprognostic (1.04e-1)"	"unprognostic (7.60e-2)"	"prognostic favourable (3.94e-6)"	"unprognostic (1.72e-2)"	"prognostic favourable (4.47e-4)"	"unprognostic (4.59e-2)"	"unprognostic (9.00e-3)"	"prognostic favourable (3.03e-5)"	"unprognostic (2.92e-3)"	"prognostic unfavourable (1.82e-4)"	"unprognostic (7.76e-2)"	"unprognostic (1.08e-1)"	"unprognostic (3.56e-2)"	"prognostic favourable (9.15e-5)"	14.7	12.1	11.0	21.5	12.5	12.8	17.6	19.0	10.0	21.8	15.7	13.1	9.6	8.6	17.2	55.8	12.7	14.6	12.8	11.7	8.2	5.4	10.9	10.4	15.8	21.0	14.5	4.9	18.9	11.2	12.5	19.8	13.0	11.4	23.8	15.7	14.4	14.4	13.5	9.3	19.1	20.8	17.0	10.9	31.3	13.5	13.0	11.4	34.6	20.8	7.3	23.4	14.4	14.2	6.9	3.8	5.6	5.5	12.6	13.0	5.1	10.6	2.7	7.9	15.1	5.7	11.1	6.4	11.8	10.0	9.8	16.3	5.7	4.6	11.9	7.6	5.8	4.0	10.0	6.3	11.7	3.3	16.5	16.3	14.6	8.3	5.1	9.3	10.1	10.5	8.7	5.3	8.2	7.8	8.5	0.1	9.0	1.0	13.6	45.8	8.3	9.0	6.1	8.2	8.3	7.6	13.3	6.8	10.7	5.4	6.4	6.6	4.7	7.2	7.1	9.1	3.5	13.7	6.0	19.5	25.8	14.2	2.8	8.9	6.8	4.8	4.1	5.6	13.0	4.8	8.5	6.0	7.2	9.2	3.3	6.9	10.6	10.2	3.6	12.6	5.5	3.8	8.7	5.1	11.0	12.5	19.0	10.0	8.2	5.4	14.5	4.9	11.4	11.4
ZNF326	"FLJ20403, ZAN75, Zfp326, ZIRD"	ENSG00000162664	"Zinc finger protein 326"	Q5BKZ1	1	89995112-90035531	"Predicted intracellular proteins"	"mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Activator, DNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA028450, HPA028461, HPA028466"	Supported		Enhanced	"Nucleoplasm,Golgi apparatus,Vesicles"				Nucleoplasm	"Golgi apparatus, Vesicles"	"HPA028450: , HPA028461: AB_10601777, HPA028466: AB_10601677"	"prognostic favourable (9.46e-4)"	"unprognostic (2.45e-1)"	"unprognostic (7.25e-3)"	"unprognostic (1.09e-1)"	"unprognostic (5.28e-3)"	"unprognostic (1.67e-2)"	"unprognostic (8.61e-3)"	"unprognostic (1.70e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.17e-2)"	"unprognostic (3.66e-2)"	"unprognostic (1.33e-2)"	"unprognostic (2.62e-2)"	"unprognostic (8.59e-2)"	"unprognostic (1.33e-1)"	"unprognostic (2.29e-1)"	"prognostic favourable (2.84e-4)"	12.7	13.4	18.4	12.7	27.8	45.2	17.7	20.2	18.5	11.8	14.1	23.2	16.3	18.5	18.3	17.1	17.5	11.9	13.9	12.5	19.2	15.2	13.4	15.2	11.5	15.3	26.1	14.1	21.8	20.2	14.4	18.0	14.5	22.8	13.3	20.7	23.9	15.7	9.4	19.2	14.5	18.9	17.8	31.3	11.0	14.6	10.6	27.8	17.3	14.1	10.5	15.1	11.9	17.2	6.8	8.4	3.6	6.1	7.8	4.3	2.2	16.9	15.5	24.1	11.5	10.8	5.1	25.5	17.2	6.7	14.3	8.9	14.4	12.3	21.2	12.3	8.8	15.3	25.1	11.2	19.6	12.4	12.0	19.1	15.1	13.0	3.6	22.4	9.4	4.5	5.3	14.2	9.0	8.2	25.5	9.3	11.4	8.0	23.1	12.8	22.7	17.6	16.5	24.5	5.7	11.8	19.0	21.2	13.8	19.8	18.4	8.4	10.1	5.9	11.2	16.8	16.9	14.1	17.0	7.9	7.7	21.2	4.0	17.7	10.7	2.1	5.1	3.6	4.0	6.1	3.2	4.2	3.2	3.4	4.0	6.8	3.2	4.3	2.5	7.8	4.6	8.4	2.8	2.2	18.4	27.8	20.2	18.5	19.2	15.2	26.1	14.1	22.8	27.8